<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Prophylactic lidocaine for myocardial infarction - Martí-Carvajal, AJ - 2015 | Cochrane Library</title> <meta content="Prophylactic lidocaine for myocardial infarction - Martí-Carvajal, AJ - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008553.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Prophylactic lidocaine for myocardial infarction - Martí-Carvajal, AJ - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008553.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008553.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Prophylactic lidocaine for myocardial infarction" name="citation_title"/> <meta content="Arturo J Martí-Carvajal" name="citation_author"/> <meta content="Universidad UTE (Cochrane Ecuador)" name="citation_author_institution"/> <meta content="arturo.marti.carvajal@gmail.com" name="citation_author_email"/> <meta content="Daniel Simancas-Racines" name="citation_author"/> <meta content="Universidad Tecnológica Equinoccial" name="citation_author_institution"/> <meta content="Vidhu Anand" name="citation_author"/> <meta content="University of Minnesota" name="citation_author_institution"/> <meta content="Shrikant I Bangdiwala" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD008553.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/08/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008553.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008553.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008553.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Arrhythmia Agents [*therapeutic use]; Arrhythmias, Cardiac [mortality, *prevention &amp; control]; Bradycardia [mortality, prevention &amp; control]; Lidocaine [*therapeutic use]; Myocardial Infarction [*complications, mortality]; Randomized Controlled Trials as Topic; Ventricular Fibrillation [mortality, prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008553.pub2&amp;doi=10.1002/14651858.CD008553.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="9nGOjNGw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008553\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008553\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008553\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008553\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008553.pub2",title:"Prophylactic lidocaine for myocardial infarction",firstPublishedDate:"Aug 21, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008553.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008553.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008553.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008553.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008553.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008553.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008553.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008553.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008553.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008553.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4103 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008553.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-sec-0128"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-sec-0048"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-sec-0122"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/appendices#CD008553-sec-0133"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/supinfo/CD008553StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/supinfo/CD008553StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Prophylactic lidocaine for myocardial infarction</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/information#CD008553-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Arturo J Martí-Carvajal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/information#CD008553-cr-0005">Daniel Simancas-Racines</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/information#CD008553-cr-0006">Vidhu Anand</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008553.pub2/information#CD008553-cr-0007">Shrikant I Bangdiwala</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/information/en#CD008553-sec-0144">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 August 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008553.pub2">https://doi.org/10.1002/14651858.CD008553.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008553-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008553-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008553-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008553-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008553-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008553-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008553-abs-0001" lang="en"> <section id="CD008553-sec-0001"> <h3 class="title" id="CD008553-sec-0001">Background</h3> <p>Coronary artery disease is a major public health problem affecting both developed and developing countries. Acute coronary syndromes include unstable angina and myocardial infarction with or without ST‐segment elevation (electrocardiogram sector is higher than baseline). Ventricular arrhythmia after myocardial infarction is associated with high risk of mortality. The evidence is out of date, and considerable uncertainty remains about the effects of prophylactic use of lidocaine on all‐cause mortality, in particular, in patients with suspected myocardial infarction. </p> </section> <section id="CD008553-sec-0002"> <h3 class="title" id="CD008553-sec-0002">Objectives</h3> <p>To determine the clinical effectiveness and safety of prophylactic lidocaine in preventing death among people with myocardial infarction. </p> </section> <section id="CD008553-sec-0003"> <h3 class="title" id="CD008553-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2015, Issue 3), MEDLINE Ovid (1946 to 13 April 2015), EMBASE (1947 to 13 April 2015) and Latin American Caribbean Health Sciences Literature (LILACS) (1986 to 13 April 2015). We also searched Web of Science (1970 to 13 April 2013) and handsearched the reference lists of included papers. We applied no language restriction in the search. </p> </section> <section id="CD008553-sec-0004"> <h3 class="title" id="CD008553-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials assessing the effects of prophylactic lidocaine for myocardial infarction. We considered all‐cause mortality, cardiac mortality and overall survival at 30 days after myocardial infarction as primary outcomes. </p> </section> <section id="CD008553-sec-0005"> <h3 class="title" id="CD008553-sec-0005">Data collection and analysis</h3> <p>We performed study selection, risk of bias assessment and data extraction in duplicate. We estimated risk ratios (RRs) for dichotomous outcomes and measured statistical heterogeneity using I<sup>2</sup>. We used a random‐effects model and conducted trial sequential analysis. </p> </section> <section id="CD008553-sec-0006"> <h3 class="title" id="CD008553-sec-0006">Main results</h3> <p>We identified 37 randomised controlled trials involving 11,948 participants. These trials compared lidocaine versus placebo or no intervention, disopyramide, mexiletine, tocainide, propafenone, amiodarone, dimethylammonium chloride, aprindine and pirmenol. Overall, trials were underpowered and had high risk of bias. Ninety‐seven per cent of trials (36/37) were conducted without an a priori sample size estimation. Ten trials were sponsored by the pharmaceutical industry. Trials were conducted in 17 countries, and intravenous intervention was the most frequent route of administration. </p> <p>In trials involving participants with proven or non‐proven acute myocardial infarction, lidocaine versus placebo or no intervention showed no significant differences regarding all‐cause mortality (213/5879 (3.62%) vs 199/5848 (3.40%); RR 1.02, 95% CI 0.82 to 1.27; participants = 11727; studies = 18; I<sup>2</sup> = 15%); low‐quality evidence), cardiac mortality (69/4184 (1.65%) vs 62/4093 (1.51%); RR 1.03, 95% CI 0.70 to 1.50; participants = 8277; studies = 12; I<sup>2</sup> = 12%; low‐quality evidence) and prophylaxis of ventricular fibrillation (76/5128 (1.48%) vs 103/4987 (2.01%); RR 0.78, 95% CI 0.55 to 1.12; participants = 10115; studies = 16; I<sup>2</sup> = 18%; low‐quality evidence). In terms of sinus bradycardia, lidocaine effect is imprecise compared with effects of placebo or no intervention (55/1346 (4.08%) vs 49/1203 (4.07%); RR 1.09, 95% CI 0.66 to 1.80; participants = 2549; studies = 8; I<sup>2</sup> = 21%; very low‐quality evidence). In trials involving only participants with proven acute myocardial infarction, lidocaine versus placebo or no intervention showed no significant differences in all‐cause mortality (148/2747 (5.39%) vs 135/2506 (5.39%); RR 1.01, 95% CI 0.79 to 1.30; participants = 5253; studies = 16; I<sup>2</sup> = 9%; low‐quality evidence). No significant differences were noted between lidocaine and any other antiarrhythmic drug in terms of all‐cause mortality and ventricular fibrillation. Data on overall survival 30 days after myocardial infarction were not reported. Lidocaine compared with placebo or no intervention increased risk of asystole (35/3393 (1.03%) vs 14/3443 (0.41%); RR 2.32, 95% CI 1.26 to 4.26; participants = 6826; studies = 4; I<sup>2</sup> = 0%; very low‐quality evidence) and dizziness/drowsiness (74/1259 (5.88%) vs 16/1274 (1.26%); RR 3.85, 95% CI 2.29 to 6.47; participants = 2533; studies = 6; I<sup>2</sup> = 0%; low‐quality evidence). Overall, safety data were poorly reported and adverse events may have been underestimated. Trial sequential analyses suggest that additional trials may not be needed for reliable conclusions to be drawn regarding these outcomes. </p> </section> <section id="CD008553-sec-0007"> <h3 class="title" id="CD008553-sec-0007">Authors' conclusions</h3> <p>This Cochrane review found evidence of low quality to suggest that prophylactic lidocaine has very little or no effect on mortality or ventricular fibrillation in people with acute myocardial infarction. The safety profile is unclear. This conclusion is based on randomised controlled trials with high risk of bias. However (disregarding the risk of bias), trial sequential analysis suggests that additional trials may not be needed to disprove an intervention effect of 20% relative risk reduction. Smaller risk reductions might require additional higher trials. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008553-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008553-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008553-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008553-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008553-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008553-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008553-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008553-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008553-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008553-abs-0002" lang="en"> <h3>Prophylactic lidocaine for myocardial infarction</h3> <p><b>Review question</b><br/>We reviewed the clinical effectiveness and safety of prophylactic lidocaine for myocardial infarction. </p> <p><b>Background</b><br/>Coronary artery disease is a major public health problem that affects both developed and developing countries. Acute coronary syndromes include unstable angina and myocardial infarction with or without ST‐segment elevation (electrocardiogram sector is higher than baseline). Ventricular arrhythmia after myocardial infarction is associated with high risk of mortality. The evidence is out of date, and considerable uncertainty remains about the effects of prophylactic lidocaine use on all‐cause mortality, in particular, in patients with suspected myocardial infarction. </p> <p><b>Study characteristics</b><br/>We identified 37 trials conducted between 1969 and 1999. The evidence is current up to April 2015. Trials were conducted in Australia, Belgium, Brazil, Canada, Denmark, France, Germany, Italy, New Zealand, Northern Ireland, Norway, Poland, Sweden, Switzerland, The Netherlands, United Kingdom and United States of America and included 11,948 participants. Trials were conducted in pre‐hospital and in‐hospital settings and included individuals with or without proved acute myocardial infarction. Some trials did not limit results to acute myocardial infarction only. Lidocaine was given by intravenous (bolus and/or infusion) and intramuscular (alone or in combination with intravenous dosage) routes. Overall, trials included small sample sizes and reported low numbers of events. All trials had high risk of bias. Ten trials were sponsored by the pharmaceutical industry. </p> <p><b>Key results</b><br/>In people who had known or suspected heart attack, we found that lidocaine compared with placebo, no intervention or any other antiarrhythmic drug had very small or no effects on death, cardiac death and ventricular fibrillation. </p> <p><b>Quality of evidence</b><br/>Our confidence in the results of this review is low because the included trials that we synthesised were of low quality (overestimation of benefits and underestimation of harms) and were conducted with a small number of participants, leading to imprecision of results. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008553-sec-0128" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008553-sec-0128"></div> <h3 class="title" id="CD008553-sec-0129">Implications for practice</h3> <section id="CD008553-sec-0129"> <p>This Cochrane review provides low‐quality evidence to suggest that prophylactic lidocaine leads to very little or no effect on all‐cause mortality and ventricular fibrillation following myocardial infarction. These results are based on 37 trials (11,948 participants) comparing lidocaine at any dosage and route of administration versus placebo or no intervention or antiarrhythmic drugs. Included trials showed no benefit for preventing death among individuals with acute myocardial infarction at low or high risk of death. Results are based on the findings of randomised controlled trials at high risk of bias, and safety data remain unclear. Therefore, we conclude that based on this systematic review and meta‐analyses comparing lidocaine versus placebo, no intervention or other antiarrhythmic drugs, prescription of lidocaine prophylactically is not justified in acute myocardial infarction. </p> </section> <h3 class="title" id="CD008553-sec-0130">Implications for research</h3> <section id="CD008553-sec-0130"> <p>Trial sequential analysis suggests that no additional trials may be needed to disprove an intervention effect of 20% relative risk reduction for assessing benefits of prophylactic lidocaine in myocardial infarction. Smaller risk reductions might require higher trials. Potential trials should include clinical outcomes such as all‐cause mortality, ventricular fibrillation and adverse events. Trials should be designed according to the SPIRIT statement (<a href="./references#CD008553-bbs2-0104" title="ChanAW , TetzlaffJM , GøtzschePC , AltmanDG , MannH , BerlinJA , et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ2013;346:e7586.">Chan 2013</a>) and reported according to the CONSORT statement to improve the quality of reporting of efficacy and harms in clinical research (<a href="./references#CD008553-bbs2-0132" title="IoannidisJP , EvansSJ , GotzschePC , O'NeillRT , AltmanDG , SchulzK , et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine2004;141(10):781-8. [PMID: 15545678]">Ioannidis 2004</a><a href="./references#CD008553-bbs2-0151" title="MoherD , HopewellS , SchulzKF , MontoriV , GotzschePC , DevereauxPJ . CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ2010;340:c869.">Moher 2010</a>). Future trials should be planned in accordance with the recommendations of the Patient‐Centered Outcomes Research Initiative (<a href="./references#CD008553-bbs2-0094" title="BaschE , AronsonN , BergA , FlumD , GabrielS , GoodmanSN , HelfandM , et al. Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective. JAMA2012;307(15):1636-40. [PMID: 22511692]">Basch 2012</a>; <a href="./references#CD008553-bbs2-0113" title="GabrielSE , NormandSL . Getting the methods right - the Foundation of Patient-Centered Outcomes Research. New England Journal of Medicine2012;367(9):787-90. [PMID: 22830434]">Gabriel 2012</a>; <a href="./references#CD008553-bbs2-0150" title="McKinneyM . 'Time is of the essence'. PCORI moves to implement comparative effectiveness research, funding. Modern Health Care2012;42(5):12-3. [PMID: 22356074]">McKinney 2012</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008553-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008553-sec-0008"></div> <div class="table" id="CD008553-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Lidocaine compared with placebo or no intervention for acute myocardial infarction</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lidocaine compared with placebo or no intervention for acute myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with acute myocardial infarction<br/><b>Settings:</b> pre‐hospital and in‐hospital<br/><b>Intervention:</b> lidocaine<br/><b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo or no intervention</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lidocaine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: ranging between unknown and 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>35 per 1000</b><br/>(29 to 42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> <br/>(0.85 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11727<br/>(18 studies<sup>a</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac mortality</b> </p> <p>Follow‐up: ranging between unknown and 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b><br/>(11 to 23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b> <br/>(0.70 to 1.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8277<br/>(12 studies<sup>a</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall survival at 30 days after myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No trial assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventricular fibrillation</b><br/>Electrocardiogram </p> <p>Follow‐up: ranging between unknown and 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b><br/>(11 to 23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> <br/>(0.55 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10115<br/>(16 studies<sup>a</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events (AEs; adverse drug reaction): asystole</b> </p> <p>Follow‐up: ranging between unknown and 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> <p>(5 to 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.32</b><br/>(1.26 to 4.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6826</p> <p>(4 studies<sup>a</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>b,f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events (AEs; adverse drug reaction): sinus bradycardia</b> </p> <p>Follow‐up: ranging between unknown and 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> <br/>(27 to 73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.09</b><br/>(0.66 to 1.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2549</p> <p>(8 studies<sup>a</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>b,h,i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (AEs; adverse drug reaction): drowsiness/dizziness</b> </p> <p>Follow‐up: ranging between unknown and 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> <p>(29 to 81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.85</b><br/>(2.29 to 6.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2533<br/>(6 studies<sup>a</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>j.k.l</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Trials include participants with proven or unproven acute myocardial infarction.<br/><sup>b</sup>Downgraded two levels because of limitations in trial design or execution (high attrition bias).<br/><sup>c</sup>Assumed risk was gotten from control group risk (3.4%).<br/><sup>d</sup>Assumed risk was gotten from control group risk (1.5%).<br/><sup>e</sup>Assumed risk was gotten from control group risk (2.1%).<br/><sup>f</sup>Assumed risk was gotten from control group risk (0.41%).<br/><sup>g</sup>Downgraded one level because of imprecision (low number of events with an impact on the precision of effect estimates).<br/><sup>h</sup>Assumed risk was gotten from control group risk (4.1%).<br/><sup>i</sup>Downgraded one level because of imprecision (low number of events with an impact on the precision of effect estimates).<br/><sup>j</sup>Downgraded one level because of limitations in trial design or execution (high attrition bias).<br/><sup>k</sup>Downgraded one level because of imprecision (low number of events with an impact on the precision of effect estimates).<br/><sup>l</sup>Assumed risk was gotten from control group risk (1.3%). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008553-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Lidocaine compared with disopyramide for myocardial infarction</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lidocaine compared with disopyramide for myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with myocardial infarction<br/><b>Settings:</b> in‐hospital<br/><b>Intervention:</b> lidocaine<br/><b>Comparison:</b> disopyramide </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Disopyramide</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lidocaine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: ranging between 12 hours and 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>98 per 1000</b><br/>(33 to 291) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.39</b> <br/>(0.47 to 4.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac mortality</b><br/>Follow‐up: ranging between 12 hours and 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b><br/>(9 to 200) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> <br/>(0.21 to 4.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a,b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall survival at 30 days after myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No trial assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventricular fibrillation</b> </p> <p>Follow‐up: 12 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>79 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> </p> <p>(3 to 242)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.32</b><br/>(0.04 to 2.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>e,f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events (AEs; adverse drug reaction): asystole</b> </p> <p>Follow‐up: 12 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> <p>(0 to 209)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b><br/>(0.01 to 7.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>e,f,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (AEs; adverse drug reaction):</b> <br/><b>sinoatrial block</b> </p> <p>Follow‐up: 24 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b><br/>2 to 438 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> </p> <p>(0.06 to 14.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>i,j,k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (AEs; adverse drug reaction):</b> <br/><b>cardiac blocks (high‐degree atrioventricular block and bundle)</b> </p> <p>Follow‐up: 24 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>152 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>86 per 1000</b><br/>(23 to 330) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.57</b><br/>(0.15 to 2.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>j,k,l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of limitations in trial design or execution (high attrition bias).<br/><sup>b</sup>Downgraded two levels because of imprecision (small sample and very low number of events with an impact on the precision of effect estimates).<br/><sup>c</sup>Assumed risk was gotten from control group risk (7%).<br/><sup>d</sup>Assumed risk was gotten from control group risk (4.1%).<br/><sup>e</sup>Downgraded one level because of limitations in trial design.<br/><sup>f</sup>Downgraded two levels because of imprecision (small sample and very low number of events with an impact on the precision of effect estimates).<br/><sup>g</sup>Assumed risk was gotten from control group risk (7.9%).<br/><sup>h</sup>Assumed risk was gotten from control group risk (2.6%).<br/><sup>i</sup>Downgraded one level because of limitations in trial design or execution (high attrition bias).<br/><sup>j</sup>Downgraded two levels because of imprecision (small sample and very low number of events with an impact on the precision of effect estimates).<br/><sup>k</sup>Assumed risk was gotten from control group risk (3%).<br/><sup>l</sup>Assumed risk was gotten from control group risk (15.2%). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008553-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Lidocaine compared with tocainide for myocardial infarction</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lidocaine compared with tocainide for myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with myocardial infarction<br/><b>Settings:</b> in‐hospital<br/><b>Intervention:</b> lidocaine<br/><b>Comparison:</b> tocainide </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Tocainide</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lidocaine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: 48 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b><br/>(5 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b> <br/>(0.08 to 17.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac mortality</b><br/>Follow‐up: 48 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b><br/>(5 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b> <br/>(0.08 to 17.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival at 30 days after myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a> nor <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a> assessed this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventricular fibrillation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a> reported no participants with VF. <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a> did not mention this outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (AEs; adverse drug reaction): any adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>444 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>751 per 1000</b> </p> <p>(476 to 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.69</b><br/>(1.07 to 2.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As the result of severe inconsistencies regarding reporting data on adverse events, we preferred to show the evidence using this approach </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of limitations in trial design and execution of trials.<br/><sup>b</sup>Downgraded two levels because of imprecision (small sample and very low number of events with an impact on the precision of effect estimates).<br/><sup>c</sup>Assumed risk was gotten from control group risk (6.3%).<br/><sup>d</sup>Assumed risk was gotten from control group risk (44.4%). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008553-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Lidocaine compared with mexiletine for myocardial infarction</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lidocaine compared with mexiletine for myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with myocardial infarction<br/><b>Settings:</b> in‐hospital<br/><b>Intervention:</b> lidocaine<br/><b>Comparison:</b> mexiletine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Mexiletine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lidocaine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 48 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b><br/>(1 to 621) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> <br/>(0.01 to 7.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac mortality</b> </p> <p>Follow‐up: 48 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b><br/>(1 to 621) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> <br/>(0.01 to 7.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival at 30 days after myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neither <a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a> nor <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a> assessed this outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventricular fibrillation</b> </p> <p>Follow‐up: 48 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.00</b> <br/>(0.13 to 67.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events in the control group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (AEs; adverse drug reaction): atrioventricular block</b><br/>Follow‐up: 48 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b><br/>(1 to 621) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.33</b> <br/>(0.01 to 7.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events (AEs; adverse drug reaction): composite neurological adverse event (confusion, vertigo, nystagmus, vomiting and diplopia)</b><br/>Follow‐up: between 3 hours and 48 hours<sup>d</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>459 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>289 per 1000</b> </p> <p>(74 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.63</b><br/>(0.16 to 2.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of limitations in the trial design.<br/><sup>b</sup>Downgraded two levels because of imprecision (small sample and very low number of events with an impact on the precision of effect estimates).<br/><sup>c</sup>Assumed risk was gotten from control group risk (8.3%).<br/><sup>d</sup><a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a> and <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a> used 'composite neurological adverse' terms for reporting this adverse event.<br/><sup>e</sup>Assumed risk was gotten from control group risk (45.9%). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008553-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Lidocaine compared with propafenone for myocardial infarction</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lidocaine compared with propafenone for myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with myocardial infarction<br/><b>Settings:</b> in‐hospital<br/><b>Intervention:</b> lidocaine<br/><b>Comparison:</b> propafenone </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Propafenone</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lidocaine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival at 30 days after myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventricular fibrillation</b> </p> <p>Follow‐up: 24 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.00</b> <br/>(0.14 to 65.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control group had no event</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (AEs; adverse drug reaction): heart failure</b><br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 6.38</b> <br/>(0.32 to 127.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control group had no event</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (AEs; adverse drug reaction): bilateral bundle branch block</b><br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b><br/>(1 to 279) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.43</b> <br/>(0.02 to 10.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (AEs; adverse drug reaction): neuropsychiatric disturbances</b><br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 6.95</b><br/>(0.86 to 55.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control group had no event</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of limitations in trial design and execution of the trial.<br/><sup>b</sup>Downgraded two levels because of imprecision (small sample and very low number of events with an impact on the precision of effect estimates).<br/><sup>c</sup>Assumed risk was gotten from control group risk (2.8%). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008553-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Lidocaine compared with amiodarone for myocardial infarction</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lidocaine compared with amiodarone for myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with myocardial infarction<br/><b>Settings:</b> in‐hospital<br/><b>Intervention:</b> lidocaine<br/><b>Comparison:</b> amiodarone </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Amiodarone</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lidocaine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: not stated</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiac mortality</b><br/>Follow‐up: not stated </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall survival at 30 days after myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ventricular fibrillation</b> </p> <p>Follow‐up: not stated</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.44</b> <br/>(0.18 to 46.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No ventricular fibrillation in control group</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bradycardia</b><br/>Follow‐up: not stated </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b><br/>(1 to 512) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.23</b> <br/>(0.01 to 5.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypotension</b><br/>Follow‐up: not stated </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b><br/>(2 to 520) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.14</b> <br/>(0.01 to 2.60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diplopia plus sleepiness</b><br/>Follow‐up: not stated </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.06</b> <br/>(0.09 to 46.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No diplopia in control group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of limitations in trial design.<br/><sup>b</sup>Downgraded two levels because of imprecision (small sample and very low number of events with an impact on the precision of effect estimates).<br/><sup>c</sup>Assumed risk was gotten from control group risk (10%).<br/><sup>d</sup>Assumed risk was gotten from control group risk (20%). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008553-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Lidocaine compared with dimethylammonium for myocardial infarction</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lidocaine compared with dimethylammonium for myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with myocardial infarction<br/><b>Settings:</b> in‐hospital<br/><b>Intervention:</b> lidocaine<br/><b>Comparison:</b> dimethylammonium </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Dimethylammonium</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lidocaine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: unclear </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac mortality</b><br/>Follow‐up: unclear </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival at 30 days after myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventricular fibrillation</b><br/>Follow‐up: unclear </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypotension</b><br/>Follow‐up: unclear </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>312 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>266 per 1000</b><br/>(88 to 809) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b> <br/>(0.28 to 2.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tachycardia</b><br/>Follow‐up: unclear </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b><br/>(0 to 500) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.06</b> <br/>(0.00 to 1.0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bradycardia</b><br/>Follow‐up: unclear </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b><br/>(1 to 505) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.35</b> <br/>(0.02 to 8.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of limitations in trial design or execution (high attrition bias).<br/><sup>b</sup>Downgraded two levels because of imprecision (small sample and very low number of events with an impact on the precision of effect estimates).<br/><sup>c</sup>Assumed risk was gotten from control group risk (31.3%).<br/><sup>d</sup>Assumed risk was gotten from control group risk (50%).<br/><sup>e</sup>Assumed risk was gotten from control group risk (6.3%). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008553-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Lidocaine compared with aprindine for myocardial infarction</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lidocaine compared with aprindine for myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with myocardial infarction<br/><b>Settings:</b> in‐hospital<br/><b>Intervention:</b> lidocaine<br/><b>Comparison:</b> aprindine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Aprindine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lidocaine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 3 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac mortality</b><br/>Follow‐up: 3 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival at 30 days after myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventricular fibrillation</b> <br/>Follow‐up: 3 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a> did not mention this outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Coma</b><br/>Follow‐up: 3 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.00</b> <br/>(0.13 to 67.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No coma in control group</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b><br/>Follow‐up: 3 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.00</b> <br/>(0.27 to 94.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No seizures in control group</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Agitation</b><br/>Follow‐up: 3 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/>(2 to 628) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.20</b> <br/>(0.01 to 3.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of limitations in trial design.<br/><sup>b</sup>Downgraded two levels because of imprecision (small sample and very low number of events with an impact on the precision of effect estimates).<br/><sup>c</sup>Assumed risk was gotten from control group risk (16.7%). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008553-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Lidocaine compared with pirmenol for myocardial infarction</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lidocaine compared with pirmenol for myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with myocardial infarction<br/><b>Settings:</b> in‐hospital<br/><b>Intervention:</b> lidocaine<br/><b>Comparison:</b> pirmenol </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo or no intervention</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lidocaine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 24 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac mortality</b><br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall survival at 30 days after myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventricular fibrillation</b> <br/>Follow‐up: 24 hours. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Safety (AEs; adverse drug reaction): any adverse event</b> </p> <p>Follow‐up: 24 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>555 per 1000</b> </p> <p>(235 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.11</b><br/>(0.47 to 2.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> <p>(1 study<sup>a</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>b,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Trial includes participants with proven or unproven acute myocardial infarction.<br/><sup>b</sup>Downgraded one level because of limitations in the trial design.<br/><sup>c</sup>Downgraded two levels because of imprecision (very small sample size and very low number of events with an impact on the precision of effect estimates).<br/><sup>d</sup>Assumed risk was gotten from control group risk (50%). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008553-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008553-sec-0009"></div> <p>See <a href="./appendices#CD008553-sec-0134">Appendix 1</a> for a medical and epidemiological glossary. </p> <section id="CD008553-sec-0010"> <h3 class="title" id="CD008553-sec-0010">Description of the condition</h3> <p>Coronary artery disease is a major public health problem (<a href="./references#CD008553-bbs2-0115" title="GazianoT , ReddyKS , PaccaudF , HortonS , ChaturvediV . Cardiovascular disease. In: JamisonDT , BremanJG , MeashamAR , AlleyneG , ClaesonM , Evans DB et al, editors(s). Disease Control Priorities in Developing Countries. 2nd edition. Washington (DC): IBRD/The World Bank and Oxford University Press, 2006.">Gaziano 2006</a>; <a href="./references#CD008553-bbs2-0143" title="LeysD . Atherothrombosis: a major health burden. Cerebrovascular Diseases2001;11(Suppl 2):1-4. [PMID: 11316915]">Leys 2001</a>; <a href="./references#CD008553-bbs2-0148" title="MansonJE , RidkerPM , GazianoJM , Hennekens. Myocardial Infarction: Epidemiologic Overview. In: MansonJE , RidkerPM , GazianoJM , Hennekens, editors(s). Prevention of Myocardial Infarction. New York: Oxford University Press, 1996:3-31.">Manson 1996</a>; <a href="./references#CD008553-bbs2-0181" title="WatkinsLO . Epidemiology and burden of cardiovascular disease. Clinical Cardiology2004;27(Suppl 3):2-6. [PMID: 15239484]">Watkins 2004</a>) that affects both developed and developing countries (<a href="./references#CD008553-bbs2-0099" title="BraunwaldE . Heart Disease: A Textbook of Cardiovascular Medicine. 6th edition. Philadelphia: W. B. Saunders Company, 2001.">Braunwald 2001</a>; <a href="./references#CD008553-bbs2-0115" title="GazianoT , ReddyKS , PaccaudF , HortonS , ChaturvediV . Cardiovascular disease. In: JamisonDT , BremanJG , MeashamAR , AlleyneG , ClaesonM , Evans DB et al, editors(s). Disease Control Priorities in Developing Countries. 2nd edition. Washington (DC): IBRD/The World Bank and Oxford University Press, 2006.">Gaziano 2006</a>). The burden of coronary artery disease depends on several modifiable and non‐modifiable risk factors and varies by geographical region (<a href="./references#CD008553-bbs2-0088" title="AlterDA , StukelTA , NewmanA . The relationship between physician supply, cardiovascular health service use and cardiac disease burden in Ontario: supply-need mismatch. The Canadian Journal of Cardiology2008;24:187-93. [PMID: 18340387]">Alter 2008</a>; <a href="./references#CD008553-bbs2-0093" title="BaineyKR , JugduttBI . Increased burden of coronary artery disease in South-Asians living in North America. Need for an aggressive management algorithm. Atherosclerosis2009;204:1-10. [PMID: 18980768]">Bainey 2009</a>; <a href="./references#CD008553-bbs2-0116" title="GiannakoulasG , DimopoulosK , EngelR , GoktekinO , KucukdurmazZ , VatankuluMA , et al. Burden of coronary artery disease in adults with congenital heart disease and its relation to congenital and traditional heart risk factors. American Journal of Cardiology2009;103:1445-50. [PMID: 19427444]">Giannakoulas 2009</a>; <a href="./references#CD008553-bbs2-0117" title="GoldenbergI , MossAJ , RyanD , PietrasikG , ZarebaW , McNittS , et al. Cumulative burden of atherosclerotic risk genotypes and the age at onset of a first myocardial infarction: a case-only carriership approach. Annals of Noninvasive Electrocardiology2008;13:287-94. [PMID: 18713330]">Goldenberg 2008</a>; <a href="./references#CD008553-bbs2-0119" title="GorterPM , VisserenFL , AlgraA , van derGraafY , SMART Study Group. The impact of site and extent of clinically evident cardiovascular disease and atherosclerotic burden on new cardiovascular events in patients with Type 2 diabetes. The SMART study. Diabetic Medicine2007;24:1352-60. [PMID: 18042079]">Gorter 2007</a>; <a href="./references#CD008553-bbs2-0120" title="GoyalA , YusufS . The burden of cardiovascular disease in the Indian subcontinent. The Indian Journal of Medical Research2006;124:235-44. [PMID: 17085827]">Goyal 2006</a>; <a href="./references#CD008553-bbs2-0134" title="KerrAJ , McLachlanA , FurnessS , BroadJ , RiddellT , JacksonR , et al. The burden of modifiable cardiovascular risk factors in the coronary care unit by age, ethnicity, and socioeconomic status - PREDICT CVD-9. The New Zealand Medical Journal2008;121:20-33. [PMID: 19079434]">Kerr 2008</a>; <a href="./references#CD008553-bbs2-0146" title="Lloyd-WilliamsF , O'FlahertyM , MwatsamaM , BirtC , IrelandR , CapewellS . Estimating the cardiovascular mortality burden attributable to the European Common Agricultural Policy on dietary saturated fats. Bulletin of the World Health Organization2008;86:535-41. [PMID: 18670665]">Lloyd‐Williams 2008</a>; <a href="./references#CD008553-bbs2-0169" title="SteptoeA , Shamaei-TousiA , GylfeA , HendersonB , BergströmS , MarmotM . Socioeconomic status, pathogen burden and cardiovascular disease risk. Heart2007;93:1567-70. [PMID: 17488763]">Steptoe 2007</a>). The epidemiology of coronary artery disease has been reviewed widely, as have methods of prevention (<a href="./references#CD008553-bbs2-0141" title="LabartheDR . Epidemiology and Prevention of Cardiovascular Disease. Gaithersburg, Maryland: Aspen Publishers, 1998.">Labarthe 1998</a>; <a href="./references#CD008553-bbs2-0148" title="MansonJE , RidkerPM , GazianoJM , Hennekens. Myocardial Infarction: Epidemiologic Overview. In: MansonJE , RidkerPM , GazianoJM , Hennekens, editors(s). Prevention of Myocardial Infarction. New York: Oxford University Press, 1996:3-31.">Manson 1996</a>). </p> <p>Acute coronary syndromes include unstable angina and myocardial infarction with or without ST‐segment elevation (electrocardiogram sector is higher than baseline) (<a href="./references#CD008553-bbs2-0138" title="KolanskyDM . Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden. The American Journal of Managed Care2009;15(Suppl 2):36-41. [PMID: 19355807]">Kolansky 2009</a>). Acute myocardial infarction is the most important clinical entity of acute coronary syndromes; its definition is based on troponin elevation together with ischaemic symptoms, typical electrocardiogram changes or imaging evidence of loss of viable myocardium (<a href="./references#CD008553-bbs2-0177" title="ThygesenK , AlpertJS , JaffeAS , WhiteHD . Diagnostic application of the universal definition of myocardial infarction in the intensive care unit. Current Opinion in Critical Care2008;14:543-8. [PMID: 18787447]">Thygesen 2008</a>). The epidemiology and burden of acute myocardial infarction have been described widely (<a href="./references#CD008553-bbs2-0085" title="al-AdsaniA , MemonA , PenevaA , BaidasG . Clinical epidemiology of acute myocardial infarction in Kuwait. Acta Cardiologica2000;55:17-23. [PMID: 10707754]">al‐Adsani 2000</a>; <a href="./references#CD008553-bbs2-0103" title="Cabadés O'CallaghanA . The REGICOR registry and the epidemiology of myocardial infarction in Spain: forging a path. Revista Española de Cardiología2007;60:342-5. [PMID: 17521541]">Cabadés 2007</a>; <a href="./references#CD008553-bbs2-0145" title="LjungR , HallqvistJ . Accumulation of adverse socioeconomic position over the entire life course and the risk of myocardial infarction among men and women: results from the Stockholm Heart Epidemiology Program (SHEEP). Journal of Epidemiology and Community Health2006;60:1080-4. [PMID: 17108306]">Ljung 2006</a>; <a href="./references#CD008553-bbs2-0148" title="MansonJE , RidkerPM , GazianoJM , Hennekens. Myocardial Infarction: Epidemiologic Overview. In: MansonJE , RidkerPM , GazianoJM , Hennekens, editors(s). Prevention of Myocardial Infarction. New York: Oxford University Press, 1996:3-31.">Manson 1996</a>; <a href="./references#CD008553-bbs2-0156" title="PopC , PopL , DicuD . Epidemiology of acute myocardial infarction in Romanian county hospitals: a population-based study in the Baia Mare district. Romanian Journal of Internal Medicine2004;42:607-23. [PMID: 16366134]">Pop 2004</a>; <a href="./references#CD008553-bbs2-0161" title="RichMW . Epidemiology, clinical features, and prognosis of acute myocardial infarction in the elderly. The American Journal of Geriatric Cardiology2006;15:7-11. [PMID: 16415640]">Rich 2006</a>; <a href="./references#CD008553-bbs2-0162" title="RogerVL . Epidemiology of myocardial infarction. The Medical Clinics of North America2007;91:537-52. [PMID: 17640535]">Roger 2007</a>). </p> <p>The most frequent complications of acute myocardial infarction are cardiac arrhythmias, conduction abnormalities and left ventricular systolic dysfunction (heart failure). Of these, ventricular arrhythmias are associated with the worst prognosis for people with acute myocardial infarction (<a href="./references#CD008553-bbs2-0124" title="HenkelDM , WittBJ , GershBJ , JacobsenSJ , WestonSA , MeverdenRA , et al. Ventricular arrhythmias after acute myocardial infarction: a 20-year community study. American Heart Journal2006;151:806-12. [PMID: 16569539]">Henkel 2006</a>; <a href="./references#CD008553-bbs2-0129" title="HreybeH , SabaS . Location of acute myocardial infarction and associated arrhythmias and outcome. Clinical Cardiology2009;32:274-7. [PMID: 19452487]">Hreybe 2009</a>; <a href="./references#CD008553-bbs2-0135" title="KhairyP , ThibaultB , TalajicM , DubucM , RoyD , GuerraPG , et al. Prognostic significance of ventricular arrhythmias post-myocardial infarction. The Canadian Journal of Cardiology2003;19:1393-404. [PMID: 14631474]">Khairy 2003</a>; <a href="./references#CD008553-bbs2-0154" title="PicciniJP , BergerJS , BrownDL . Early sustained ventricular arrhythmias complicating acute myocardial infarction. The American Journal of Medicine2008;121:797-804. [PMID: 18724970]">Piccini 2008</a>; <a href="./references#CD008553-bbs2-0158" title="RahimiK , WatzlawekS , ThieleH , SecknusMA , HayerizadehBF , NiebauerJ , et al. Incidence, time course, and predictors of early malignant ventricular arrhythmias after non-ST-segment elevation myocardial infarction in patients with early invasive treatment. European Heart Journal2006;27:1706-11. [PMID: 16774984]">Rahimi 2006</a>; <a href="./references#CD008553-bbs2-0167" title="SinglaI , HreybeH , SabaS . Risk of death and recurrent ventricular arrhythmias in survivors of cardiac arrest concurrent with acute myocardial infarction. Indian Pacing and Electrophysiology Journal2008;8:5-13. [PMID: 18270598]">Singla 2008</a>; <a href="./references#CD008553-bbs2-0178" title="VelazquezEJ , FrancisGS , ArmstrongPW , AylwardPE , DiazR , O'ConnorCM , VALIANT registry. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. European Heart Journal2004;25:1911-9. [PMID: 15522470]">Velazquez 2004</a>; <a href="./references#CD008553-bbs2-0182" title="WeirRA , McMurrayJJ . Epidemiology of heart failure and left ventricular dysfunction after acute myocardial infarction. Current Heart Failure Reports2006;3:175-80. [PMID: 17129511]">Weir 2006</a>; <a href="./references#CD008553-bbs2-0185" title="WolfeCL , NibleyC , BhandariA , ChatterjeeK , ScheinmanM . Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation1991;84:1543-51. [PMID: 1914096]">Wolfe 1991</a>). Ventricular arrhythmias after myocardial infarction are associated with high risk of mortality (<a href="./references#CD008553-bbs2-0124" title="HenkelDM , WittBJ , GershBJ , JacobsenSJ , WestonSA , MeverdenRA , et al. Ventricular arrhythmias after acute myocardial infarction: a 20-year community study. American Heart Journal2006;151:806-12. [PMID: 16569539]">Henkel 2006</a>). Between 3% and 10% of uncomplicated acute myocardial infarctions will be affected by ventricular fibrillation (<a href="./references#CD008553-bbs2-0068" title="NonemanJW , RogersJF . Lidocaine prophylaxis in acute myocardial infarction. Medicine1978;57(6):501-15. [PMID: 362121]">Noneman 1978</a>). Mortality is due mainly to sudden death, which is caused by acute ventricular tachyarrhythmia, often triggered by acute coronary events that may occur in persons without known cardiac disease or in association with structural heart disease (<a href="./references#CD008553-bbs2-0095" title="Bayés de LunaA , CoumelP , LeclercqJF . Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. American Heart Journal1989;117:151-9. [PMID: 2911968]">Bayés de Luna 1989</a><a href="./references#CD008553-bbs2-0130" title="HuikuriHV , CastellanosA , MyerburgRJ . Sudden death due to cardiac arrhythmias. New England Journal of Medicine2001;345:1473-82. [PMID: 11794197]">Huikuri 2001</a>). Ventricular fibrillation is the most frequent ventricular tachyarrhythmia, and it usually occurs secondary to ventricular tachyarrhythmia (<a href="./references#CD008553-bbs2-0095" title="Bayés de LunaA , CoumelP , LeclercqJF . Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. American Heart Journal1989;117:151-9. [PMID: 2911968]">Bayés de Luna 1989</a>). The presence of arrhythmias in patients with acute myocardial infarction is associated with a poor prognosis (<a href="./references#CD008553-bbs2-0179" title="VolpiA , CavalliA , SantoroE , TognoniG . Incidence and prognosis of secondary ventricular fibrillation in acute myocardial infarction. Evidence for a protective effect of thrombolytic therapy. GISSI Investigators. Circulation1990;82:1279-88. [PMID: PubMed: 2205418]">Volpi 1990</a>). </p> <p>In the era of thrombolysis, early or late primary ventricular fibrillation in patients with first acute myocardial infarction is an independent predictor of in‐hospital mortality (<a href="./references#CD008553-bbs2-0180" title="VolpiA , CavalliA , SantoroL , NegriE . Incidence and prognosis of early primary ventricular fibrillation in acute myocardial infarction - results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2) database. American Journal of Cardiology1998;82:265-71. [PMID: 9708651]">Volpi 1998</a>). After adjustment for other variables, patients with ventricular arrhythmias continue to be at significantly higher risk of 30‐day or one‐year mortality, both of which are significantly increased in patients with sustained ventricular fibrillation or ventricular tachyarrhythmia after myocardial infarction as compared with patients without these arrhythmias (<a href="./references#CD008553-bbs2-0087" title="Al-KhatibSM , StebbinsAL , CaliffRM , LeeKL , GrangerCB , WhiteHD , et al. Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial. American Heart Journal2003;145:515-21. [PMID: 12660676]">Al‐Khatib 2003</a>). </p> <p>Although different schemes have been used to classify death according to presumed mechanisms, considerable evidence shows that between one‐quarter and one‐half of cardiac deaths are sudden and are due to arrhythmia (<a href="./references#CD008553-bbs2-0108" title="CrystalE , ConnollySJ , DorianP . Prevention and treatment of life-threatening ventricular arrhythmia and sudden death. In: YusufS , CairnsJA , CammAJ , FallenEL , GershBJ , editors(s). Evidence-Based Cardiology. 2nd edition. London: BMJ Books, 2003:577-86.">Crystal 2003</a>; <a href="./references#CD008553-bbs2-0114" title="GardnerMJ , LeatherR , TeoK . Prevention of sudden death from ventricular arrhythmia. Epidemiology. Canadian Journal of Cardiology2000;16:10-2. [PMID: 10887270]">Gardner 2000</a>; <a href="./references#CD008553-bbs2-0118" title="GoldsteinS . The epidemiology of tachyfibrillation in sudden death. Pacing and Clinical Electrophysiology1986;9 (Pt 2):1339-42. [PMID: 2432559]">Goldstein 1986</a>; <a href="./references#CD008553-bbs2-0139" title="KoplanBA , StevensonWG . Ventricular tachycardia and sudden cardiac death. Mayo Clinic Proceedings2009;84:289-97. [PMID: 19252119]">Koplan 2009</a>; <a href="./references#CD008553-bbs2-0140" title="KuchM , JaniszewskiM , MamcarzA , Cudnoch-JedrzejewskaA , DuzniewskiM . Major adverse cardiac event predictors in survivors of myocardial infarction with asymptomatic left ventricular dysfunction or chronic heart failure. Medical Science Monitor2009;15:40-8. [PMID: 19478711]">Kuch 2009</a>; <a href="./references#CD008553-bbs2-0152" title="MyerburgRJ . Epidemiology of ventricular tachycardia/ventricular fibrillation and sudden cardiac death. Pacing and Clinical Electrophysiology1986;9 (Pt 2):1334-8. [PMID: 2432558]">Myerburg 1986</a>; <a href="./references#CD008553-bbs2-0168" title="SolomonSD , ZelenkofskeS , McMurrayJJ , FinnPV , VelazquezE , ErtlG , Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. New England Journal of Medicine2005;352:2581-8. [PMID: 15972864]">Solomon 2005</a>). Thus prevention of sudden death is an important clinical goal (<a href="./references#CD008553-bbs2-0108" title="CrystalE , ConnollySJ , DorianP . Prevention and treatment of life-threatening ventricular arrhythmia and sudden death. In: YusufS , CairnsJA , CammAJ , FallenEL , GershBJ , editors(s). Evidence-Based Cardiology. 2nd edition. London: BMJ Books, 2003:577-86.">Crystal 2003</a>). </p> </section> <section id="CD008553-sec-0011"> <h3 class="title" id="CD008553-sec-0011">Description of the intervention</h3> <p>Since the 1950s, lidocaine, a local anaesthetic, has been used to control ventricular arrhythmias associated with myocardial infarction and cardiac surgery (<a href="./references#CD008553-bbs2-0128" title="HitchcockP , KeownKK . The management of cardiac arrhythmias during cardiac surgery. Southern Medical Journal1959;52:702-6. [PMID: 13659168]">Hitchcock 1959</a>). For decades, lidocaine was used as a standard intravenous antiarrhythmic agent to prevent complications such as ventricular tachyarrhythmia and ventricular fibrillation after myocardial infarction (<a href="./references#CD008553-bbs2-0123" title="HarrisonDC . Arrhythmia prophylaxis after acute myocardial infarction: a decade of controversy. Cardiovascular Drugs and Therapy1989;2:783-9. [PMID: 2488092]">Harrison 1989</a>). The dosage of lidocaine therapy was established by Aps et al., who recommended "a bolus (75‐100 mg) followed by 4 mg/min for 30 minutes, 2 mg/min for two hours, and 1 mg/min thereafter" for patients affected with uncomplicated myocardial infarction (<a href="./references#CD008553-bbs2-0092" title="ApsC , BellJA , JenkinsBS , Poole-WilsonPA , ReynoldsF . Logical approach to lignocaine therapy. British Medical Journal1976;1(6000):13-5. [PMID: 1247716]">Aps 1976</a>). Asystole is associated with lidocaine use (<a href="./references#CD008553-bbs2-0091" title="ApplebaumD , HalperinE . Asystole following a conventional therapeutic dose of lidocaine. The American Journal of Emergency Medicine1986;4:143-5. [PMID: 3511923]">Applebaum 1986</a>; <a href="./references#CD008553-bbs2-0127" title="HillGJ . Lidocaine asystole. JAMA1973;224:401. [PMID: 4739545]">Hill 1973</a>; <a href="./references#CD008553-bbs2-0149" title="Manyari-OrtegaDE , BrennanFJ . Lidocaine-induced cardiac asystole. Chest1978;74:227-9. [PMID: 354896]">Manyari‐Ortega 1978</a>; <a href="./references#CD008553-bbs2-0163" title="SadikotR , PatelN , SmithE , BissettJ , TalleyJD . Lidocaine-induced cardiac asystole. The Journal of the Arkansas Medical Society1997;93:410-1. [PMID: 9009551]">Sadikot 1997</a>), although evidence shows that use of lidocaine may not be associated with increased mortality rates (<a href="./references#CD008553-bbs2-0086" title="AlexanderJH , GrangerCB , SadowskiZ , AylwardPE , WhiteHD , ThompsonTD , et al. Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb Investigators. American Heart Journal1999;137:799-805. [PMID: 10220627]">Alexander 1999</a>). Lidocaine does not interact with the autonomic nervous system (<a href="./references#CD008553-bbs2-0089" title="AndersonJL . Current understanding of lidocaine as an antiarrhythmic agent: a review. Clinical Therapeutics1984;6:125-41. [PMID: 6200230]">Anderson 1984</a>) but causes toxicity of the central nervous system (seizures, tremor, dysarthria, altered levels of consciousness and nystagmus), some of which is associated with high blood levels of lidocaine (<a href="./references#CD008553-bbs2-0102" title="BruntonLL , ParkerKL , BlumenthalDK , BuxtonILO . Goodman &amp; Gilman’s Manual of Pharmacology and Therapeutics. 11th edition. New York: The McGraw-Hill Companies, Inc, 2008. [DOI: 10.1036/0071443436]">Brunton 2008</a>). Lidocaine is also known as lignocaine, but in this review, we use the name lidocaine. </p> <p>Lidocaine is not used much anymore in high‐income countries, but it continues to be used in many low‐income countries (<a href="./references#CD008553-bbs2-0160" title="Reyes CaorsiW . Reflexiones sobre las guías clínicas. A propósito del caso de la lidocaína. Revista Uruguaya de Cardiología2006;21(3):267-9.">Reyes Caorsi 2006</a>), and it is recommended in guidelines on management of patients with myocardial infarction (<a href="./references#CD008553-bbs2-0090" title="Sociedad Uruguaya de Cardiología. Consenso uruguayo de manejo del infarto agudo de miocardio con elevación del segmento ST. Revista Uruguaya de Cardiología2006;21(1):48-95.">Anonimous 2006</a>) and patients with ventricular arrhythmias and the prevention of sudden cardiac death (<a href="./references#CD008553-bbs2-0188" title="ZipesDP , CammAJ , BorggrefeM , BuxtonAE , ChaitmanB , FromerM , American College of Cardiology, American Heart Association Task Force, European Society of Cardiology Committee for Practice Guidelines. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death?executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). European Heart Journal2006;27:2099-140. [PMID: 16923744]">Zipes 2006</a>). Furthermore, many published studies were conducted to explore this issue (<a href="./references#CD008553-bbs2-0155" title="PicciniJP , SchultePJ , PieperKS , MehtaRH , WhiteHD , Van de WerfF , et al. Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. Critical Care Medicine2011;39(1):78-83. [PMID: 20959785]">Piccini 2011</a>; <a href="./references#CD008553-bbs2-0171" title="TagawaT , NakaoK , NakamuraA , YamasakiN , TsuchiyaT , NagayasuT . [How to treat arrhythmias in thoracic surgery]. Kyobu Geka. The Japanese Journal of Thoracic Surgery2008;61(8 Suppl):715-20. [PMID: 20715416]">Tagawa 2008</a>; <a href="./references#CD008553-bbs2-0172" title="TakayaT , OkamotoM , YodoiK , HataK , KijimaY , NakajimaH , et al. Torsades de Pointes with QT prolongation related to donepezil use. Journal of Cardiology2009;54(3):507-11. [PMID: 19944332]">Takaya 2009</a>). </p> </section> <section id="CD008553-sec-0012"> <h3 class="title" id="CD008553-sec-0012">How the intervention might work</h3> <p>Lidocaine is an antiarrhythmic drug of type IB Vaugham‐Williams classification that works by inhibiting rapid sodium channels (a characteristic effect of this class of drugs) (<a href="./references#CD008553-bbs2-0102" title="BruntonLL , ParkerKL , BlumenthalDK , BuxtonILO . Goodman &amp; Gilman’s Manual of Pharmacology and Therapeutics. 11th edition. New York: The McGraw-Hill Companies, Inc, 2008. [DOI: 10.1036/0071443436]">Brunton 2008</a>; <a href="./references#CD008553-bbs2-0107" title="CollinsworthKA , KalmanSM , HarrisonDC . The clinical pharmacology of lidocaine as an antiarrhythymic drug. Circulation1974;50:1217-30. [PMID: 4609637]">Collinsworth 1974</a>). Details of the electrophysiological effects of lidocaine on the heart are presented by <a href="./references#CD008553-bbs2-0107" title="CollinsworthKA , KalmanSM , HarrisonDC . The clinical pharmacology of lidocaine as an antiarrhythymic drug. Circulation1974;50:1217-30. [PMID: 4609637]">Collinsworth 1974</a>. These effects, which were observed in animal studies, briefly include the following: decreased automaticity of pacemaker tissue and sinoatrial node, increased ventricular fibrillation threshold and increased atrioventricular node conduction time according to dosage (<a href="./references#CD008553-bbs2-0107" title="CollinsworthKA , KalmanSM , HarrisonDC . The clinical pharmacology of lidocaine as an antiarrhythymic drug. Circulation1974;50:1217-30. [PMID: 4609637]">Collinsworth 1974</a>). The antiarrhythmic mechanism and efficacy of lidocaine are related to extracellular potassium concentration (<a href="./references#CD008553-bbs2-0107" title="CollinsworthKA , KalmanSM , HarrisonDC . The clinical pharmacology of lidocaine as an antiarrhythymic drug. Circulation1974;50:1217-30. [PMID: 4609637]">Collinsworth 1974</a>). Lidocaine may affect sinus node conduction or function (<a href="./references#CD008553-bbs2-0137" title="KleinHO , JutrinI , KaplinskyE . Cerebral and cardiac toxicity of a small dose of lignocaine. British Medical Journal1975;37:775-8. [PMID: 808233]">Klein 1975</a>; <a href="./references#CD008553-bbs2-0144" title="LippestadCT , ForfangK . Production of sinus arrest by lignocaine. British Medical Journal1971;1(5748):537. [PMID: 5547575]">Lippestad 1971</a>). </p> </section> <section id="CD008553-sec-0013"> <h3 class="title" id="CD008553-sec-0013">Why it is important to do this review</h3> <p>Numerous randomised controlled trials were conducted to assess the clinical effectiveness and safety of lidocaine in preventing ventricular tachyarrhythmia and ventricular fibrillation among patients with myocardial infarction. In general, lidocaine used to reduce rates of ventricular tachyarrhythmia and ventricular fibrillation is beneficial but is associated with adverse effects (hypotension, neurological complications and other problems) that might be related to dosage. However, five systematic reviews used meta‐analysis to verify no evidence of benefit in reducing the mortality rate (<a href="./references#CD008553-bbs2-0048" title="DeSilvaRA , HennekensCH , LownB , CasscellsW . Lignocaine prophylaxis in acute myocardial infarction: an evaluation of randomised trials. Lancet1981;2(8251):855-8. [PMID: 6116964]">De Silva 1981</a>; <a href="./references#CD008553-bbs2-0058" title="HineLK , LairdN , HewittP , ChalmersTC . Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Archives of Internal Medicine1989;149:2694-8. [PMID: 2688587]">Hine 1989</a>; <a href="./references#CD008553-bbs2-0064" title="MacMahonS , CollinsR , PetoR , KosterRW , YusufS . Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA1988;260:1910-6. [PMID: 3047448]">MacMahon 1988</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0079" title="TeoKK , YusufS , FurbergCD . Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA1993;270:1589-95. [PMID: 8371471]">Teo 1993</a>). These reviews, published between 1981 and 1999, are now more than 10 years out of date. An update of the evidence is required for the following reasons. </p> <p> <ul id="CD008553-list-0001"> <li> <p>Reviews consistently reported high clinical heterogeneity between trials but did not report tools used to assess risk of bias (<a href="./references#CD008553-bbs2-0048" title="DeSilvaRA , HennekensCH , LownB , CasscellsW . Lignocaine prophylaxis in acute myocardial infarction: an evaluation of randomised trials. Lancet1981;2(8251):855-8. [PMID: 6116964]">De Silva 1981</a>; <a href="./references#CD008553-bbs2-0058" title="HineLK , LairdN , HewittP , ChalmersTC . Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Archives of Internal Medicine1989;149:2694-8. [PMID: 2688587]">Hine 1989</a>; <a href="./references#CD008553-bbs2-0064" title="MacMahonS , CollinsR , PetoR , KosterRW , YusufS . Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA1988;260:1910-6. [PMID: 3047448]">MacMahon 1988</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0079" title="TeoKK , YusufS , FurbergCD . Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA1993;270:1589-95. [PMID: 8371471]">Teo 1993</a>). </p> </li> <li> <p>Currently, the I<sup>2</sup> statistic is the favoured method for assessing statistical heterogeneity (<a href="./references#CD008553-bbs2-0125" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [PMID: 12958120]">Higgins 2003</a>), although previously the Chi<sup>2</sup> test was applied (<a href="./references#CD008553-bbs2-0048" title="DeSilvaRA , HennekensCH , LownB , CasscellsW . Lignocaine prophylaxis in acute myocardial infarction: an evaluation of randomised trials. Lancet1981;2(8251):855-8. [PMID: 6116964]">De Silva 1981</a>; <a href="./references#CD008553-bbs2-0058" title="HineLK , LairdN , HewittP , ChalmersTC . Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Archives of Internal Medicine1989;149:2694-8. [PMID: 2688587]">Hine 1989</a>; <a href="./references#CD008553-bbs2-0064" title="MacMahonS , CollinsR , PetoR , KosterRW , YusufS . Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA1988;260:1910-6. [PMID: 3047448]">MacMahon 1988</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0079" title="TeoKK , YusufS , FurbergCD . Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA1993;270:1589-95. [PMID: 8371471]">Teo 1993</a>). </p> </li> <li> <p>Different summary measures such as Peto odds ratios (<a href="./references#CD008553-bbs2-0064" title="MacMahonS , CollinsR , PetoR , KosterRW , YusufS . Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA1988;260:1910-6. [PMID: 3047448]">MacMahon 1988</a>), odds ratios (<a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>) and risk differences (<a href="./references#CD008553-bbs2-0058" title="HineLK , LairdN , HewittP , ChalmersTC . Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Archives of Internal Medicine1989;149:2694-8. [PMID: 2688587]">Hine 1989</a>) showed no significant differences between non‐surrogate clinical outcomes such as death. Use of risk ratio as a summary statistic for meta‐analysis with binary data may have revealed significant differences in mortality (<a href="./references#CD008553-bbs2-0110" title="DeeksJJ . Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine2002;21:1575–1600. [DOI: 10.1002/sim.1188] [PMID: 12111921]">Deeks 2002</a>). Only <a href="./references#CD008553-bbs2-0048" title="DeSilvaRA , HennekensCH , LownB , CasscellsW . Lignocaine prophylaxis in acute myocardial infarction: an evaluation of randomised trials. Lancet1981;2(8251):855-8. [PMID: 6116964]">De Silva 1981</a> used risk ratios, but the endpoint was incidence of ventricular fibrillation. </p> </li> <li> <p>Systematic reviews did not conduct sensitivity analyses (trials with low risk of bias vs trials with high risk of bias). </p> </li> <li> <p>Overall, the main outcome was a surrogate marker: ventricular extrasystole/ventricular fibrillation. Although choosing a surrogate marker is not strictly inappropriate, this is not currently recommended (<a href="./references#CD008553-bbs2-0165" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Interpreting results and drawing conclusions. In: HigginsJPT , GreenS , editors(s). Cochrane Handbook for Systematic Reviews of Interventions. West Sussex, England: Wiley-Blackwell, 2009:359-87.">Schünemann 2009</a>). </p> </li> <li> <p>We did not include trials comparing lidocaine versus any other antiarrhythmic drug. These trials should be included because indirectness is a reason for reducing confidence in the evidence (<a href="./references#CD008553-bbs2-0121" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , and GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336:924-6. [PMID: 18436948]">Guyatt 2008</a>). </p> </li> <li> <p><a href="./references#CD008553-bbs2-0058" title="HineLK , LairdN , HewittP , ChalmersTC . Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Archives of Internal Medicine1989;149:2694-8. [PMID: 2688587]">Hine 1989</a> excluded trials that were not published in the English language. This decision may have led to oversampling of statistically significant studies (i.e. language bias) (<a href="./references#CD008553-bbs2-0097" title="BorensteinM , HedgesLV , HigginsJPT , RothsteinHR . Publication Bias. In: BorensteinM , HedgesLV , HigginsJPT , RothsteinHR , editors(s). Introduction to Meta-Analysis. First edition. West Sussex, United Kingdom: Wiley, 2009:277-92.">Borenstein 2009</a>). </p> </li> <li> <p><a href="./references#CD008553-bbs2-0064" title="MacMahonS , CollinsR , PetoR , KosterRW , YusufS . Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA1988;260:1910-6. [PMID: 3047448]">MacMahon 1988</a> and <a href="./references#CD008553-bbs2-0079" title="TeoKK , YusufS , FurbergCD . Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA1993;270:1589-95. [PMID: 8371471]">Teo 1993</a> did not include trials of cross‐over design. <a href="./references#CD008553-bbs2-0048" title="DeSilvaRA , HennekensCH , LownB , CasscellsW . Lignocaine prophylaxis in acute myocardial infarction: an evaluation of randomised trials. Lancet1981;2(8251):855-8. [PMID: 6116964]">De Silva 1981</a>, <a href="./references#CD008553-bbs2-0058" title="HineLK , LairdN , HewittP , ChalmersTC . Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Archives of Internal Medicine1989;149:2694-8. [PMID: 2688587]">Hine 1989</a> and <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a> included cross‐over trials; however, they did not report the methods used for analysis. </p> </li> </ul> </p> <p>In addition, lidocaine is used in low‐income countries (<a href="./references#CD008553-bbs2-0090" title="Sociedad Uruguaya de Cardiología. Consenso uruguayo de manejo del infarto agudo de miocardio con elevación del segmento ST. Revista Uruguaya de Cardiología2006;21(1):48-95.">Anonimous 2006</a>; <a href="./references#CD008553-bbs2-0160" title="Reyes CaorsiW . Reflexiones sobre las guías clínicas. A propósito del caso de la lidocaína. Revista Uruguaya de Cardiología2006;21(3):267-9.">Reyes Caorsi 2006</a>). </p> <p>In conclusion, the evidence is out of date and considerable uncertainty remains about the effects of prophylactic lidocaine use in all‐cause mortality, in particular, in patients with suspected acute myocardial infarction. This Cochrane review seeks to update current knowledge and resolve uncertainties. The research question is this: "What is the clinical effectiveness and safety of prophylactic lidocaine for preventing death in people with acute myocardial infarction?" </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008553-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008553-sec-0014"></div> <p>To determine the clinical effectiveness and safety of prophylactic lidocaine in preventing death among people with acute myocardial infarction. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008553-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008553-sec-0015"></div> <section id="CD008553-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008553-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials irrespective of design (parallel and cross‐over) or publication status (unpublished or published as an article, an abstract or a letter). We applied no language, country or sample size limitations and included trials conducted in a hospital or community setting, or both. We also applied no limits with respect to period of follow‐up, pre‐hospital or in‐hospital setting, lidocaine use or bolus with or without infusion. </p> </section> <section id="CD008553-sec-0018"> <h4 class="title">Types of participants</h4> <p>Adults (≥ 18 years) with acute myocardial infarction. We applied no restrictions by definition of acute myocardial infarction. </p> </section> <section id="CD008553-sec-0019"> <h4 class="title">Types of interventions</h4> <p>As acute myocardial infarction requires different medical and non‐medical treatments (i.e. primary intervention), lidocaine is considered a complementary intervention. Thus, for the purpose of this review, eligible trials compared the same primary interventions with and without lidocaine. </p> <section id="CD008553-sec-0020"> <h5 class="title">Intervention</h5> <p>Lidocaine. We applied no restrictions by route of administration (intravenous, intra‐muscular or both) or dose. </p> </section> <section id="CD008553-sec-0021"> <h5 class="title">Comparison</h5> <p>Placebo. Standard care or antiarrhythmic drug alone or in any combination.</p> </section> </section> <section id="CD008553-sec-0022"> <h4 class="title">Types of outcome measures</h4> <section id="CD008553-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008553-list-0002"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Cardiac mortality.</p> </li> <li> <p>Overall survival at 30 days after myocardial infarction (MI), which was defined as the proportion of survivors in a group. The proportion of persons in a specified group alive at the beginning of the time interval who survive to the end of the interval (<a href="./references#CD008553-bbs2-0157" title="Porta M (Editor). A Dictionary of Epidemiology. Fifth edition. New York: Oxford University Press, 2008.">Porta 2008</a>). </p> </li> </ul> </p> </section> <section id="CD008553-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008553-list-0003"> <li> <p>Ventricular fibrillation: assessed by counting how many participants developed this arrhythmia. </p> </li> <li> <p>Adverse events: numbers and types of adverse events defined as any untoward medical occurrences not necessarily having a causal relationship with treatment. We reported separately on adverse events that led to treatment discontinuation and those that did not lead to treatment discontinuation. We defined a serious adverse event according to the International Conference on Harmonisation (ICH) Guidelines (<a href="./references#CD008553-bbs2-0131" title="International Conference on Harmonisation Expert Working Group. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice 1997 CFR &amp; ICH Guidelines. PA 19063-2043, USA: Barnett International/PAREXEL, 1997.">ICH‐GCP 1997</a>) as any event that at any dose resulted in death, was life‐threatening, required in‐patient hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability or was a congenital anomaly/birth defect, and any important medical event that may have jeopardised the patient or required intervention to prevent it. We considered all other adverse events as non‐serious. </p> </li> </ul> </p> </section> </section> </section> <section id="CD008553-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008553-sec-0026"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases to find reports of relevant randomised controlled trials. </p> <p> <ul id="CD008553-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (2015, Issue 3 of 12).</p> </li> <li> <p>MEDLINE (Ovid, 1946 to Week 1 April 2015).</p> </li> <li> <p>EMBASE Classic and EMBASE (Ovid, 1947 to 10 April 2015).</p> </li> <li> <p>Latin American Caribbean Health Sciences Literature (LILACS) (13 April 2015).</p> </li> <li> <p>Web of Science (Thomson Reuters, 1970 to 13 April 2015).</p> </li> </ul> </p> <p>We used Cochrane sensitive‐maximising RCT filters to search MEDLINE and EMBASE (<a href="./references#CD008553-bbs2-0142" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.">Lefebvre 2011</a>). <a href="./appendices#CD008553-sec-0135">Appendix 2</a> shows the search strategies. </p> </section> <section id="CD008553-sec-0027"> <h4 class="title">Searching other resources</h4> <p>We searched the Clinical Trials Search Portal of the World Health Organization (<a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a>) for ongoing and unpublished trials. </p> <p>We also searched the following websites.</p> <p> <ul id="CD008553-list-0005"> <li> <p><a href="http://www.excelenciaclinica.es" target="_blank">http://www.excelenciaclinica.es</a>. </p> </li> <li> <p>Scirus (<a href="http://www.scirus.com" target="_blank">www.scirus.com</a>). </p> </li> <li> <p><a href="http://www.evidence.nhs.uk/" target="_blank">http://www.evidence.nhs.uk/</a>. </p> </li> </ul> </p> <p>We checked the reference lists of all trials identified by the above methods, and we imposed no language restrictions. </p> </section> </section> <section id="CD008553-sec-0028"> <h3 class="title" id="CD008553-sec-0028">Data collection and analysis</h3> <p>We summarised data using standard methodologies of The Cochrane Collaboration (<a href="./references#CD008553-bbs2-0126" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org2011.">Higgins 2011</a>). </p> <section id="CD008553-sec-0029"> <h4 class="title">Selection of studies</h4> <p>Two review authors (AM‐C, DS‐R) independently assessed each reference identified by the search against the inclusion criteria. Through discussion, we resolved disagreements that arose. We retrieved in full references that appeared to meet the inclusion criteria for further independent assessment by two review authors. </p> </section> <section id="CD008553-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>One review author (AM‐C) independently extracted data from included trials using a spreadsheet data extraction form; the other review author (DS‐R) checked entered data for accuracy. We extracted the following data: eligibility criteria, demographics (age, sex, country), characteristics of included patients (treatment setting, lidocaine use (dosage, administration route)), types of control comparison treatments and outcomes. We discussed discrepancies between review authors to reach final consensus and used a pre‐formed sheet (<a href="./references#CD008553-bbs2-0187" title="Sheet to enter data for performing a Cochrane review. ZavalaD , MartíA , Peña-MartíG , ComunianG . Valencia: Universidad de Carabobo, 2006. http://www.cochrane.fcs.uc.edu.ve/hrs/.">Zavala 2006</a>). </p> </section> <section id="CD008553-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (AM‐C, DS‐R, VA) independently assessed the risk of bias of each included trial using the domain‐based evaluation as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions,</i> Section 5.1.0 (<a href="./references#CD008553-bbs2-0126" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org2011.">Higgins 2011</a>; <a href="./references#CD008553-bbs2-0147" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub2]">Lundh 2012</a>; <a href="./references#CD008553-bbs2-0164" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429-38. [PMID: 22945832]">Savović 2012</a>; <a href="./references#CD008553-bbs2-0186" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ2008;336(7644):601-5. [PMID: 18316340]">Wood 2008</a>). Two review authors (of AM‐C, DS‐R, VA) checked the assessment. Review authors discussed discrepancies and achieved consensus. </p> <p>The definition of each classification is given below.</p> <section id="CD008553-sec-0032"> <h5 class="title">Generation of allocation sequence</h5> <p> <ul id="CD008553-list-0006"> <li> <p>Low risk of bias: if the allocation sequence was generated by a computer or a random number table, drawing of lots, tossing of a coin, shuffling of cards or throwing dice. </p> </li> <li> <p>Unclear risk of bias: if the trial was described as randomised but the method used for allocation sequence generation was not described. </p> </li> <li> <p>High risk of bias: if a system involving dates, names or admittance numbers was used for allocation of participants. These studies are known as quasi‐randomised and were excluded from the review when beneficial effects were assessed. </p> </li> </ul> </p> </section> <section id="CD008553-sec-0033"> <h5 class="title">Allocation concealment</h5> <p> <ul id="CD008553-list-0007"> <li> <p>Low risk of bias: if allocation of participants involved a central independent unit, an on‐site locked computer, identical‐appearing numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed envelopes. </p> </li> <li> <p>Unclear risk of bias: if the trial was described as randomised but the method used to conceal the allocation was not described. </p> </li> <li> <p>High risk of bias: if the allocation sequence was known to investigators who assigned participants, or if the study was quasi‐randomised. The latter studies were excluded from the review when beneficial effects were assessed. </p> </li> </ul> </p> </section> <section id="CD008553-sec-0034"> <h5 class="title">Blinding (or masking)</h5> <p>We assessed each trial (as low, unclear or high risk) with regard to the following levels of blinding. </p> <p> <ul id="CD008553-list-0008"> <li> <p>Blinding of clinician (person delivering treatment) to treatment allocation.</p> </li> <li> <p>Blinding of participant to treatment allocation.</p> </li> <li> <p>Blinding of outcome assessor to treatment allocation.</p> </li> </ul> </p> </section> <section id="CD008553-sec-0035"> <h5 class="title">Incomplete outcome data</h5> <p> <ul id="CD008553-list-0009"> <li> <p>Low risk of bias: if numbers of and reasons for dropouts and withdrawals in all intervention groups were described, or if it was specified that no dropouts or withdrawals occurred. </p> </li> <li> <p>Unclear risk of bias: if the report gave the impression that no dropouts or withdrawals occurred, but this was not specifically stated. </p> </li> <li> <p>High risk of bias: if numbers of or reasons for dropouts and withdrawals were not described. </p> </li> </ul> </p> <p>We further examined the percentage of dropouts overall in each trial and per randomisation arm, and we evaluated from published information whether intention‐to‐treat analysis was performed or could be performed. </p> </section> <section id="CD008553-sec-0036"> <h5 class="title">Selective outcome reporting</h5> <p> <ul id="CD008553-list-0010"> <li> <p>Low risk of bias: if pre‐defined or clinically relevant and reasonably expected outcomes were reported on. </p> </li> <li> <p>Unclear risk of bias: if not all pre‐defined or clinically relevant and reasonably expected outcomes were reported on or were not reported on fully, or if it was unclear whether data on these outcomes were recorded. </p> </li> <li> <p>High risk of bias: if one or more clinically relevant and reasonably expected outcomes were not reported on; data on these outcomes were likely to have been recorded. </p> </li> </ul> </p> </section> <section id="CD008553-sec-0037"> <h5 class="title">Other bias</h5> <p> <ul id="CD008553-list-0011"> <li> <p>Low risk of bias: if the trial appeared to be free of other components that could put it at risk of bias. </p> </li> <li> <p>Unclear risk of bias: if the trial may or may not be free of other components that could put it at risk of bias. </p> </li> <li> <p>High risk of bias: if other factors in the trial could put it at risk of bias.</p> </li> </ul> </p> </section> <section id="CD008553-sec-0038"> <h5 class="title">Overall risk of bias</h5> <p>We made explicit judgements about whether randomised controlled trials were at high risk of bias, according to the criteria given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008553-bbs2-0126" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org2011.">Higgins 2011</a>). We assessed risk of bias as high if any of the above domains were unclear or had high risk of bias. </p> <p>Trials that showed adequate generation of allocation sequence, allocation concealment, blinding and handling of incomplete outcome data, and no selective outcome reporting, and that were without other risks of bias were considered trials with low risk of bias. We explored the impact of the risk of bias by undertaking subgroup analyses. </p> <p>One review author (AM‐C) entered the information using <a href="./references#CD008553-bbs2-0159" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2011.">RevMan 2011</a> software. Two review authors (DS‐R, VA) checked the entered data. </p> </section> </section> <section id="CD008553-sec-0039"> <h4 class="title">Measures of treatment effect</h4> <p>For each binary outcome such as all‐cause mortality, cardiac mortality, ventricular fibrillation, adverse events and adverse drug reactions, we calculated the risk ratio (RR) with 95% confidence interval (CI). </p> <p>We would have attempted to assess time‐to‐event outcomes and overall survival at 30 days by using the hazard ratio (HR) with 95% CI if included trials had reported this outcome. This will be done in future updates if trials report this outcome. </p> <p>We planned to include cross‐over trials, but none were available. If cross‐over trials become available in the future, we will use the inverse variance method to pool data from these trials and will apply the Becker‐Balagtas marginal estimated odds ratio to summarise ventricular fibrillation (<a href="./references#CD008553-bbs2-0112" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31:140-9. [PMID: 11914310]">Elbourne 2002</a>). </p> </section> <section id="CD008553-sec-0040"> <h4 class="title">Dealing with missing data</h4> <p>We assessed the percentage of dropouts for each included trial and for each intervention group, and we evaluated whether an intention‐to‐treat (ITT) analysis had been performed or could have been performed from available published information. </p> <p>To undertake an ITT analysis, we sought data from trial authors on numbers of participants in treatment groups, irrespective of compliance and whether or not participants were later thought to be ineligible or otherwise excluded from treatment or lost to follow‐up. If this information was not forthcoming, we undertook a complete participant analysis, knowing that it may be biased. </p> </section> <section id="CD008553-sec-0041"> <h4 class="title">Assessment of heterogeneity</h4> <p>We quantified statistical heterogeneity using the I<sup>2</sup> statistic, which describes the percentage of total variation across trials due to heterogeneity rather than to sampling error (<a href="./references#CD008553-bbs2-0125" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [PMID: 12958120]">Higgins 2003</a>). We considered statistical heterogeneity to be present if I<sup>2</sup> was greater than 50% (<a href="./references#CD008553-bbs2-0126" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org2011.">Higgins 2011</a>). </p> </section> <section id="CD008553-sec-0042"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed publication bias and other bias by using a funnel plot (<a href="./references#CD008553-bbs2-0170" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ2011;343:d4002. [PMID: 21784880]">Sterne 2011</a>). We assessed publication bias for all‐cause mortality and ventricular fibrillation using Comprehensive Meta‐Analysis software (<a href="./references#CD008553-bbs2-0106" title="Comprehensive Meta-analysis. BorensteinM , HedgesL , HigginsJ , RothsteinH . Englewood NJ, USA: Biostat, 2005.">CMA 2005</a>). </p> </section> <section id="CD008553-sec-0043"> <h4 class="title">Data synthesis</h4> <p>We used random‐effects methods to determine pool estimates and 95% confidence intervals.</p> <section id="CD008553-sec-0044"> <h5 class="title">Trial sequential analysis</h5> <p>Meta‐analysis of cumulative data may run the risk of random errors ('play of chance') due to sparse data and repetitive analyses of cumulative data (<a href="./references#CD008553-bbs2-0100" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61:763-9.2008;61(8):763-9. [PMID: 18411040]">Brok 2008</a>; <a href="./references#CD008553-bbs2-0101" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta-analyses may be inconclusive - Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology2009;38(1):287-98. [PMID: 18824466]">Brok 2009</a>; <a href="./references#CD008553-bbs2-0173" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses. International Journal of Epidemiology2009;38(1):276-86. [PMID: 18824467]">Thorlund 2009</a>; <a href="./references#CD008553-bbs2-0174" title="ThorlundK , AnemaA , MillsE . Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology2010;2:57-66. [PMID: 20865104 ]">Thorlund 2010</a>; <a href="./references#CD008553-bbs2-0175" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis - a simulation study. PLoS One2011;6(10):e25491. [PMID: 22028777]">Thorlund 2011a</a>; <a href="./references#CD008553-bbs2-0183" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75. [PMID: 18083463]">Wetterslev 2008</a>; <a href="./references#CD008553-bbs2-0184" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in a random-effects meta-analysis. BMC Medical Research Methodology2009;9:86. [PMID: 20042080]">Wetterslev 2009</a>). To assess risks of random error in our cumulative meta‐analyses, we conducted diversity‐adjusted trial sequential analyses based on the proportion with the outcome in the control group; an a priori set relative risk reduction of 20%; alpha of 5% and beta of 20%; and squared diversity in the meta‐analysis (<a href="./references#CD008553-bbs2-0109" title="TSA - Trial Sequential Analysis. Copenhagen Trial Unit. http://ctu.dk/tsa/ (accessed 29 September 2011), 2011.">CTU 2011</a>; <a href="./references#CD008553-bbs2-0173" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses. International Journal of Epidemiology2009;38(1):276-86. [PMID: 18824467]">Thorlund 2009</a>; <a href="./references#CD008553-bbs2-0176" title="User Manual for Trial Sequential Analysis (TSA). ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . http://ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 30 April 2012), 2011.">Thorlund 2011b</a>). </p> </section> </section> <section id="CD008553-sec-0045"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Despite statistical heterogeneity less than 50% for primary outcomes, we conducted the following pre‐planned subgroup analyses. </p> <p> <ul id="CD008553-list-0012"> <li> <p>Route of administration of lidocaine (intravenous vs intramuscular).</p> </li> <li> <p>Pre‐hospital setting lidocaine use versus In‐hospital setting lidocaine use.</p> </li> <li> <p>Doses of lidocaine.</p> </li> </ul> </p> <p>We were not able to conduct subgroup analysis by age and gender; congestive heart failure, cardiogenic shock or bradycardia/atrioventricular block before randomisation. </p> <p>We performed subgroup analyses for primary outcomes.</p> <p>We had planned to conduct meta‐regression analyses. However, we did not use this approach because we found low statistical heterogeneity in meta‐analyses for primary outcomes. </p> <p>Furthermore, we conducted the following post hoc subgroup analyses (undertaken after results of the studies had been compiled). </p> <p> <ul id="CD008553-list-0013"> <li> <p>Acute myocardial infarction patients only.</p> </li> <li> <p>Trials without suspicion of industry bias versus trials with suspicion of industry bias. </p> </li> </ul> </p> </section> <section id="CD008553-sec-0046"> <h4 class="title">Sensitivity analysis</h4> <p>We would have used the following procedures (and will apply these in future updates, if possible) in conducting sensitivity analysis to compare trials having 'low risk of bias' versus trials having 'high risk of bias' (<a href="./references#CD008553-bbs2-0126" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org2011.">Higgins 2011</a>). As all included trials were rated as having high risk of bias, we were not able to conduct sensitivity analysis as planned. </p> <p>We conducted a sensitivity analysis in the following way.</p> <p> <ul id="CD008553-list-0014"> <li> <p>Repeating the analysis while taking attrition bias into consideration (best‐worst case scenario and worst‐best case scenario). </p> </li> </ul> </p> <section id="CD008553-sec-0047"> <h5 class="title">'Summary of findings' tables</h5> <p>We used the principles of the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) system (<a href="./references#CD008553-bbs2-0121" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , and GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336:924-6. [PMID: 18436948]">Guyatt 2008</a>; <a href="./references#CD008553-bbs2-0122" title='GuyattG , OxmanAD , KunzR , VistGE , Falck‐YtterY , SchunemannHJ . What is "quality of evidence" and why is it important to clinicians. BMJ2008;336:995-8. [PMID: 18456631]'>Guyatt 2008b</a>) in our review to assess the quality of the body of evidence associated with specific outcomes (all‐cause mortality, cardiac mortality, overall survival at 30 days after myocardial infarction, ventricular fibrillation, adverse events) and constructed a 'Summary of findings (SoF)' table using GRADE software. The GRADE approach is used to appraise the quality of a body of evidence according to the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. Assessment of the quality of a body of evidence considers within‐study risk of bias (methodological quality), directness of the evidence, heterogeneity of the data, precision of effect estimates and risk of publication bias. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008553-sec-0048" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008553-sec-0048"></div> <section id="CD008553-sec-0049"> <h3 class="title">Description of studies</h3> <section id="CD008553-sec-0050"> <h4 class="title">Results of the search</h4> <p>We identified 1230 references by using our search strategies. Thirty‐seven trials (45 references) involving 11,948 participants met our inclusion criteria (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a>; <a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>; <a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>; <a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>; <a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>). See <a href="#CD008553-fig-0001">Figure 1</a> for details. </p> <div class="figure" id="CD008553-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008553-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD008553-sec-0051"> <h4 class="title">Included studies</h4> <p>Tables of <a href="./references#CD008553-sec-0150" title="">Characteristics of included studies</a> show detailed descriptions of the studies. </p> <section id="CD008553-sec-0052"> <h5 class="title">Lidocaine and populations assessed in included trials</h5> <p>The 37 randomised controlled trials reported comparisons between lidocaine and several different control interventions. </p> <p>Twenty‐four trials compared lidocaine versus placebo (without or with co‐interventions). Comparisons included saline solution (<a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>) and 5% dextrose solution (<a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>). Characteristics of controls were not sufficiently described in <a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>; and <a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>. </p> <p>Thirteen trials compared lidocaine versus another antiarrhythmic drug (with or without co‐interventions). Comparisons included disopyramide (<a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>; <a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>), amiodarone (<a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>), dimethylammonium chloride (<a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>), pirmenol (<a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a>), mexiletine (<a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>), aprindine (<a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>), propafenone (<a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>) and tocainide (<a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>). </p> <p>Co‐interventions used most often in experimental and control groups were lidocaine (<a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>), oxygen (<a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>), hydromorphone or pentazocine (<a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>), defibrillation (<a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>), electroversion (<a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>), mexiletine (<a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>), pacemaker (<a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>), subcutaneous heparin (<a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>), nitroglycerin (<a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>), morphine sulphate (<a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>), furosemide (<a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>), intracoronary thrombolysis (<a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>), digitalis (<a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>) and atropine (<a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>). Twenty trials did not report use of a co‐intervention (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>; <a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>; <a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>). </p> <p>Twenty‐six trials used intravenous lidocaine (<a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a>; <a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a>; <a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>; <a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>, six used intramuscular lidocaine (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>) and three used intravenous and intramuscular lidocaine (<a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>). Two studies used intravenous and oral routes (<a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>). </p> <p>The follow‐up period varied between trials: one hour (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>), two hours (<a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>), three hours (<a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>), 12 hours (<a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>), 24 hours (<a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>; <a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>; <a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>), 48 hours (<a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>), 72 hours (<a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>), 504 hours (<a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>) and 720 hours (<a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>). Four trials did not report follow‐up (<a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>), and for three trials, the follow‐up period was unclear (<a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>; <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>). </p> <p>Diagnostic criteria for myocardial infarction varied among included trials. Five trials used World Health Organization criteria (<a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>); nine trials used Lawrie's criteria (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>; <a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>); and 15 trials used clinical signs, electrocardiograms and laboratory enzymes alone or in combination (<a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>; <a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>). Eight trials had unclear diagnostic criteria or did not report them (<a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>). </p> <p>Included trials were conducted in participants with proved or suspected myocardial infarction. Seventeen trials included participants with confirmed acute myocardial infarction (<a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a>; <a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>), and 20 trials included participants with acute myocardial infarction or suspected acute myocardial infarction (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>; <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>; <a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>; <a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>). </p> <p>Three trials were conducted in a pre‐hospital setting (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>), 31 in a hospital setting (<a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>; <a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a>; <a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>; <a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>; <a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>) and three in both settings (<a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>). </p> <p>Thirty‐one trials reported participants' age. Overall, the mean age of participants was older than 50 years (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a>; <a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>; <a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>; <a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>). Six trials did not report participants' age (<a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>). Thirty‐one trials reported the percentage of included male participants, which was 75.06 ± 11.58 (minimum 50, maximum 95, median 76) (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>; <a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>; <a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>), and six trials did not report the gender of participants (<a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>). </p> </section> <section id="CD008553-sec-0053"> <h5 class="title">Trial locations</h5> <p>Included trials were conducted between 1969 and 1999 in 17 countries: three in Australia (<a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>), one in Belgium (<a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>), one in Brazil (<a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>), four in Canada (<a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>), one in Denmark (<a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>), one in France (<a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>), one in Germany (<a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>), three in Italy (<a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>; <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>), one in New Zealand (<a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>), one in Northern Ireland (<a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>), two in Norway (<a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>), two in Poland (<a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>), four in Sweden (<a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>; <a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>), one in Switzerland (<a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a>), three in The Netherlands (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>), four in the United Kingdom (<a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>) and four in the United States of America (<a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>). </p> </section> <section id="CD008553-sec-0054"> <h5 class="title">Trial methods</h5> <p>The mean sample size was 357.22 ± 994.08 (minimum 19, maximum 6024, median 150). One trial reported sample size estimation a priori (<a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>). Thirty‐six trials were conducted without sample size estimated a priori (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a>; <a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>; <a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>; <a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>; <a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>). </p> <p>Thirty‐six trials used a parallel study design (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a>; <a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>; <a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>; <a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>). Thirty‐two trials used two comparison groups (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a>; <a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>; <a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>; <a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>), two trials three comparison groups (<a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>) and two trials four comparison groups (<a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>; <a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>). One trial had a cross‐over design (<a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>). </p> </section> </section> <section id="CD008553-sec-0055"> <h4 class="title">Excluded studies</h4> <p>We excluded 43 studies for the following reasons: non‐randomised controlled trials (<a href="./references#CD008553-bbs2-0041" title="BernardR , LewinsonH , RentaC , ThysJP . Hemodynamic effects of xylocaine and ajmaline in myocardial infarction. Archives des Maladies du Coeur et des Vaisseaux1972;65(10):1215-8. [PMID: 4632665]">Bernard 1972</a>; <a href="./references#CD008553-bbs2-0042" title="BertiniG , GiglioliC , RostagnoC , ContiA , RussoL , TaddeiT , et al. Early out-of-hospital lidocaine administration decreases the incidence of primary ventricular fibrillation in acute myocardial infarction. The Journal of Emergency Medicine1993;11:667-72. [PMID: 8157902 ]">Bertini 1993</a>; <a href="./references#CD008553-bbs2-0043" title="BleifeldW , MerxKW , HeinrichKW , EffertS . Controlled trial of prophylactic treatment with lidocaine in acute myocardial infarction. European Journal of Clinical Pharmacology1973;6:119-26. [PMID: 4588851]">Bleifeld 1973</a>; <a href="./references#CD008553-bbs2-0047" title="ChurchG , BiernR . Prophylactic lidocaine in acute myocardial infarction. Circulation1972;46 Suppl 2:139. ">Church 1972</a>; <a href="./references#CD008553-bbs2-0050" title="DiederichKW , FasslH , DjonlagicH , OltmannsD , Floor-WieringaA . Lidocaine prophylaxis in the pre-hospital phase of acute myocardial infarction. Deutsche Medizinische Wochenschrift1979;104(28):1006-8. [PMID: 378632]">Diederich 1979</a>; <a href="./references#CD008553-bbs2-0052" title="FehmersMC , DunningAJ , FehmersMC , DunningAJ . Intramuscularly and orally administered lidocaine in the treatment of ventricular arrhythmias in acute myocardial infarction. American Journal of Cardiology1972;29(4):514-9. [PMID: 4111638]FehmersMC , vanDaatselaarJJ , DunningAJ . Intramuscular and oral administration of lidocaine for the treatment of ventricular arrhythmias in myocardial infarct. Nederlands Tijdschrift voor Geneeskunde1972;116(29):1214-20. ">Fehmers 1972</a>; <a href="./references#CD008553-bbs2-0054" title="GarrattKN , Holmes DR Jr, Molina-ViamonteV , ReederGS , HodgeDO , BaileyKR , et al. Intravenous adenosine and lidocaine in patients with acute myocardial infarction. American Heart Journal1998;136(2):196-204. ">Garratt 1998</a>; <a href="./references#CD008553-bbs2-0056" title="Gonzalez CarmonaV , Cheja ChayaN , Villegas BermudesJ , Gonzalez CarmonaV , Cheja ChayaN , Villegas BermudesJ . Use of lidocaine in acute myocardial infarction [Uso de lidocaína en el infarto agudo del miocardio]. Archivos del Instituto de Cardiologia de Mexico1977;47(5):604-11. ">Gonzalez 1977</a>; <a href="./references#CD008553-bbs2-0063" title="LeoneA , MoriL , BertanelliF , FabianoP . Life-threatening arrhythmias after intravenous lidocaine alone or with magnesium in myocardial infarction complicated by ventricular fibrillation. Singapore Medical Journal1991;32:169-70. [PMID: 1876891]">Leone 1991</a>; <a href="./references#CD008553-bbs2-0066" title="MillerRR , HilliardG , LiesJE , MassumiRA , ZelisR , MasonDT , et al. Hemodynamic effects of procainamide in patients with acute myocardial infarction and comparison with lidocaine. American Journal of Medicine1973;55(2):161-8. [PMID: 4722854]">Miller 1973</a>; <a href="./references#CD008553-bbs2-0067" title="MogensenL . Ventricular tachyarrhythmias and lignocaine prophylaxis in acute myocardial infarction. Acta Medica Scandinavica1971;513:1-80. [PMID: 5288550]">Mogensen 1971</a>; <a href="./references#CD008553-bbs2-0071" title="Riabokon'OS , PiotrovskiiVK , SmirnovaEB , MetelitsaVI , MazurNA . Comparative clinical study of trimecaine and lidocaine as anti-arrhythmia agents in myocardial infarct. Kardiologiia1980;20(10):40-2. [PMID: 6160280]">Riabokon' 1980</a>; <a href="./references#CD008553-bbs2-0074" title="RydenL , WaldenstromA , EhnL , HolmbergS , HusainiM . Comparison between effectiveness of intramuscular and intravenous lignocaine on ventricular arrhythmia complicating acute myocardial infarction. British Heart Journal1973;35(11):1124-31. [PMID: 4128310]">Ryden 1973</a>; <a href="./references#CD008553-bbs2-0076" title="SinghJB , KocotSL . A controlled trial of intramuscular lidocaine in the prevention of premature ventricular contractions associated with acute myocardial infarction. American Heart Journal1976;91:430-6. [PMID: 1258750]SinghJB , KocotSL . A controlled trial of intramuscular lidocaine in the prevention of premature ventricular contractions associated with acute myocardial infarction. Circulation1973;48(4 Suppl):28. SinghJB , KocotSL . Controlled trial of Intramuscular lidocaine in prevention of premature ventricular contractions associated with acute myocardial-infarction. Circulation1973;48(4):8-8. ">Singh 1976</a>; <a href="./references#CD008553-bbs2-0077" title="SzeplakiS , SzilagyiA , BoszormenyiE , BarsiB , MateK , KulcsarM , et al. Anti-ischemic effect of lidocaine in the acute phase of myocardial infarct without shock. Orvosi Hetilap1974;115(12):671-5. [PMID: 4815468]SzeplakiS , SzilagyiA , SzeplakiZ , BoszormenyiE , BarsiB , MateK , et al. Anti-ischemic effect of lidocaine in the acute state of myocardial infarction. Agressologie1973;14(5):339-45. [PMID: 4606223]">Szeplaki 1973</a>; <a href="./references#CD008553-bbs2-0078" title="SzeplakiS , SzilaigyiA , HarsanyiA , SzeplakiZ , MateK , KulcsarM , et al. Lidocaine prophylaxis in preinfarction angina and in the reactive stage of myocardial infarction. Agressologie1976;17(4):245-50. [PMID: 1008152]">Szeplaki 1976</a>; <a href="./references#CD008553-bbs2-0080" title="WojtalaM , StopczykM , WojtalaM , StopczykM . Relationship between lidocaine-induced suppression of premature excitation and reduced possibility of the appearance of ventricular fibrillation in myocardial infarction. Kardiologia Polska1982;25(7-8):647-53. [PMID: 7169751]">Wojtala 1982</a>), systematic reviews of randomised controlled trials (<a href="./references#CD008553-bbs2-0048" title="DeSilvaRA , HennekensCH , LownB , CasscellsW . Lignocaine prophylaxis in acute myocardial infarction: an evaluation of randomised trials. Lancet1981;2(8251):855-8. [PMID: 6116964]">De Silva 1981</a>; <a href="./references#CD008553-bbs2-0058" title="HineLK , LairdN , HewittP , ChalmersTC . Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Archives of Internal Medicine1989;149:2694-8. [PMID: 2688587]">Hine 1989</a>; <a href="./references#CD008553-bbs2-0064" title="MacMahonS , CollinsR , PetoR , KosterRW , YusufS . Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA1988;260:1910-6. [PMID: 3047448]">MacMahon 1988</a>; <a href="./references#CD008553-bbs2-0079" title="TeoKK , YusufS , FurbergCD . Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA1993;270:1589-95. [PMID: 8371471]">Teo 1993</a>), observational studies (<a href="./references#CD008553-bbs2-0039" title="BeloevI , TomovI , DzhonovA , OrbetsovM , StankushevaG . Effect of the use of lidocaine on patients with acute myocardial infarct. Vutreshni Bolesti1983;22(3):88-95. [PMID: 6649590]">Beloev 1983</a>; <a href="./references#CD008553-bbs2-0044" title="CampbellNP , KellyJG , AdgeyAA , McDevittDG , PantridgeJF , CampbellNP , et al. Observations on intravenous administration of lignocaine in patients with myocardial infarction. British Heart Journal1978;40(12):1371-5. ">Campbell 1978</a>; <a href="./references#CD008553-bbs2-0049" title="DesruellesJ , GerardA , WaucamptJJ , GoethalsS , DecalfA . Value of xylocaine in coronary thrombosis. Archives des Maladies du Coeur et des Vaisseaux1969;62(2):243-6. [PMID: 4983190]DesruellesJ , WaucamptJJ , GoethalsS , DecalfA . Value of lignocaine in coronary thrombosis (and especially in rhythm disorders in the initial phase of myocardial infarct). Lille Medical1969;14(10):1219-21. ">Destuelles 1969</a>; <a href="./references#CD008553-bbs2-0051" title="DjianeP , EgreA , PerchicotB , BoryM , SerradimigniA , BruguerolleB , et al. Use of intramuscular lidocaine in the acute stage of myocardial infarction. Archives des Maladies du Coeur et des Vaisseaux1981;74(8):931-8. [PMID: 6793010]EgreA , DjianeP , SerradimigniA , BruguerolleB , ValliM , BouyardP . Utilization of lidocaine in the acute phase of myocardial infarction [Utilisation de la lidocaine a la phase aigue de l'infarctus du myocarde]. Therapie1981;36(1):71-9. [PMID: 7233375]">Egre 1981</a>; <a href="./references#CD008553-bbs2-0055" title="GianellyR , von derGroebenJO , SpivackAP , HarrisonDC . Effect of lidocaine on ventricular arrhythmias in patients with coronary heart disease. New England Journal of Medicine1967;277(23):1215-9. [PMID: 4862377]">Gianelly 1967</a>; <a href="./references#CD008553-bbs2-0065" title="MazurNA , Riabokon'OS , BanshchikovGT . Prevention of ventricular fibrillation using lidocaine in the acute period of a myocardial infarct. Biulleten Vsesoiuznogo Kardiologicheskogo Nauchnogo Tsentra Amn SSSR1982;5(2):59-64. [PMID: 6182894]">Mazur 1982</a>; <a href="./references#CD008553-bbs2-0070" title="PentecostBL , De GiovanniJV , LambP , CadiganPJ , EvemyKL , FlintEJ , et al. Reappraisal of lignocaine therapy in management of myocardial infarction. British Heart Journal1981;45(1):42-7. [PMID: 7459164]">Pentecost 1981</a>; <a href="./references#CD008553-bbs2-0073" title="Ruano MarcoM , Lacueva MoyaV , Garcia PardoJ , Martin MontesN , Miquel ServetJ , RodriguezP . Lignocaine prophylaxis for reperfusion arrhythmias during treatment with streptokinase in acute myocardial infarction. Lancet1989;2(8667):872-3. [PMID: 2571805]">Ruano 1989</a>; <a href="./references#CD008553-bbs2-0075" title="ShihRD , HollanderJE , BursteinJL , NelsonLS , HoffmanRS , QuickAM . Clinical safety of lidocaine in patients with cocaine-associated myocardial infarction. Annals of Emergency Medicine1995;26:702-6. [PMID: 7492040]">Shih 1995</a>; <a href="./references#CD008553-bbs2-0081" title="WymanMG , WymanRM , CannomDS , CrileyJM . Prevention of primary ventricular fibrillation in acute myocardial infarction with prophylactic lidocaine. American Journal of Cardiology2004;94:545-51. [PMID: 15342281]">Wyman 2004</a>) and narrative reviews (<a href="./references#CD008553-bbs2-0038" title="AntmanEM , BerlinJA . Declining incidence of ventricular fibrillation in myocardial infarction. Implications for the prophylactic use of lidocaine. Circulation1992;86(3):764-73. [PMID: 1516188]">Antman 1992</a>; <a href="./references#CD008553-bbs2-0040" title="BernardR , StacquezA , DenolinH , BernardR , StacquezA , DenolinH . [Preventive treatment of arrhythmia in acute phase of myocardial infarct]. [French]. Annales de Cardiologie et d Angeiologie1970;19(1):62-4. ">Bernard 1970</a>; <a href="./references#CD008553-bbs2-0045" title="CampbellRWF . Placebo controlled study of prophylaxis of ventricular arrhythmias in acute myocardial infarction. American Heart Journal1980;100(6 II):995-9. ">Campbell 1980</a>; <a href="./references#CD008553-bbs2-0046" title="CampbellRWF . Treatment and prophylaxis of ventricular arrhythmias in acute myocardial infarction. American Journal of Cardiology1983;52:55c-9. ">Campbell 1983</a>; <a href="./references#CD008553-bbs2-0053" title="FomichevVI , PreobrazhenskiïDV . Prophylactic use of lidocaine in the acute period of myocardial infarction. Klinicheskaia Meditsina1995;73:17-20. [PMID: 7474809]">Formichev 1995</a>; <a href="./references#CD008553-bbs2-0057" title="GoodmanSL , GeidermanJM , BernsteinIJ . Prophylactic lidocaine in suspected acute myocardial infarction. JACEP1979;8(6):221-4. [PMID: 449144]">Goodman 1979</a>; <a href="./references#CD008553-bbs2-0059" title="IosavaKV , AreshidzeTK , LezhavaMG , GaprindashviliTG . Effectiveness of lidocaine use in the initial period of acute myocardial infarct. Kardiologiia1982;22(12):82-5. [PMID: 6186836]">Iosava 1982</a>; <a href="./references#CD008553-bbs2-0060" title="JaffeAS . Prophylactic lidocaine for suspected acute myocardial infarction?Heart Disease and Stroke1992;1(4):179-83. [PMID: 1344106]">Jaffe 1992</a>; <a href="./references#CD008553-bbs2-0062" title="LechleitnerP , DienstlF . Preventive use of lidocaine in the prehospital phase of acute myocardial infarct. Wiener Medizinische Wochenschrift1987;137(10-11):216-21. [PMID: 3604218]">Lechleitner 1987</a>; <a href="./references#CD008553-bbs2-0068" title="NonemanJW , RogersJF . Lidocaine prophylaxis in acute myocardial infarction. Medicine1978;57(6):501-15. [PMID: 362121]">Noneman 1978</a>; <a href="./references#CD008553-bbs2-0069" title="OltmannsD , LubbenC , PentzR , SiegersCP . Plasma levels of lidocaine after intramuscular injection and subsequent infusion in patients with acute myocardial infarction. International Journal of Clinical Pharmacology, Therapy, and Toxicology1982;20(12):582-4. [PMID: 7152740]OltmannsD , SiegersCP . Pharmacokinetics of lidocaine after intramuscular injection in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1979;68(3):131-6. [PMID: 442753]">Oltmanns 1979</a>; <a href="./references#CD008553-bbs2-0072" title="RibnerHS , IsaacsES , FrishmanWH , RibnerHS , IsaacsES , FrishmanWH . Lidocaine prophylaxis against ventricular fibrillation in acute myocardial infarction. Progress in Cardiovascular Diseases1979;21(4):287-313. [PMID: 368880 ]">Ribner 1979</a>). See the <a href="./references#CD008553-sec-0151" title="">Characteristics of excluded studies</a> table. </p> <section id="CD008553-sec-0056"> <h5 class="title">Studies awaiting classification</h5> <p>Three references were considered as 'Studies awaiting classification' (<a href="./references#CD008553-bbs2-0082" title="BolinskaH , KuczborskiM , BolinskaH , KuczborskiM . Lignocaine in the treatment of arrhythmia in acute myocardial infarct. Wiadomosci Lekarskie1971;24(19):1851-4. [PMID: 5134518]">Bolinska 1971</a>; <a href="./references#CD008553-bbs2-0083" title="HoppersteadLO , MyersMH . Prophylactic lidocaine in the early management of acute myocardial infarction. The Journal of the Maine Medical Association1980;71:77-81. [PMID: 7365324 ]">Hopperstead 1980</a>; <a href="./references#CD008553-bbs2-0084" title="KnightAL . Prophylactic lidocaine in myocardial infarction. Journal of Occupational Medicine1973;15(7):604. [PMID: 4711658]">Knight 1973</a>). See <a href="./references#CD008553-sec-0152" title="">Characteristics of studies awaiting classification</a> for details. These three studies lacked an abstract indicating whether they were randomised trials. We were not able to find the addresses of study authors and were not able to find their full‐text articles. </p> </section> </section> </section> <section id="CD008553-sec-0057"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD008553-fig-0002">Figure 2</a> and <a href="#CD008553-fig-0003">Figure 3</a> for details. </p> <div class="figure" id="CD008553-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008553-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD008553-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008553-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD008553-sec-0058"> <h4 class="title">Allocation</h4> <section id="CD008553-sec-0059"> <h5 class="title">Random sequence generation</h5> <p>Risk of bias arising from the method of generation of the allocation sequence was considered low in three trials (<a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>). Thirty‐four studies had an unclear risk of bias for this domain (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a>; <a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>; <a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>; <a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>). </p> </section> <section id="CD008553-sec-0060"> <h5 class="title">Allocation concealment</h5> <p>Risk of bias arising from the method of allocation concealment was considered low in one trial (<a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>). Thirty‐six trials had unclear risk of bias for this domain (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a>; <a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>; <a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>; <a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>; <a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>). </p> </section> </section> <section id="CD008553-sec-0061"> <h4 class="title">Blinding</h4> <p>Risk of bias due to lack of blinding of participants and personnel was rated as low in seven trials (<a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>). Risk of bias of blinding was high in 30 trials (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>; <a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>; <a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>; <a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>). </p> <p>In two trials, outcome assessment was clearly reported as blinded and detection bias was considered low (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>). Blinding was unclear or was not performed in 35 trials and risk of detection bias was considered high (<a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a>; <a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>; <a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>; <a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>). </p> </section> <section id="CD008553-sec-0062"> <h4 class="title">Incomplete outcome data</h4> <p>Risk of attrition bias was rated as low in nine trials (<a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>). Risk of attrition bias was rated as high in 28 trials (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a>; <a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>; <a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>; <a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>). </p> </section> <section id="CD008553-sec-0063"> <h4 class="title">Selective reporting</h4> <p>Risk of selective outcome reporting bias was rated as low in 22 trials (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>) and high in 15 trials (<a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a>; <a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a>; <a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>; <a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>; <a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>; <a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>). </p> </section> <section id="CD008553-sec-0064"> <h4 class="title">Other potential sources of bias</h4> <p>Risk of other bias was rated as high in all trials because of bias in presentation of data, design bias or industry bias (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a>; <a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>; <a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>; <a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>; <a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>). </p> <p>Ten trials had potential industry bias (<a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>). </p> <p>Accordingly, all trials were considered as having high risk of bias.</p> </section> </section> <section id="CD008553-sec-0065"> <h3 class="title" id="CD008553-sec-0065">Effects of interventions</h3> <p>See: <a href="./full#CD008553-tbl-0001"><b>Summary of findings 1</b> Lidocaine compared with placebo or no intervention for acute myocardial infarction</a>; <a href="./full#CD008553-tbl-0002"><b>Summary of findings 2</b> Lidocaine compared with disopyramide for myocardial infarction</a>; <a href="./full#CD008553-tbl-0003"><b>Summary of findings 3</b> Lidocaine compared with tocainide for myocardial infarction</a>; <a href="./full#CD008553-tbl-0004"><b>Summary of findings 4</b> Lidocaine compared with mexiletine for myocardial infarction</a>; <a href="./full#CD008553-tbl-0005"><b>Summary of findings 5</b> Lidocaine compared with propafenone for myocardial infarction</a>; <a href="./full#CD008553-tbl-0006"><b>Summary of findings 6</b> Lidocaine compared with amiodarone for myocardial infarction</a>; <a href="./full#CD008553-tbl-0007"><b>Summary of findings 7</b> Lidocaine compared with dimethylammonium for myocardial infarction</a>; <a href="./full#CD008553-tbl-0008"><b>Summary of findings 8</b> Lidocaine compared with aprindine for myocardial infarction</a>; <a href="./full#CD008553-tbl-0009"><b>Summary of findings 9</b> Lidocaine compared with pirmenol for myocardial infarction</a> </p> <section id="CD008553-sec-0066"> <h4 class="title">Primary outcomes</h4> <section id="CD008553-sec-0067"> <h5 class="title">All‐cause mortality</h5> <section id="CD008553-sec-0068"> <h6 class="title">Lidocaine versus placebo or no intervention</h6> <p>Meta‐analysis of 18 trials involving participants with proven or non‐proven acute myocardial infarction, comparing lidocaine versus placebo or no intervention, showed no significant differences in all‐cause mortality (213/5879 (3.62%) vs 199/5848 (3.40%); RR 1.02, 95% CI 0.82 to 1.27; participants = 11727; I<sup>2</sup> = 15%; P value = 0.86; low‐quality evidence) (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>). See <a href="./references#CD008553-fig-0011" title="">Analysis 1.1</a>. A funnel plot revealed no evidence of publication bias for this outcome (<a href="#CD008553-fig-0004">Figure 4</a>). Trial sequential analysis shows that 14 trials provided evidence that lidocaine is not able to induce a 20% RR reduction in all‐cause mortality compared with placebo or no intervention, if we disregard risks of bias (<a href="#CD008553-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD008553-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot on all‐cause mortality in 18 lidocaine vs placebo or no intervention trials Funnel plot of data from the meta‐analysis evaluating the effects of lidocaine compared with placebo for preventing all‐cause mortality in patients with proven or not proven acute myocardial infarction (18 trials). This figure shows low risk of publication bias. Individual circles represent point estimates of the included randomised controlled trials. The pattern of distribution simulates an inverted funnel. Larger trials are closer and upper to the pooled estimate. Effect sizes of smaller trials are lower and are more or less symmetrically distributed around the pooled estimate." data-id="CD008553-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Funnel plot on all‐cause mortality in 18 lidocaine vs placebo or no intervention trials</b> </p> <p>Funnel plot of data from the meta‐analysis evaluating the effects of lidocaine compared with placebo for preventing all‐cause mortality in patients with proven or not proven acute myocardial infarction (18 trials). This figure shows low risk of publication bias. Individual circles represent point estimates of the included randomised controlled trials. The pattern of distribution simulates an inverted funnel. Larger trials are closer and upper to the pooled estimate. Effect sizes of smaller trials are lower and are more or less symmetrically distributed around the pooled estimate. </p> </div> </div> </div> <div class="figure" id="CD008553-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Trial sequential analysis on all‐cause mortality in 18 lidocaine vs placebo or no intervention trials Trial sequential analysis of lidocaine vs placebo or no intervention on all‐cause mortality in participants with or without proven myocardial infarction based on the diversity‐adjusted required information size (DARIS) of 25,777 participants. This DARIS was calculated on the basis of a proportion of participants with suspected myocardial infarction of 3.40% in the control group; RRR of 20% in the experimental intervention group; alpha (α) of 5%; beta (β) of 20%; and diversity of 22%.The cumulative Z‐curve (blue line) did not cross the conventional alpha 5% boundaries (green lines) at any time. After the 14th trial, the cumulative Z‐curve crosses the trial sequential monitoring boundary for futility. Accordingly, although only 45.5% (11,727/25,777) of the DARIS has been obtained, we can reject an intervention effect of 20% or larger. This implies that no additional trials may be needed to disprove an intervention effect of 20% relative risk reduction if bias can be ignored. Smaller risk reductions may require additional trials with larger sample sizes." data-id="CD008553-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial sequential analysis on all‐cause mortality in 18 lidocaine vs placebo or no intervention trials</b> </p> <p>Trial sequential analysis of lidocaine vs placebo or no intervention on all‐cause mortality in participants with or without proven myocardial infarction based on the diversity‐adjusted required information size (DARIS) of 25,777 participants. This DARIS was calculated on the basis of a proportion of participants with suspected myocardial infarction of 3.40% in the control group; RRR of 20% in the experimental intervention group; alpha (α) of 5%; beta (β) of 20%; and diversity of 22%. </p> <p>The cumulative Z‐curve (blue line) did not cross the conventional alpha 5% boundaries (green lines) at any time. After the 14th trial, the cumulative Z‐curve crosses the trial sequential monitoring boundary for futility. Accordingly, although only 45.5% (11,727/25,777) of the DARIS has been obtained, we can reject an intervention effect of 20% or larger. This implies that no additional trials may be needed to disprove an intervention effect of 20% relative risk reduction if bias can be ignored. Smaller risk reductions may require additional trials with larger sample sizes. </p> </div> </div> </div> <p>Heterogeneity for this critical endpoint was low, as conveyed by I<sup>2</sup> values. However, because of the large number of trials and the importance of determining the effect of prophylactic lidocaine on all‐cause mortality in individuals with proven acute myocardial infarction, we conducted many subgroup analyses for this population. </p> <section id="CD008553-sec-0069"> <p><b>Subgroup analyses involving acute myocardial infarction patients only</b></p> <p>Meta‐analysis of 16 trials comparing lidocaine versus placebo or no intervention revealed no differences regarding all‐cause mortality (148/2747 (5.38%) vs 135/2506 (5.38%); RR 1.01, 95% CI 0.79 to 1.30; participants = 5253; I<sup>2</sup> = 9%; P value = 0.92) (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>). See <a href="./references#CD008553-fig-0012" title="">Analysis 1.2</a>. <a href="#CD008553-fig-0006">Figure 6</a> shows no evidence of publication bias outcome. </p> <div class="figure" id="CD008553-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot on all‐cause mortality in participants with proven acute myocardial infarction in 16 lidocaine vs placebo or no intervention trials Funnel plot of data from the meta‐analysis of effects of lidocaine compared with placebo for preventing all‐cause mortality in individuals with proven acute myocardial infarction (16 trials). This figure shows low risk of publication bias. The circles show point estimates of the included randomised controlled trials. The pattern of distribution simulates an inverted funnel. Each half of the funnel plot includes eight trials. Larger trials are closer and upper to the pooled estimate. Effect sizes of the smaller trials are lower and are more or less symmetrically distributed around the pooled estimate. The right half of the funnel plot (near the bottom corner) shows two smaller trials with higher standard error and far of the point estimate." data-id="CD008553-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Funnel plot on all‐cause mortality in participants with proven acute myocardial infarction in 16 lidocaine vs placebo or no intervention trials</b> </p> <p>Funnel plot of data from the meta‐analysis of effects of lidocaine compared with placebo for preventing all‐cause mortality in individuals with proven acute myocardial infarction (16 trials). This figure shows low risk of publication bias. The circles show point estimates of the included randomised controlled trials. The pattern of distribution simulates an inverted funnel. Each half of the funnel plot includes eight trials. Larger trials are closer and upper to the pooled estimate. Effect sizes of the smaller trials are lower and are more or less symmetrically distributed around the pooled estimate. The right half of the funnel plot (near the bottom corner) shows two smaller trials with higher standard error and far of the point estimate. </p> </div> </div> </div> <p>Trial sequential analysis shows that 13 trials provided evidence that lidocaine is not able to induce a 25% RR reduction in all‐cause mortality among participants with myocardial infarction compared with placebo or no intervention, if we disregard risks of bias (<a href="#CD008553-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD008553-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Trial sequential analysis on all‐cause mortality among participants with myocardial infarction in 16 lidocaine vs placebo or no intervention trials Trial sequential analysis of lidocaine vs placebo or no intervention on all‐cause mortality in participants with myocardial infarction based on the diversity‐adjusted required information size (DARIS) of 9854 participants. This DARIS was calculated on the basis of a proportion of participants with mortality by myocardial infarction of 5.38% in the control group; post hoc selected RRR of 25% in the experimental intervention group; alpha (α) of 5%; beta (β) of 20%; and diversity of 14%. The cumulative Z‐curve (blue line) did not cross the conventional alpha 5% boundaries (green lines). After the 12th trial, the cumulative Z‐curve crossed the trial sequential monitoring boundary for futility. Accordingly, although only 53.30% (5253/9854) of the DARIS has been obtained, we can reject an intervention effect of 25% or larger. Had we calculated the DARIS on the basis of a more realistic RRR like 20% (as we had planned) or less, the obtained information would represent a smaller part of the DARIS. Accordingly, the boundaries for futility would not have been crossed in such scenarios. Therefore, risk reduction of 20% or less may require additional trials with larger sample sizes." data-id="CD008553-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial sequential analysis on all‐cause mortality among participants with myocardial infarction in 16 lidocaine vs placebo or no intervention trials</b> </p> <p>Trial sequential analysis of lidocaine vs placebo or no intervention on all‐cause mortality in participants with myocardial infarction based on the diversity‐adjusted required information size (DARIS) of 9854 participants. This DARIS was calculated on the basis of a proportion of participants with mortality by myocardial infarction of 5.38% in the control group; post hoc selected RRR of 25% in the experimental intervention group; alpha (α) of 5%; beta (β) of 20%; and diversity of 14%. The cumulative Z‐curve (blue line) did not cross the conventional alpha 5% boundaries (green lines). After the 12th trial, the cumulative Z‐curve crossed the trial sequential monitoring boundary for futility. Accordingly, although only 53.30% (5253/9854) of the DARIS has been obtained, we can reject an intervention effect of 25% or larger. Had we calculated the DARIS on the basis of a more realistic RRR like 20% (as we had planned) or less, the obtained information would represent a smaller part of the DARIS. Accordingly, the boundaries for futility would not have been crossed in such scenarios. Therefore, risk reduction of 20% or less may require additional trials with larger sample sizes. </p> </div> </div> </div> </section> <section id="CD008553-sec-0070"> <p><b>Subgroup analysis of trials according to administration route of lidocaine</b></p> <p>Meta‐analysis of nine trials administering lidocaine by the intravenous route showed no significant differences regarding all‐cause mortality when lidocaine was compared with placebo or with no intervention (92/1100 (8.36%) vs 70/942 (7.43%); RR 1.16, 95% CI 0.82 to 1.63; participants = 2042; I<sup>2</sup> = 14%; P value = 0.40) (<a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>). Meta‐analysis of five trials administering lidocaine by the intramuscular route showed no significant differences regarding all‐cause mortality when lidocaine was compared with placebo or with no intervention (41/1436 (2.85%) vs 53/1368 (3.87%); RR 0.77, 95% CI 0.50 to 1.17; participants = 2804; I<sup>2</sup> = 4%; P value = 0.22) (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>). Meta‐analysis of two trials administering lidocaine by the intramuscular route showed no significant differences regarding all‐cause mortality when lidocaine was compared with placebo or with no intervention (15/211 (7.11%) vs 12/196 (6.12%); RR 1.17, 95% CI 0.56 to 2.42; participants = 407; I<sup>2</sup> = 0%; P value = 0.68) (<a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>). Tests for subgroup differences showed no significant differences (I<sup>2</sup> = 16.3%; P value = 0.92). See <a href="./references#CD008553-fig-0013" title="">Analysis 1.3</a>. </p> </section> <section id="CD008553-sec-0071"> <p><b>Subgroup analysis of trials with infusion administration only compared with trials with bolus and infusion administrations</b></p> <p>Meta‐analysis of three trials administering lidocaine by infusion showed no significant differences regarding all‐cause mortality only when lidocaine was compared with placebo or with no intervention (16/229 (6.98%) vs 22/237 (9.28%); RR 0.85, 95% CI 0.33 to 2.17; participants = 466; I<sup>2</sup> = 40%; P value = 0.73) (<a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>). Meta‐analysis of six trials administering lidocaine by both bolus and infusion approaches revealed no significant differences regarding all‐cause mortality when lidocaine was compared with placebo or with no intervention (76/871 (8.72%) vs 48/705 (6.81%); RR 1.30, 95% CI 0.92 to 1.83; participants = 1576; I<sup>2</sup> = 0%; P value = 0.14) (<a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>). Tests for subgroup differences showed no significant differences (I<sup>2</sup> = 0%; P value = 0.40). See <a href="./references#CD008553-fig-0014" title="">Analysis 1.4</a>. </p> </section> <section id="CD008553-sec-0072"> <p><b>Subgroup analysis according to bolus lidocaine dose</b></p> <p>One trial found no significant differences in all‐cause mortality when lidocaine administered by bolus up to 50 mg was compared with placebo or with no intervention (7/39 (17.95%) vs 4/43 (9.30%); RR 1.93, 95% CI 0.61 to 6.09; participants = 82; P value = 0.26) (<a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>). One bolus of 60 mg of lidocaine does not produce statistically significant differences when compared with to placebo or with no intervention in terms of all‐cause mortality (25/249 (10.04%) vs 8/125 (6.4%); RR 1.57, 95% CI 0.73 to 3.38; participants = 374; P value = 0.25) (<a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>). Meta‐analysis of two trials comparing a bolus of 75 mg of lidocaine versus placebo or no intervention showed no significant differences regarding all‐cause mortality (34/240 (14.17%) vs 24/232 (10.34%); RR 1.49, 95% CI 0.70 to 3.16; participants = 472; I<sup>2</sup> = 42%; P value = 0.30) (<a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>). One trial found no statistically significant differences in all‐cause mortality when lidocaine administered by bolus at a dose of 100 mg was compared with placebo or with no intervention (8/107 (7.48%) vs 10/105 (9.52%); RR 0.79, 95% CI 0.32 to 1.91; participants = 212; P value = 0.59) (<a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>). At a dose of 1 mg/kg, lidocaine did not significantly affect all‐cause mortality when compared with placebo or no intervention (2/236 (0.85%) vs 2/200 (1%); RR 0.85, 95% CI 0.12 to 5.96; participants = 436; P value = 0.87) (<a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>). Tests for subgroup differences showed no significant differences (I<sup>2</sup> = 0%; P value = 0.70). See <a href="./references#CD008553-fig-0015" title="">Analysis 1.5</a>. </p> </section> <section id="CD008553-sec-0073"> <p><b>Subgroup analysis according to number of lidocaine boluses at any dose</b></p> <p>Meta‐analysis of four trials assessing one bolus of lidocaine at any dose versus placebo or no intervention showed no statistically significant differences regarding all‐cause mortality (51/549 (9.29%) vs 26/419 (6.20%); RR 1.47, 95% CI 0.90 to 2.38; participants = 968; I<sup>2</sup> = 5%; P value = 0.12) (<a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>). Administration of two boluses at any dose of lidocaine versus placebo or no intervention did not significantly affect all‐cause mortality in participants with acute myocardial infarction (27/322 (8.38%) vs 22/286 (7.69%); RR 1.19, 95% CI 0.72 to 1.95; participants = 608; I<sup>2</sup> = 0%; P value = 0.49) (<a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>). See <a href="./references#CD008553-fig-0016" title="">Analysis 1.6</a>. </p> </section> <section id="CD008553-sec-0074"> <p><b>Subgroup analysis according to intravenous infusion dose of lidocaine</b></p> <p>Meta‐analysis of three trials comparing infusion of lidocaine between 1 mg/min and 1.5 mg/min versus placebo or no intervention showed no significant differences regarding all‐cause mortality (32/370 (8.64%) vs 14/248 (5.64%); RR 1.45, 95% CI 0.71 to 2.95; participants = 618; I<sup>2</sup> = 11%; P value = 0.31) (<a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>). Meta‐analysis of six trials comparing infusion of lidocaine between 2 mg/min and 3 mg/min versus placebo or no intervention also showed no statistically significant differences regarding all‐cause mortality (60/730 (8.21%) vs 56/694 (8.1%); RR 1.08, 95% CI 0.72 to 1.62; participants = 1424; I<sup>2</sup> = 20%; P value = 0.72) (<a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>). See <a href="./references#CD008553-fig-0017" title="">Analysis 1.7</a>. </p> </section> <section id="CD008553-sec-0075"> <p><b>Subgroup analysis according to clinical setting</b></p> <p>Meta‐analysis of two trials performed in a pre‐hospital setting showed no statistically significant differences regarding all‐cause mortality when lidocaine was compared with placebo or with no intervention (12/1034 (1.16%) vs 11/955 (1.15%); RR 1.00, 95% CI 0.46 to 2.19; participants = 1989; I<sup>2</sup> = 0%; P value = 1.00) (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>). Meta‐analysis of 11 trials performed in a hospital setting also showed no statistically significant differences regarding all‐cause mortality when lidocaine was compared with placebo or with no intervention (106/1120 (9.46%) vs 113/1130 (10%); RR 0.95, 95% CI 0.69 to 1.32; participants = 2250; I<sup>2</sup> = 30%; P value = 0.77) (<a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>). Meta‐analysis of three trials performed in both pre‐hospital and hospital settings similarly showed no significant differences in all‐cause mortality when lidocaine was compared with placebo or with no intervention (30/593 (5.1%) vs 11/421 (2.61%); RR 1.53, 95% CI 0.77 to 3.02; participants = 1014; I<sup>2</sup> = 0%; P value = 0.22) (<a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>). Tests for subgroup differences showed no significant differences (I<sup>2</sup> = 0%; P value = 0.47). See <a href="./references#CD008553-fig-0018" title="">Analysis 1.8</a>. </p> </section> <section id="CD008553-sec-0076"> <p><b>Subgroup analysis of trials without risk of industry bias compared with trials with risk of industry bias</b></p> <p>Meta‐analysis of 11 trials without risk of industry bias showed no significant differences in all‐cause mortality when lidocaine was compared with placebo or with no intervention (96/2145 (4.48%) vs 79/1972 (4.01%); RR 1.09, 95% CI 0.82 to 1.44; participants = 4117; I<sup>2</sup> = 0%; P value = 0.54) (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>). Meta‐analysis of five trials at risk of industry bias showed no significant differences in all‐cause mortality when lidocaine was compared with placebo or with no intervention (52/602 (8.64%) vs 56/534 (10.49%); RR 0.84, 95% CI 0.44 to 1.58; participants = 1136; I<sup>2</sup> = 58%; P value = 0.58) (<a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>). Tests for subgroup differences showed no significant differences (I<sup>2</sup> = 0%; P value = 0.45). See <a href="./references#CD008553-fig-0019" title="">Analysis 1.9</a>. </p> </section> <section id="CD008553-sec-0077"> <p><b>Sensitivity analyses taking attrition into consideration</b></p> <p>Of the 18 trials (11,727 participants) combined for this outcome, three trials (17% (3/18)) reported exact numbers of participants with missing events in the intervention and control groups (<a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>). Two trials involving 614 participants reported information for this outcome overall (<a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>). Thirteen trials did not report information for this outcome in any comparison group (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>). Thus, three trials reported missing data for intervention groups and control groups involving 6.60% of participants (774/11,727). Furthemore, these three trials involved 18.8% of events in the experimental group (40/213) and 13.6% of events in the control group (27/199). </p> </section> <section id="CD008553-sec-0078"> <p><b>'Best‐worse case' scenario</b></p> <p>In a best‐worst case scenario analysis, we found no statistically significant differences in proportions of all‐cause mortality (40/448 (8.93%) vs 48/326 (14.72%); RR 0.57, 95% CI 0.30 to 1.08; participants = 774; I<sup>2</sup> = 49%; P value &lt; 0.08). </p> </section> <section id="CD008553-sec-0079"> <p><b>'Worst‐best case' scenario</b></p> <p>In a worst‐best case scenario analysis, we found no statistically significant differences in proportions of all‐cause mortality (100/448 (22.32%) vs 27/326 (8.28%); RR 2.20, 95% CI 1.02 to 4.73; participants = 774; I<sup>2</sup> = 67%; P value = 0.04). </p> <p>See <a href="./references#CD008553-fig-0020" title="">Analysis 1.10</a>. </p> </section> </section> <section id="CD008553-sec-0080"> <h6 class="title">Lidocaine versus disopyramide</h6> <p>Meta‐analysis of two trials comparing lidocaine versus disopyramide showed no significant differences in terms of all‐cause mortality (7/73 (9.59%) vs 5/71 (7.04%); RR 1.39, 95% CI 0.47 to 4.13; participants = 144; I<sup>2</sup> = 0%; P value = 0.55; very‐low‐quality evidence) (<a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>). See <a href="./references#CD008553-fig-0026" title="">Analysis 2.1</a>. </p> <section id="CD008553-sec-0081"> <p><b>Sensitivity analyses taking attrition into consideration</b></p> <p><a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a> and <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a> reported the exact numbers of participants with missing events in lidocaine and disopyramide groups. </p> </section> <section id="CD008553-sec-0082"> <p><b>'Best‐worse case' scenario</b></p> <p>In a best‐worst case scenario analysis, we found no significant differences in proportions of participants for all‐cause mortality (7/73 (9.59%) vs 12/71 (16.90%); RR 0.49, 95% CI 0.08 to 3.02; participants = 144; I<sup>2</sup> = 62%; P value = 0.44). </p> </section> <section id="CD008553-sec-0083"> <p><b>'Worst‐best case' scenario</b></p> <p>In a worst‐best case scenario analysis, we found no significant differences in proportions of participants for all‐cause mortality (15/73 (20.54%) vs 5/71 (7.04%); RR 2.75, 95% CI 1.05 to 7.20; participants = 144; I<sup>2</sup> = 0%; P value = 0.04). </p> <p>See <a href="./references#CD008553-fig-0027" title="">Analysis 2.2</a>. </p> </section> </section> <section id="CD008553-sec-0084"> <h6 class="title">Lidocaine versus tocainide</h6> <p>One trial comparing lidocaine versus tocainide showed no significant differences in risk of all‐cause mortality (1/13 (7.6%) vs 1/16 (6.25%); RR 1.23, 95% CI 0.08 to 17.83; participants = 29; P value = 0.88; very‐low‐quality evidence) (<a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>). See <a href="./references#CD008553-fig-0032" title="">Analysis 3.1</a>. </p> <section id="CD008553-sec-0085"> <p><b>Sensitivity analyses taking attrition into consideration</b></p> <p><a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a> reported the exact numbers of participants with missing events in lidocaine and tocainide groups. </p> </section> <section id="CD008553-sec-0086"> <p><b>'Best‐worse case' scenario</b></p> <p>In a best‐worst case scenario analysis, we found no statistically significant differences in proportions of participants for all‐cause mortality (1/13 (7.7%) vs 2/16 (12.5%); RR 0.62, 95% CI 0.06 to 6.05; participants = 29; P value = 0.68). </p> </section> <section id="CD008553-sec-0087"> <p><b>'Worst‐best case' scenario</b></p> <p>In a worst‐best case scenario analysis, we found no statistically significant differences in proportions of participants for all‐cause mortality (2/13 (15.4%) vs 1/16 (6.25%); RR 2.46, 95% CI 0.25 to 24.21; participants = 29; P value = 0.44). </p> <p>See <a href="./references#CD008553-fig-0033" title="">Analysis 3.2</a>. </p> </section> </section> <section id="CD008553-sec-0088"> <h6 class="title">Lidocaine versus mexiletine</h6> <p>No significant differences in risk of all‐cause mortality were noted between lidocaine and mexiletine (0/12 (0%) vs 1/12 (8.33%); RR 0.33, 95% CI 0.01 to 7.45; participants = 24; P value = 0.49; very‐low‐quality evidence) (<a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>). See <a href="./references#CD008553-fig-0036" title="">Analysis 4.1</a>. </p> </section> </section> <section id="CD008553-sec-0089"> <h5 class="title">Cardiac mortality</h5> <section id="CD008553-sec-0090"> <h6 class="title">Lidocaine versus placebo or no intervention</h6> <p>Meta‐analysis of 12 trials showed no significant differences regarding cardiac mortality in participants with or without proved acute myocardial infarction when lidocaine was compared with placebo or with no intervention (69/4184 (1.65%) vs 62/4093 (1.51%); RR 1.03, 95% CI 0.70 to 1.50; participants = 8277; I<sup>2</sup> = 12%; P value = 0.90; low‐quality evidence) (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>). See <a href="./references#CD008553-fig-0021" title="">Analysis 1.11</a>.<br/><br/><a href="#CD008553-fig-0007">Figure 7</a> shows no evidence of publication bias outcome. Trial sequential analysis shows 11 trials provided evidence showing that lidocaine is not able to induce a 30% RR reduction in cardiac mortality compared with placebo or with no intervention, if we disregard risks of bias (<a href="#CD008553-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD008553-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Trial sequential analysis on cardiac mortality in 12 lidocaine vs placebo or no intervention trials Trial sequential analysis of lidocaine vs placebo or no intervention on cardiac mortality in participants with or without proven myocardial infarction based on the diversity‐adjusted required information size (DARIS) of 22,745 participants. This DARIS was calculated on the basis of a proportion of participants with cardiac mortality among those with suspected myocardial infarction of 1.51% in the control group; post hoc selected RRR of 30% in the experimental intervention group; alpha (α) of 5%; beta (β) of 20%; and diversity of 14%. The cumulative Z‐curve (blue line) crossed the conventional alpha of 5% (green line) after 3 trials suggested harm. After 10 trials, however, the cumulative Z‐curve (blue line) crossed the trial sequential monitoring boundary for futility. Accordingly, after only 36.4% (8277/22,745) of the DARIS had been obtained, we were able to reject an intervention effect of 30% or larger. Had we calculated the DARIS on the basis of a more realistic RRR like 20% (as originally planned) or less, the obtained evidence would represent a smaller part of the DARIS. Accordingly, boundaries for futility would not have been crossed in such scenarios. Therefore, risk reductions of 20% or less may require additional trials with larger sample sizes." data-id="CD008553-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial sequential analysis on cardiac mortality in 12 lidocaine vs placebo or no intervention trials</b> </p> <p>Trial sequential analysis of lidocaine vs placebo or no intervention on cardiac mortality in participants with or without proven myocardial infarction based on the diversity‐adjusted required information size (DARIS) of 22,745 participants. This DARIS was calculated on the basis of a proportion of participants with cardiac mortality among those with suspected myocardial infarction of 1.51% in the control group; post hoc selected RRR of 30% in the experimental intervention group; alpha (α) of 5%; beta (β) of 20%; and diversity of 14%. The cumulative Z‐curve (blue line) crossed the conventional alpha of 5% (green line) after 3 trials suggested harm. After 10 trials, however, the cumulative Z‐curve (blue line) crossed the trial sequential monitoring boundary for futility. Accordingly, after only 36.4% (8277/22,745) of the DARIS had been obtained, we were able to reject an intervention effect of 30% or larger. Had we calculated the DARIS on the basis of a more realistic RRR like 20% (as originally planned) or less, the obtained evidence would represent a smaller part of the DARIS. Accordingly, boundaries for futility would not have been crossed in such scenarios. Therefore, risk reductions of 20% or less may require additional trials with larger sample sizes. </p> </div> </div> </div> <section id="CD008553-sec-0091"> <p><b>Subgroup analysis of trials not suspected to be at risk of industry bias versus trials suspected to be at risk of industry bias</b></p> <p>Meta‐analysis of eight trials without risk of industry bias showed no significant differences regarding cardiac mortality among participants with and those without proved acute myocardial infarction when lidocaine was compared with placebo or with no intervention (35/3681 (0.95%) vs 42/3706 (1.13%); RR 0.85, 95% CI 0.52 to 1.39; participants = 7387; I<sup>2</sup> = 14%; P value = 0.51) (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>). Meta‐analysis of four trials at risk of industry bias showed no significant differences regarding cardiac mortality when lidocaine was compared with placebo or with no intervention (34/503 (6.76%) vs 20/387 (5.16%); RR 1.36, 95% CI 0.77 to 2.39; participants = 890; I<sup>2</sup> = 0%; P value = 0.29) (<a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>). Tests for subgroup differences showed no significant differences (I<sup>2</sup> = 34.4%; P value = 0.22). See <a href="./references#CD008553-fig-0022" title="">Analysis 1.12</a>. </p> </section> </section> <section id="CD008553-sec-0092"> <h6 class="title">Lidocaine versus disopyramide</h6> <p>Regarding cardiac mortality, one meta‐analysis of two trials found no significant differences between lidocaine and placebo (3/71 (4.23%) vs 3/73 (4.10%); RR 1.02, 95% CI 0.21 to 4.87; participants = 144; I<sup>2</sup> = 0%; P value = 0.98; very‐low‐quality evidence) (<a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>). See <a href="./references#CD008553-fig-0028" title="">Analysis 2.3</a>. </p> </section> <section id="CD008553-sec-0093"> <h6 class="title">Lidocaine versus tocainide</h6> <p>One trial comparing lidocaine with tocainide showed no significant differences in risk of cardiac mortality (1/13 (7.7%) vs 1/16 (6.25%); RR 1.23, 95% CI 0.08 to 17.83; participants = 29; P value = 0.88; very‐low‐quality evidence) (<a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>). See <a href="./references#CD008553-fig-0034" title="">Analysis 3.3</a>. </p> </section> <section id="CD008553-sec-0094"> <h6 class="title">Lidocaine versus mexiletine</h6> <p>No significant differences in risk of cardiac mortality were noted between lidocaine and mexiletine (0/12 (0%) versus 1/12 (8.33%); (RR 0.33, 95% CI 0.01 to 7.45; participants = 24; P = 0.49, very low quality evidence) (<a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>). See <a href="./references#CD008553-fig-0037" title="">Analysis 4.2</a>. </p> </section> </section> <section id="CD008553-sec-0095"> <h5 class="title">Overall survival at 30 days after myocardial infarction</h5> <p>Trials did not assess this outcome.</p> </section> </section> <section id="CD008553-sec-0096"> <h4 class="title">Secondary outcomes</h4> <section id="CD008553-sec-0097"> <h5 class="title">Ventricular fibrillation</h5> <section id="CD008553-sec-0098"> <h6 class="title">Lidocaine versus placebo or no intervention</h6> <p>Meta‐analysis of 16 trials showed no significant differences between lidocaine and placebo or no intervention regarding prophylaxis of ventricular fibrillation in participants with or without proven acute myocardial infarction (76/5128 (1.48%) vs 103/4987 (2.07%); RR 0.78, 95% CI 0.55 to 1.12; participants = 10115; I<sup>2</sup> = 18%; P value = 0.18; low‐quality evidence) (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0002" title="BakerJA , CollinsJV , EvansTR . Prophylaxis of ventricular dysrhythmias following acute myocardial infarction: a double-blind trial of continuous intravenous infusion of lignocaine. Guy's Hospital Reports1971;120:1-7. [PMID: 4934490]">Baker 1971</a>; <a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0015" title="KuckKH , BleifeldW , MatheyDG . Uneffective Lidocain prophylaxis of reperfusion arrhythmia in patients with acute myocardial infarction. Zeitschrift fur Kardiologie1984;73(Suppl 1):64. KuckKH , JannaschB , SchluterM , SchoferJ , MatheyDG . Ineffective use of lidocaine in preventing reperfusion arrhythmias in patients with acute myocardial infarct [Inneffektive lidocaineprophylaxe von reperfusions arrhythmien bei patienten mit akutem myokardinfarkt]. Zeitschrift fur Kardiologie1985;74(3):185-90. [PMID: 3158128]">Kuck 1985</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>; <a href="./references#CD008553-bbs2-0035" title="ValentinePA , FrewJL , MashfordML , SlomanJG . A double-blind trial of lidocaine in acute myocardial infarction. The Medical Journal of Australia1973;11(Suppl):43-5. ValentinePA , FrewJL , MashfordML , SlomanJG . Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. New England Journal of Medicine1974;19:1327-31. [PMID: 4610393]">Valentine 1974</a>). See <a href="./references#CD008553-fig-0023" title="">Analysis 1.13</a>. <a href="#CD008553-fig-0009">Figure 9</a> shows no evidence of publication bias. Trial sequential analysis reveals that 16 trials provided evidence to show that lidocaine is not able to induce a 30% RR reduction in cardiac mortality compared with placebo or with no intervention, if we disregard risks of bias (<a href="#CD008553-fig-0010">Figure 10</a>). </p> <div class="figure" id="CD008553-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Funnel plot of data from the meta‐analysis of effects of lidocaine compared with placebo for preventing ventricular fibrillation in individuals with proven or non‐proven acute myocardial infarction (15 trials). This figure shows low risk of publication bias. Circles show point estimates of the included randomised controlled trials. The pattern of distribution simulates an inverted funnel. Trials are symmetrically distributed in each of the halves. Larger trials are closer and upper to the pooled estimate. Effect sizes of the smaller trials are lower and are more or less symmetrically distributed around the pooled estimate." data-id="CD008553-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of data from the meta‐analysis of effects of lidocaine compared with placebo for preventing ventricular fibrillation in individuals with proven or non‐proven acute myocardial infarction (15 trials). This figure shows low risk of publication bias. Circles show point estimates of the included randomised controlled trials. The pattern of distribution simulates an inverted funnel. Trials are symmetrically distributed in each of the halves. Larger trials are closer and upper to the pooled estimate. Effect sizes of the smaller trials are lower and are more or less symmetrically distributed around the pooled estimate. </p> </div> </div> </div> <div class="figure" id="CD008553-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Trial sequential analysis on prevention of ventricular fibrillation in 15 lidocaine vs placebo or no intervention trials Trial sequential analysis of lidocaine vs placebo or no intervention on prevention of ventricular fibrillation in participants with or without proven myocardial infarction based on the diversity‐adjusted required information size (DARIS) of 19,271 individuals. This DARIS was calculated on the basis of a proportion of participants with ventricular fibrillation of 2.01% in the control group; post hoc selected RRR of 30% in the experimental intervention group; alpha (α) of 5%; beta (β) of 20%; and diversity of 24%. The cumulative Z‐curve (blue line) did not cross conventional alpha 5% boundaries (green lines). After the 10th trial, the cumulative Z‐curve crosses the trial sequential monitoring boundary for futility. Accordingly, after only 52.2% (10,066/19,271) of the DARIS had been obtained, we were able to reject an intervention effect of 30% or larger. Had we calculated the DARIS on the basis of a more realistic RRR like 20% (as originally planned) or less, the obtained evidence would represent a smaller portion of the DARIS. Accordingly, the boundaries for futility would not have been crossed in such scenarios. Therefore, risk reductions of 20% or less may require additional trials with larger sample sizes." data-id="CD008553-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial sequential analysis on prevention of ventricular fibrillation in 15 lidocaine vs placebo or no intervention trials</b> </p> <p>Trial sequential analysis of lidocaine vs placebo or no intervention on prevention of ventricular fibrillation in participants with or without proven myocardial infarction based on the diversity‐adjusted required information size (DARIS) of 19,271 individuals. This DARIS was calculated on the basis of a proportion of participants with ventricular fibrillation of 2.01% in the control group; post hoc selected RRR of 30% in the experimental intervention group; alpha (α) of 5%; beta (β) of 20%; and diversity of 24%. The cumulative Z‐curve (blue line) did not cross conventional alpha 5% boundaries (green lines). After the 10th trial, the cumulative Z‐curve crosses the trial sequential monitoring boundary for futility. Accordingly, after only 52.2% (10,066/19,271) of the DARIS had been obtained, we were able to reject an intervention effect of 30% or larger. Had we calculated the DARIS on the basis of a more realistic RRR like 20% (as originally planned) or less, the obtained evidence would represent a smaller portion of the DARIS. Accordingly, the boundaries for futility would not have been crossed in such scenarios. Therefore, risk reductions of 20% or less may require additional trials with larger sample sizes. </p> </div> </div> </div> </section> <section id="CD008553-sec-0099"> <h6 class="title">Lidocaine versus disopyramide</h6> <p>One trial comparing lidocaine versus disopyramide provided very‐low‐quality evidence regarding ventricular fibrillation (1/38 (2.6%) vs 3/38 (7.9%); RR 0.33, 95% CI 0.04 to 3.06; participants = 76; P value = 0.33) (<a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>). See <a href="./references#CD008553-fig-0029" title="">Analysis 2.4</a>. </p> </section> <section id="CD008553-sec-0100"> <h6 class="title">Lidocaine versus tocainide</h6> <p>Two trials assessed this comparison (<a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>). However, <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a> reported that no participants experienced ventricular fibrillation. On the other hand, <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a> did not mention this outcome. </p> </section> <section id="CD008553-sec-0101"> <h6 class="title">Lidocaine versus mexiletine</h6> <p>No significant differences in risk of ventricular fibrillation were noted between comparison groups (1/12 (8.33%) vs 0/12 (0%); RR 3.00, 95% CI 0.13 to 67.06; participants = 24; P value = 0.49; very‐low‐quality evidence) (<a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>). See <a href="./references#CD008553-fig-0038" title="">Analysis 4.3</a>. </p> </section> <section id="CD008553-sec-0102"> <h6 class="title">Lidocaine versus amiodarone</h6> <p>No significant differences in risk of ventricular fibrillation were noted between comparison groups (2/15 (13.33%) vs 0/10 (0%); RR 3.44, 95% CI 0.18 to 64.88; participants = 25; P value = 0.41; very‐low‐quality evidence) (<a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>). See <a href="./references#CD008553-fig-0042" title="">Analysis 6.1</a>. </p> </section> <section id="CD008553-sec-0103"> <h6 class="title">Lidocaine versus propafenone</h6> <p>No significant differences in risk of ventricular fibrillation were noted between comparison groups (1/10 (1%) vs 0/10 (0%); RR 3.00, 95% CI 0.14 to 65.90; participants = 20; P value = 0.49; low‐quality evidence) (<a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>). See <a href="./references#CD008553-fig-0040" title="">Analysis 5.1</a>. </p> </section> </section> <section id="CD008553-sec-0104"> <h5 class="title">Adverse events</h5> <section id="CD008553-sec-0105"> <h6 class="title">Cardiovascular adverse events</h6> <section id="CD008553-sec-0106"> <p><b>Lidocaine versus placebo or no intervention</b></p> <p>Lidocaine significantly increased the risk of asystole over placebo or no intervention (35/3393 (1.03%) vs 14/3443 (0.41%); RR 2.32, 95% CI 1.26 to 4.26; participants = 6826; I<sup>2</sup> = 0%; very‐low‐quality evidence) (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>). No significant differences were noted between lidocaine and placebo or no intervention regarding sinus bradycardia (55/1346 (4.09%) vs 49/1203 (4.07%); RR 1.09, 95% CI 0.66 to 1.80; participants = 2549; I<sup>2</sup> = 21%; P value = 0.74; very‐low‐quality evidence) (<a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>); bundle branch block (83/853 (9.73%) vs 75/733 (10.23%); RR 1.07, 95% CI 0.80 to 1.44; participants = 1586; I<sup>2</sup> = 0%; P value = 0.64) (<a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>); non‐complete atrioventricular block (78/888 (8.79%) vs 75/773 (9.70%); RR 1.01, 95% CI 0.75 to 1.37; participants = 1661; I<sup>2</sup> = 0%%; P value = 0.93) (<a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>); complete atrioventricular block (13/443 (2.93%) vs 5/315 (1.59%); RR 1.77, 95% CI 0.66 to 4.78; participants = 758; I<sup>2</sup> = 0%; P value = 0.26) (<a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a>); unknown grade atrioventricular block (66/919 (7.18%) vs 56/808 (6.93%); RR 1.12, 95% CI 0.75 to 1.67; participants = 1727; I<sup>2</sup> = 7%; P value = 0.49) (<a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>); pulmonary edema (83/868 (9.56%) vs 71/762 (9.32%); RR 1.08, 95% CI 0.80 to 1.46; participants = 1630; I<sup>2</sup> = 0%; P value = 0.51) (<a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>); cardiogenic shock (77/868 (8.87%) vs 73/762 (9.58%); RR 1.04, 95% CI 0.77 to 1.41; participants = 1630; I<sup>2</sup> = 0%; P value = 0.79) (<a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>); hypotension (87/814 (10.69%) vs 88/885 (9.94%); RR 1.07, 95% CI 0.81 to 1.41; participants = 1699; I<sup>2</sup> = 0%; P value = 0.59) (<a href="./references#CD008553-bbs2-0008" title="DarbyS , CruickshankJC , BennettMA , PentecostBL . Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet1972;1(7755):817-9. [PMID: 4111579]">Darby 1972</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0036" title="WennerblomB , HolmbergS , RydénL , WedelH . Antiarrhythmic efficacy and side-effects of lidocaine given in the prehospital phase of acute myocardial infarction. European Heart Journal1982;3:516-24. [PMID: 6761121]">Wennerblom 1982</a>); cardiac arrest (76/1149 (6.61%) vs 76/1181 (6.43%); RR 1.03, 95% CI 0.77 to 1.39; participants = 2330; I<sup>2</sup> = 0%; P value = 0.85) (<a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>); and heart failure (134/851 (15.74%) vs 170/800 (21.25%); RR 0.91, 95% CI 0.63 to 1.33; participants = 1751; I<sup>2</sup> = 62%; P value = 0.64) (<a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>). See <a href="./references#CD008553-fig-0024" title="">Analysis 1.14</a>. </p> </section> <section id="CD008553-sec-0107"> <p><b>Lidocaine versus disopyramide</b></p> <p>No significant differences were noted between lidocaine and disopyramide regarding pulmonary oedema (2/73 (2.73%) vs 4/71 (5.63%); RR 0.62, 95% CI 0.12 to 3.10; participants = 144; I<sup>2</sup> = 0%; P value = 0.56) (<a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>; <a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>); cardiogenic shock (2/38 (5.26%) vs 1/38 (2.63%); RR 2.00, 95% CI 0.19 to 21.14; participants = 76; P value = 0.56) (<a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>); asystole (0/38 (0%) vs 1/38 (2.63%); RR 0.33, 95% CI 0.01 to 7.93; participants = 76; P value = 0.50; very‐low‐quality evidence) (<a href="./references#CD008553-bbs2-0020" title="Pedersen-BjergaardO , LindenegO , SvendsenTL , EnkB , FridbergM . Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease. Ugeskrift for Laeger1986;148:1349-51. [PMID: 3523916]">Pedersen 1986</a>); sinoatrial block (1/35 (2.85%) vs 1/33 (3.03%); RR 0.94, 95% CI 0.06 to 14.47; participants = 68; P value = 0.97; very‐low‐quality evidence) (<a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>) and cardiac block (high‐degree atrioventricular block and bundle branch block) (3/35 (8.57%) vs 5/33 (15.15%); RR 0.57, 95% CI 0.15 to 2.18; participants = 68; P value = 0.51; very‐low‐quality evidence) (<a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>). See <a href="./references#CD008553-fig-0030" title="">Analysis 2.5</a>. </p> </section> <section id="CD008553-sec-0108"> <p><b>Lidocaine versus tocainide</b></p> <p>Meta‐analysis of two trials shows increased risk of any adverse event in the lidocaine group compared with the tocainide group (25/33 (75.75%) vs 16/36 (44.44%); RR 1.69, 95% CI 1.07 to 2.68; participants = 69; I<sup>2</sup> = 17%); very‐low‐quality evidence) (<a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a>). See <a href="./references#CD008553-fig-0035" title="">Analysis 3.4</a>. </p> </section> <section id="CD008553-sec-0109"> <p><b>Lidocaine versus mexiletine</b></p> <p>No significant differences were noted between lidocaine and mexiletine groups in terms of cardiogenic shock (0/12 (0%) vs 1/12 (8.33%); RR 0.33, 95% CI 0.01 to 7.45; participants = 24; P value = 0.49); incomplete atrioventricular block (0/12 (0%) vs 1/12 (8.33%); RR 0.33, 95% CI 0.01 to 7.45; participants = 24; P value = 0.49) and pulmonary oedema (3/12 (25%) vs 2/12 (16.66%); RR 1.50, 95% CI 0.30 to 7.43; participants = 24; P value = 0.62; very‐low‐quality evidence) (<a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>). See <a href="./references#CD008553-fig-0039" title="">Analysis 4.4</a>. </p> </section> <section id="CD008553-sec-0110"> <p><b>Lidocaine versus propafenone</b></p> <p>One trial showed no significant differences between lidocaine and propafenone regarding heart failure (2/28 (7.14%) vs 0/36 (0%); RR 6.38, 95% CI 0.32 to 127.77; participants = 64; P value = 0.23; very‐low‐quality evidence) and bilateral bundle branch block (0/28 (0%) vs 1/36 (2.78%); RR 0.43, 95% CI 0.02 to 10.06; participants = 64; P value = 0.60; very‐low‐quality evidence) (<a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>). See <a href="./references#CD008553-fig-0041" title="">Analysis 5.2</a>. </p> </section> <section id="CD008553-sec-0111"> <p><b>Lidocaine versus amiodarone</b></p> <p><a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a> found no significant differences between lidocaine and amiodarone regarding bradycardia (0/15 (0%) vs 1/10 (10%); RR 0.23, 95% CI 0.01 to 5.12; participants = 25; P value = 0.35; very‐low‐quality evidence) and hypotension (0/15 (0%) vs 12/10 (20%); RR 0.14, 95% CI 0.01 to 2.60; participants = 25; P value = 0.19; very‐low‐quality evidence). See <a href="./references#CD008553-fig-0043" title="">Analysis 6.2</a>. </p> </section> <section id="CD008553-sec-0112"> <p><b>Lidocaine versus dimethylammonium</b></p> <p>One trial found no significant differences between lidocaine and dimethylammonium in terms of hypotension (4/15 (26.7%) vs 5/16 (31.25%); RR 0.85, 95% CI 0.28 to 2.59; participants = 31; P value = 0.78; very‐low‐quality evidence); rise in blood pressure (0/15 (0%) vs 5/16 (31.25%); RR 0.10, 95% CI 0.01 to 1.61; participants = 31; P value = 0.10; very‐low‐quality evidence); tachycardia (0/15 (0%) vs 8/16 (50%); RR 0.06, 95% CI 0.00 to 1.00; participants = 31; P value = 0.05; very‐low‐quality evidence); and bradycardia (0/15 (0%) vs 1/16 (6.25%); RR 0.35, 95% CI 0.02 to 8.08; participants = 31; P value = 0.52; very‐low‐quality evidence) (<a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>). See <a href="./references#CD008553-fig-0044" title="">Analysis 7.1</a>. </p> </section> </section> <section id="CD008553-sec-0113"> <h6 class="title">Neurological adverse events</h6> <section id="CD008553-sec-0114"> <p><b>Lidocaine versus placebo or no intervention</b></p> <p>Meta‐analysis of three trials showed no significant differences between lidocaine and placebo or no intervention in terms of seizures (4/3248 (0.12%) vs 0/3263 (0%); RR 3.58, 95% CI 0.59 to 21.85; participants = 6481; I<sup>2</sup> = 0%; P value = 0.17) (<a href="./references#CD008553-bbs2-0001" title="KosterRW , DunningAJ . Prehospital prevention of ventricular-fibrillation in acute myocardial infarction - Lidocaine Intervention Trial Amsterdam. Circulation1983;68(4):275. Lidocaine Intervention Trial Amsterdam. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine1985;313:1105-10. [PMID: 3900727 ]">ALIT 1985</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>). Lidocaine, compared with placebo or with no intervention, increased significantly the risk of dizziness/drowsiness (74/1259 (5.88%) vs 16/1274(1.25%); RR 3.85, 95% CI 2.29 to 6.47; participants = 2533; I<sup>2</sup> = 0%; low‐quality evidence) (<a href="./references#CD008553-bbs2-0011" title="HargartenK , ChapmanPD , StuevenHA , WaiteEM , MateerJR , HaeckerP , et al. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain. Annals of Emergency Medicine1990;19:1274-9. [PMID: 2240724]">Hargarten 1990</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0017" title="LieKI , LiemKL , DurrerD . A double blind randomized study of intramuscular lidocaine in preventing primary ventricular fibrillation. American Journal of Cardiology1977;39(2):275. LieKI , LiemKL , LouridtzWJ , JanseMJ , WillebrandsAF , DurrerD . Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. American Journal of Cardiology1978;42:486-8. [PMID: 356578]">Lie 1978</a>; <a href="./references#CD008553-bbs2-0018" title="BerntsenRF , RasmussenK . Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North-Norwegian Lidocaine Intervention Trial. American Heart Journal1992;124:1478-83. [PMID: 1462902]">NNLIT 1992</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>). Lidocaine and placebo or no intervention do not differ significantly regarding nausea/vomiting (30/245 (12.24%) vs 24/240 (10%); RR 1.62, 95% CI 0.45 to 5.89; participants = 485; I<sup>2</sup> = 64%; I<sup>2</sup> = 64%; P value = 0.46) (<a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>). Risk of speech disturbances is not statistically significant in the lidocaine group compared with the placebo or no intervention group (16/438 (3.65%) vs 1/431 (0.23%); RR 4.34, 95% CI 1.00 to 18.81; participants = 869; I<sup>2</sup> = 0%; P value = 0.05) (<a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>). Comparison groups did not differ in terms of confusion (17/3386 (0.50%) vs 6/3423 (0.17%); RR 2.44, 95% CI 0.76 to 7.81; participants = 6809; I<sup>2</sup> = 21%; P value = 0.13) (<a href="./references#CD008553-bbs2-0019" title="O'BrienKP , TaylorPM , CroxsonRS . Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. The Medical Journal of Australia1973;2 Suppl:36-7. [PMID: 4598559]">O'Brien 1973</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>) or agitation (3/186 (0.50%) vs 2/186 (0.17%); RR 1.35, 95% CI 0.26 to 7.06; participants = 372; I<sup>2</sup> = 0%; P value = 0.73) (<a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>; <a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>). Two trials reporting overall neurological adverse events showed no significant differences between comparison groups (22/307 (7.17%) vs 11/295 (3.73%); RR 2.24, 95% CI 0.44 to 11.31; participants = 602; I<sup>2</sup> = 73%; P value = 0.33) (<a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a>; <a href="./references#CD008553-bbs2-0021" title="PharandC , KlugerJ , O'RangersE , UjhelyiM , FisherJ , ChowM . Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction. Clinical Pharmacology and Therapeutics1995;57:471-8. [PMID: 7712677]">Pharand 1995</a>). See <a href="./references#CD008553-fig-0025" title="">Analysis 1.15</a>. </p> </section> <section id="CD008553-sec-0115"> <p><b>Lidocaine versus disopyramide</b></p> <p>No significant differences between comparison groups were noted in risk of confusion (3/35 (8.57%) vs 0/33 (0%); RR 6.61, 95% CI 0.35 to 123.30; participants = 68; P value = 0.21; very‐low‐quality evidence) (<a href="./references#CD008553-bbs2-0028" title="RonnevikPK , GundersenT , AbrahamsenAM . Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. European Heart Journal1987;8(1):19-24. [PMID: 2880718]">Ronnevik 1987</a>). See <a href="./references#CD008553-fig-0031" title="">Analysis 2.6</a>. </p> </section> <section id="CD008553-sec-0116"> <p><b>Lidocaine versus mexiletine</b></p> <p>Meta‐analysis of two trials revealed very‐low‐quality evidence when lidocaine was compared with mexiletine regarding risk of composite neurological adverse events (nausea/vomiting, confusion, vertigo, nystagmus) (9/37 (24.32%) vs 17/37 (45.94%); RR 0.63, 95% CI 0.16 to 2.47; participants = 74; I<sup>2</sup> = 26%; P value = 0.51) (<a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a>; <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a>). See <a href="./references#CD008553-fig-0039" title="">Analysis 4.4</a>. </p> </section> <section id="CD008553-sec-0117"> <p><b>Lidocaine versus propafenone</b></p> <p>Very‐low‐quality evidence was found when lidocaine was compared with propafenone regarding mental or neurological symptoms (6/38 (15.78%) vs 0/46 (0%); RR 6.95, 95% CI 0.86 to 55.94; participants = 84; I<sup>2</sup> = 0%; P value = 0.07) (<a href="./references#CD008553-bbs2-0026" title="RehnqvistN , EricssonCG , ErikssonS , OlssonG , SvenssonG . Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Medica Scandinavica1984;16:525-30. [PMID: 6395642]">Rehnqvist 1984</a>; <a href="./references#CD008553-bbs2-0034" title="TouboulP , MoleurP , MathieuMP , VranceaF , FerryS , KirkorianG , et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. European Heart Journal1988;9:1188-93. [PMID: 3234410]">Touboul 1988</a>). See <a href="./references#CD008553-fig-0041" title="">Analysis 5.2</a>. </p> </section> <section id="CD008553-sec-0118"> <p><b>Lidocaine versus amiodarone</b></p> <p>No significant differences in risk of diplopia/sleepiness were noted between groups (1/15 (6.67%) vs 0/10 (0%); RR 2.06, 95% CI 0.09 to 46.11; participants = 25; P value = 0.65; very‐low‐quality evidence) (<a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a>). See <a href="./references#CD008553-fig-0043" title="">Analysis 6.2</a>. </p> </section> <section id="CD008553-sec-0119"> <p><b>Lidocaine versus dimethylammonium</b></p> <p>One trial found very‐low‐quality evidence when lidocaine was compared with dimethylammonium regarding risks of nausea and vomiting (1/15 (6.66%) vs 7/16 (43.75%); RR 0.15, 95% CI 0.02 to 1.10; participants = 31; P value = 0.06); vertigo (1/156.67%) vs 0/16 (0%); RR 3.19, 95% CI 0.14 to 72.69; participants = 31; P value = 0.47) and paraesthesia (0/15 (0%) vs 7/16 (43.75%); RR 0.07, 95% CI 0.00 to 1.14; participants = 31; P value = 0.06) (<a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>). See <a href="./references#CD008553-fig-0044" title="">Analysis 7.1</a>. </p> </section> <section id="CD008553-sec-0120"> <p><b>Lidocaine versus aprindine</b></p> <p>Very‐low‐quality evidence was found when lidocaine was compared with aprindine in terms of coma (1/12 (8.33%) vs 0/12 (0%); RR 3.00, 95% CI 0.13 to 67.06; participants = 24; P value = 0.49); seizures (2/12 (16.67%) vs 0/12 (0%); RR 5.00, 95% CI 0.27 to 94.34; participants = 24; P value = 0.28); agitation (0/12 (0%) vs 2/12 (16.67%); RR 0.20, 95% CI 0.01 to 3.77; participants = 24; P value = 0.28) and disturbances of speech (2/12 (16.67%) vs 0/12 (0%); RR 5.00, 95% CI 0.27 to 94.34; participants = 24, P = 0.28) (<a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>). See <a href="./references#CD008553-fig-0045" title="">Analysis 8.1</a>. </p> </section> <section id="CD008553-sec-0121"> <p><b>Lidocaine versus pirmenol</b></p> <p>One trial found very‐low‐quality evidence when lidocaine was compared with pirmenol regarding adverse events (5/9 (55.55%) vs 5/10 (50%); RR 1.11, 95% CI 0.47 to 2.60; participants = 19; P value = 0.81) (<a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a>). See <a href="./references#CD008553-fig-0046" title="">Analysis 9.1</a>. </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008553-sec-0122" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008553-sec-0122"></div> <section id="CD008553-sec-0123"> <h3 class="title" id="CD008553-sec-0123">Summary of main results</h3> <p>This Cochrane systematic review on prophylactic lidocaine for myocardial infarction found 37 randomised controlled trials incorporating 11,948 participants. Trials reported comparisons between lidocaine versus placebo or no intervention, as well as versus eight antiarrhythmic drugs (i.e., disopyramide, tocainide, mexiletine, propafenone, amiodarone, dimethylammonium chloride, aprindine and pirmenol). Overall, trials had high risks of bias and were underpowered. Ninety‐seven per cent of trials (36/37) did not report an a priori sample size estimation. Drug companies sponsored at least 10 trials, suggesting potential risk of industry bias. Trials were conducted in 17 countries (Australia, Belgium, Brazil, Canada, Denmark, France, Germany, Italy, New Zealand, Northern Ireland, Norway, Poland, Sweden, Switzerland, The Netherlands, United Kingdom and United States of America), in general in pre‐hospital and/or hospital settings. Included participants had proven or non‐proven acute myocardial infarction. </p> <p>We were able to meta‐analyse data for all‐cause mortality. One meta‐analysis of 18 trials involved participants with proven or non‐proven acute myocardial infarction; investigators compared lidocaine versus placebo or no intervention and found no statistically significant differences between comparison groups (<a href="./full#CD008553-tbl-0001">summary of findings Table 1</a>). A second meta‐analysis combined two trials and compared lidocaine versus disopyramide. Researchers found no significant differences between antiarrhythmic drugs (<a href="./full#CD008553-tbl-0002">summary of findings Table 2</a>). Non‐pooled trials examining lidocaine versus tocainide or mexiletine did not differ significantly in terms of all‐cause mortality (<a href="./full#CD008553-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD008553-tbl-0004">summary of findings Table 4</a>, respectively). </p> <p>We were able to meta‐analyse data from 12 trials on cardiac mortality, which showed that lidocaine did not result in significant differences in cardiac mortality compared with placebo or no intervention (<a href="./full#CD008553-tbl-0001">summary of findings Table 1</a>). Meta‐analysis of two trials revealed no significant differences between lidocaine and disopyramide in reducing cardiac mortality (<a href="./full#CD008553-tbl-0002">summary of findings Table 2</a>). Similarly, lidocaine did not differ significantly from tocainide and mexiletine in terms of cardiac mortality (<a href="./full#CD008553-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD008553-tbl-0004">summary of findings Table 4</a>, respectively). </p> <p>Lidocaine compared with placebo or no intervention, disopyramide, mexiletine and propafenone did not significantly reduce the proportions of participants developing ventricular fibrillation (<a href="./full#CD008553-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD008553-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD008553-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD008553-tbl-0005">summary of findings Table 5</a>). </p> <p>Lidocaine compared with placebo or no intervention significantly increased risks of asystole, drowsiness and dizziness (<a href="./full#CD008553-tbl-0001">summary of findings Table 1</a>). No significant differences were noted between lidocaine and disopyramide, tocainide, mexiletine, propafenone, amiodarone, dimethylammonium and aprindine in terms of adverse events ‐ cardiovascular or neurological (<a href="./full#CD008553-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD008553-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD008553-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD008553-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD008553-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD008553-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD008553-tbl-0007">summary of findings Table 7</a>; <a href="./full#CD008553-tbl-0008">summary of findings Table 8</a>). However, safety data were poorly reported overall, and adverse events may be underestimated. No trials reported data on overall survival at 30 days after myocardial infarction. </p> </section> <section id="CD008553-sec-0124"> <h3 class="title" id="CD008553-sec-0124">Overall completeness and applicability of evidence</h3> <p>This Cochrane review found evidence suggesting that prophylactic lidocaine for myocardial infarction is not useful in preventing all‐cause mortality nor ventricular fibrillation. However, this conclusion is based on randomised controlled trials with high risk of bias. Furthermore, the safety profile of lidocaine is unclear from data reported in the included trials. </p> <p>We conducted subgroup analyses of participants with proven acute myocardial infarction including administration route, infusion administration only compared with bolus and infusion administrations, bolus lidocaine dose, number of lidocaine boluses at any dose, intravenous infusion doses of lidocaine and clinical setting. Furthermore, we performed sensitivity analyses that included trials without risk of industry bias versus trials with risk of industry bias, while taking attrition into consideration. Both types of analyses were conducted for all‐cause mortality. Results show consistency and are based on data from trials that included a broad range of participants with different co‐morbidities, for whom different treatment approaches were provided. Although these aspects could be considered as a threat to applicability, consistency in results derived from our analyses shows that the included trials may represent a broad spectrum of patients with low and high risk of mortality. </p> <p>We tried to identify all published and unpublished data, as well as ongoing studies, to warrant confidence in the completeness of data gathered in the review. However, we cannot rule out that calculated effects are overestimated as the result of poor methodological quality (design, analysis) and small sample size of randomised controlled trials. Furthermore, we cannot rule out an underestimation of safety findings. </p> <p><a href="#CD008553-fig-0005">Figure 5</a>, <a href="#CD008553-fig-0007">Figure 7</a>, <a href="#CD008553-fig-0008">Figure 8</a> and <a href="#CD008553-fig-0010">Figure 10</a> seem to present overly optimistic considerations regarding which intervention effects can be proved or disproved; these illustrations show that lidocaine could have effects that would be not only statistically significant but clinically significant as well. However, much larger trials are needed to prove or disprove these effects. </p> </section> <section id="CD008553-sec-0125"> <h3 class="title" id="CD008553-sec-0125">Quality of the evidence</h3> <p>Grades of Recommendation, Assessment, Development and Evaluation (GRADE) assessments were conducted on outcomes of meta‐analyses and non‐pooled trials. No trials were graded as providing strong evidence, primarily because small sample sizes were used (even after meta‐analysis), and because studies were found to have high risk of bias due to lack of adequate randomisation methods, lack of blinding, high attrition, unclear reporting of outcomes and other biases such as industry bias and bias in the presentation of data. Furthermore, we graded evidence as low or very low in quality because of imprecision in clinically relevant outcomes. </p> <p>See <a href="./full#CD008553-tbl-0001">summary of findings Table 1</a>, <a href="./full#CD008553-tbl-0002">summary of findings Table 2</a>, <a href="./full#CD008553-tbl-0003">summary of findings Table 3</a>, <a href="./full#CD008553-tbl-0004">summary of findings Table 4</a>, <a href="./full#CD008553-tbl-0005">summary of findings Table 5</a>, <a href="./full#CD008553-tbl-0006">summary of findings Table 6</a>, <a href="./full#CD008553-tbl-0007">summary of findings Table 7</a> and <a href="./full#CD008553-tbl-0008">summary of findings Table 8</a> for complete assessments and the rationale for ratings. </p> <p>We suspected 10 trials to be at potential risk of industry bias (<a href="./references#CD008553-bbs2-0003" title="BennettMA , WilnerJM, PentecostBL . Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet1970;2:909-11. [PMID: 4097285]">Bennett 1970</a>; <a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a>; <a href="./references#CD008553-bbs2-0006" title="ChopraMP , PortalRW , AberCP , ChopraMP , PortalRW , AberCP . Lignocaine therapy after acute myocardial infarction. British Medical Journal1969;1(5638):213-6. [PMID: 5762622]ChopraMP , ThadaniD , PortalRW , AberCP . Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double blind trial. British Medical Journal1971;3:668-70. [PMID: 4936439]">Chopra 1971</a>; <a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a>; <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a>; <a href="./references#CD008553-bbs2-0016" title="LieKI , WellensHJ , Van CapelleFJ , DurrerD , LieKI , WellensHJ , et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine1974;291(25):1324-6. LieKI , WellensHJ , VanCFJ , DurrerD . A double blind randomized study of lidocaine in preventing primary ventricular fibrillation. Circulation1974;50(4 Suppl 3). ">Lie 1974</a>; <a href="./references#CD008553-bbs2-0022" title="PittA , LippH , AndersonST . Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971;1(7700):612-6. [PMID: 4101228]">Pitt 1971</a>; <a href="./references#CD008553-bbs2-0024" title="RademakerAW , KellenJ , TamYK , WyseDG . Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clinical Pharmacology and Therapeutics1986;40(1):71-80. [PMID: 3522031]">Rademaker 1986</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0032" title="SbarbaroJA , RawlingDA , FozzardHA . Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. American Journal of Cardiology1979;44(3):513-20. [PMID: 474432]">Sbarbaro 1979</a>). This review conducted a subgroup analysis of trials at risk of industry bias versus trials without risk of industry bias that examined lidocaine versus placebo or no intervention. Review authors were not able to detect significant differences between subgroups in risk of all‐cause mortality (<a href="./references#CD008553-fig-0019" title="">Analysis 1.9</a>). </p> <p>Trials with high risk of bias generate SPIN randomised controlled trials, which distort results presented by using specific reporting strategies, whatever their motive, to highlight that the experimental treatment is beneficial, despite a statistically non‐significant difference for the primary outcome, or to distract the reader from statistically non‐significant results when published reports of randomised controlled trials present such results for primary outcomes (<a href="./references#CD008553-bbs2-0098" title="BoutronI , DuttonS , RavaudP , AltmanDG . Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 2010;303(20):2058-64.. JAMA2010;303(10):2058-64. [PMID: 20501928]">Boutron 2010</a>). </p> <p>This Cochrane review has identified the following issues, which may be particularly relevant to consider as future trials are planned. Overall, information on all‐cause mortality and cardiac mortality has been found to be inconsistent because included trials did not appropriately discriminate between participants with proven and non‐proven myocardial infarction, and because investigators used different outcome definitions for 'ventricular arrhythmias' and reported outcomes inconsistently. Researchers should adopt an agreed upon set of core outcomes for each medical condition (<a href="./references#CD008553-bbs2-0105" title="ClarkeM . Standardising outcomes for clinical trials and systematic reviews. Trials2007;8:39. [PMID: 18039365]">Clarke 2007</a>) with the goal of reducing the impact of outcome reporting bias (<a href="./references#CD008553-bbs2-0136" title="KirkhamJJ , DwanKM , AltmanDG , GambleC , DoddS , SmythR , et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ2010;340:c365. [PMID: 20156912]">Kirkham 2010</a>). </p> <p>The impact of outcome reporting bias may be reduced if investigators adopt the recommendations of the Patient‐Centered Outcomes Research Institute (PCORI) (<a href="./references#CD008553-bbs2-0153" title="Patient-Centered Outcomes Research Institute (PCORI). Preliminary draft methodology report: “Our questions, our decisions: Standards for patient‐centered outcomes research”. http://www.pcori.org/assets/Preliminary-Draft-Methodology-Report.pdf (accessed 10 September 2013)2012;(1-61).">PCORI 2012</a>), an independent, non‐profit organisation established by the US Congress to conduct research with the goal of providing information about the best available evidence required to make informed decisions. Research conducted by PCORI is intended to help patients better understand available prevention, treatment and care options, and the science that supports those options (<a href="./references#CD008553-bbs2-0094" title="BaschE , AronsonN , BergA , FlumD , GabrielS , GoodmanSN , HelfandM , et al. Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective. JAMA2012;307(15):1636-40. [PMID: 22511692]">Basch 2012</a>; <a href="./references#CD008553-bbs2-0113" title="GabrielSE , NormandSL . Getting the methods right - the Foundation of Patient-Centered Outcomes Research. New England Journal of Medicine2012;367(9):787-90. [PMID: 22830434]">Gabriel 2012</a>; <a href="./references#CD008553-bbs2-0166" title="SelbyJV , BealAC , FrankL . The Patient-Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda. JAMA2012;307(15):1583-4. [PMID: 22511682]">Selby 2012</a>). </p> </section> <section id="CD008553-sec-0126"> <h3 class="title" id="CD008553-sec-0126">Potential biases in the review process</h3> <p>A systematic review process involves a group of biases called 'significance‐chasing biases', such as publication bias and selective outcome reporting bias (<a href="./references#CD008553-bbs2-0133" title="IoannidisJP . Meta-research: the art of getting it wrong. Research Synthesis Methods2010;10(3-4):169-84.">Ioannidis 2010</a>). Publication bias represents a major threat to the validity of a systematic review, particularly a review that includes small trials. However, this Cochrane review is at low risk of publication bias because a meticulous trial search was conducted by research authors, which ensured identification of randomised controlled trials reported in English and non‐English languages. Also, review authors found no evidence of asymmetry in the funnel plot prepared for all‐cause mortality among participants with proven or non‐proven myocardial infarction (<a href="#CD008553-fig-0004">Figure 4</a>; <a href="#CD008553-fig-0006">Figure 6</a>) and ventricular fibrillation (<a href="#CD008553-fig-0009">Figure 9</a>). </p> <p>Selective outcome reporting bias is seen in suppression of information on specific outcomes and is similar to publication bias in whole studies or trials, in that ‘negative’ results remain unpublished (<a href="./references#CD008553-bbs2-0133" title="IoannidisJP . Meta-research: the art of getting it wrong. Research Synthesis Methods2010;10(3-4):169-84.">Ioannidis 2010</a>). We were surprised to find that many trials did not provide data on all‐cause mortality, ventricular fibrillation or safety. The authors of this Cochrane review observed that 38% of included randomised controlled trials are at high risk of selective outcome reporting. For example, adverse events were reported in nine trials comparing lidocaine versus placebo or no intervention, and all‐cause mortality was reported in 18 trials assessing this comparison. This indicates that safety data for 50% (11,727/2) of randomly assigned participants in trials comparing lidocaine versus placebo or no intervention remain unknown. </p> </section> <section id="CD008553-sec-0127"> <h3 class="title" id="CD008553-sec-0127">Agreements and disagreements with other studies or reviews</h3> <p>Overall, our results are similar to those of other, non‐Cochrane reviews (<a href="./references#CD008553-bbs2-0048" title="DeSilvaRA , HennekensCH , LownB , CasscellsW . Lignocaine prophylaxis in acute myocardial infarction: an evaluation of randomised trials. Lancet1981;2(8251):855-8. [PMID: 6116964]">De Silva 1981</a>; <a href="./references#CD008553-bbs2-0058" title="HineLK , LairdN , HewittP , ChalmersTC . Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Archives of Internal Medicine1989;149:2694-8. [PMID: 2688587]">Hine 1989</a>; <a href="./references#CD008553-bbs2-0064" title="MacMahonS , CollinsR , PetoR , KosterRW , YusufS . Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA1988;260:1910-6. [PMID: 3047448]">MacMahon 1988</a>; <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>; <a href="./references#CD008553-bbs2-0079" title="TeoKK , YusufS , FurbergCD . Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA1993;270:1589-95. [PMID: 8371471]">Teo 1993</a>). These five reviews differ from one another in their eligibility criteria, and from this Cochrane review in the following ways: (1) inclusion of non‐randomised clinical trials by <a href="./references#CD008553-bbs2-0064" title="MacMahonS , CollinsR , PetoR , KosterRW , YusufS . Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA1988;260:1910-6. [PMID: 3047448]">MacMahon 1988</a> (one; <a href="./references#CD008553-bbs2-0076" title="SinghJB , KocotSL . A controlled trial of intramuscular lidocaine in the prevention of premature ventricular contractions associated with acute myocardial infarction. American Heart Journal1976;91:430-6. [PMID: 1258750]SinghJB , KocotSL . A controlled trial of intramuscular lidocaine in the prevention of premature ventricular contractions associated with acute myocardial infarction. Circulation1973;48(4 Suppl):28. SinghJB , KocotSL . Controlled trial of Intramuscular lidocaine in prevention of premature ventricular contractions associated with acute myocardial-infarction. Circulation1973;48(4):8-8. ">Singh 1976</a>); <a href="./references#CD008553-bbs2-0058" title="HineLK , LairdN , HewittP , ChalmersTC . Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Archives of Internal Medicine1989;149:2694-8. [PMID: 2688587]">Hine 1989</a> (two; <a href="./references#CD008553-bbs2-0043" title="BleifeldW , MerxKW , HeinrichKW , EffertS . Controlled trial of prophylactic treatment with lidocaine in acute myocardial infarction. European Journal of Clinical Pharmacology1973;6:119-26. [PMID: 4588851]">Bleifeld 1973</a>; <a href="./references#CD008553-bbs2-0067" title="MogensenL . Ventricular tachyarrhythmias and lignocaine prophylaxis in acute myocardial infarction. Acta Medica Scandinavica1971;513:1-80. [PMID: 5288550]">Mogensen 1971</a> and <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a> (three; <a href="./references#CD008553-bbs2-0043" title="BleifeldW , MerxKW , HeinrichKW , EffertS . Controlled trial of prophylactic treatment with lidocaine in acute myocardial infarction. European Journal of Clinical Pharmacology1973;6:119-26. [PMID: 4588851]">Bleifeld 1973</a>; <a href="./references#CD008553-bbs2-0067" title="MogensenL . Ventricular tachyarrhythmias and lignocaine prophylaxis in acute myocardial infarction. Acta Medica Scandinavica1971;513:1-80. [PMID: 5288550]">Mogensen 1971</a>; <a href="./references#CD008553-bbs2-0076" title="SinghJB , KocotSL . A controlled trial of intramuscular lidocaine in the prevention of premature ventricular contractions associated with acute myocardial infarction. American Heart Journal1976;91:430-6. [PMID: 1258750]SinghJB , KocotSL . A controlled trial of intramuscular lidocaine in the prevention of premature ventricular contractions associated with acute myocardial infarction. Circulation1973;48(4 Suppl):28. SinghJB , KocotSL . Controlled trial of Intramuscular lidocaine in prevention of premature ventricular contractions associated with acute myocardial-infarction. Circulation1973;48(4):8-8. ">Singh 1976</a>); (2) inclusion by <a href="./references#CD008553-bbs2-0064" title="MacMahonS , CollinsR , PetoR , KosterRW , YusufS . Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA1988;260:1910-6. [PMID: 3047448]">MacMahon 1988</a> and <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a> of one trial with bias in the presentation of data (<a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>; this trial randomly assigned participants to lidocaine and placebo, but published results compared two approaches: prophylactic vs selective); (3) inability of Cochrane review authors to extract data from <a href="./references#CD008553-bbs2-0014" title="KostukWJ , BeanlandsDS . Prophylactic lidocaine in acute myocardial infarction. Circulation1969;39 Suppl III:125. ">Kostuk 1969</a> and <a href="./references#CD008553-bbs2-0031" title="SandlerG , ReyN , AmonkarJ . Prophylactic intramuscular lidocaine in myocardial infarction. Current Therapeutic Research1976;20:563-71. ">Sandler 1976</a> (because these trials were at high risk of selective outcome reporting, i.e. investigators did not report all‐cause mortality or ventricular fibrillation data; however, both trials were included by <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a>); (4) inclusion by <a href="./references#CD008553-bbs2-0064" title="MacMahonS , CollinsR , PetoR , KosterRW , YusufS . Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA1988;260:1910-6. [PMID: 3047448]">MacMahon 1988</a> and <a href="./references#CD008553-bbs2-0030" title="SadowskiZP , AlexanderJH , SkrabuchaB , DyduszynskiA , KuchJ , NartowiczE , et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal1999;137:792-8. [PMID: 10220626]">Sadowski 1999</a> of data from a trial with bias in the presentation of data (<a href="./references#CD008553-bbs2-0037" title="WyseDG , KellenJ , RademakerA . Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology1988;12:507-13. [PMID: 3292630]">Wyse 1988</a>; we considered this trial to have high risk of bias in selective outcome reporting for the above mentioned reason); (5) assessment by <a href="./references#CD008553-bbs2-0064" title="MacMahonS , CollinsR , PetoR , KosterRW , YusufS . Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA1988;260:1910-6. [PMID: 3047448]">MacMahon 1988</a> of data from <a href="./references#CD008553-bbs2-0010" title="DunnHM , McCombJM , KinneyCD , CampbellNP , ShanksRG , MacKenzieG , et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal1985;110:353-62. [PMID: 3895875 ]DunnHM , McCombJM . Prophylactic lignocaine in early phase of suspected myocardial infarction [abstract]. Irish Journal Medical Sci1984;153(2):81-2. ">Dunn 1985</a> on lidocaine use through intramuscular and intravenous bolus; (6) publication bias of one meta‐analysis due to exclusion of non‐English language trials (<a href="./references#CD008553-bbs2-0058" title="HineLK , LairdN , HewittP , ChalmersTC . Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Archives of Internal Medicine1989;149:2694-8. [PMID: 2688587]">Hine 1989</a>); (7) inclusion by Cochrane review authors of head‐to‐head comparisons of lidocaine versus other antiarrhythmic drugs such as disopyramide, tocainide, mexiletine, propafenone, amiodarone, dimethylammonium chloride, aprindine and pirmenol; and, finally, (8) inclusion in this Cochrane systematic review of additional trials (not included in the non‐Cochrane reviews) comparing lidocaine versus placebo or no intervention (<a href="./references#CD008553-bbs2-0023" title="PoprawskiK , KrugH , OchotnyR , PiszczekI , JankowskiJ , Straburzyńska-MigajE , et al. Effectiveness of lidocaine in the prevention of primary ventricular fibrillation in acute myocardial infarction. Multiple initial intravenous doses of the drug. Kardiologia Polska1987;30:661-8. [PMID: 3330156]">Poprawski 1987</a>; <a href="./references#CD008553-bbs2-0029" title="RossiP , LombardiM , LottoA , PudduV . Intramuscular injection of lidocaine in prevention of complications and mortality in acute myocardial infarction: double blind study on 246 cases [La lidocaina per via intramuscolare nella prevenzione delle compliczioni e della mortalitá nell´infarto miocardico acuto: Studio a doppio cieco di 246 casi]. Giornale Italiano di Cardiologia1976;6:220-4. [PMID: 795696]">Rossi 1976</a>; <a href="./references#CD008553-bbs2-0033" title="SolimeneMC , BellottiG , RamiresJA , LageS , SilvaLA , BarchiCA , et al. Value of lidocaine in the prevention of ventricular arrhythmias in the acute phase of myocardial infarct [Valor da lidocaína na profilaxia das disritmias ventriculares na fase aguda do infarto do miocárdio]. Arquivos Brasileiros de Cardiologia1983;40(6):377-81. [PMID: 6199006]">Solimene 1983</a>; inclusion of these additional studies allowed us to obtain more accurate estimates for our outcomes of interest). Despite these differences, all systematic reviews have reached similar results for the most relevant outcomes, showing no significant effects derived from prophylactic lidocaine use on all‐cause mortality, cardiac mortality and ventricular fibrillation. However, a limitation of this Cochrane review was introduced by trials that included participants both with and without myocardial infarction. Trial authors must report data on the entire study population and on those with proven myocardial infarction to reduce uncertainty. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008553-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008553-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008553-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008553-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot on all‐cause mortality in 18 lidocaine vs placebo or no intervention trials Funnel plot of data from the meta‐analysis evaluating the effects of lidocaine compared with placebo for preventing all‐cause mortality in patients with proven or not proven acute myocardial infarction (18 trials). This figure shows low risk of publication bias. Individual circles represent point estimates of the included randomised controlled trials. The pattern of distribution simulates an inverted funnel. Larger trials are closer and upper to the pooled estimate. Effect sizes of smaller trials are lower and are more or less symmetrically distributed around the pooled estimate." data-id="CD008553-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p><b>Funnel plot on all‐cause mortality in 18 lidocaine vs placebo or no intervention trials</b> </p> <p>Funnel plot of data from the meta‐analysis evaluating the effects of lidocaine compared with placebo for preventing all‐cause mortality in patients with proven or not proven acute myocardial infarction (18 trials). This figure shows low risk of publication bias. Individual circles represent point estimates of the included randomised controlled trials. The pattern of distribution simulates an inverted funnel. Larger trials are closer and upper to the pooled estimate. Effect sizes of smaller trials are lower and are more or less symmetrically distributed around the pooled estimate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis on all‐cause mortality in 18 lidocaine vs placebo or no intervention trials Trial sequential analysis of lidocaine vs placebo or no intervention on all‐cause mortality in participants with or without proven myocardial infarction based on the diversity‐adjusted required information size (DARIS) of 25,777 participants. This DARIS was calculated on the basis of a proportion of participants with suspected myocardial infarction of 3.40% in the control group; RRR of 20% in the experimental intervention group; alpha (α) of 5%; beta (β) of 20%; and diversity of 22%.The cumulative Z‐curve (blue line) did not cross the conventional alpha 5% boundaries (green lines) at any time. After the 14th trial, the cumulative Z‐curve crosses the trial sequential monitoring boundary for futility. Accordingly, although only 45.5% (11,727/25,777) of the DARIS has been obtained, we can reject an intervention effect of 20% or larger. This implies that no additional trials may be needed to disprove an intervention effect of 20% relative risk reduction if bias can be ignored. Smaller risk reductions may require additional trials with larger sample sizes." data-id="CD008553-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-05.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p><b>Trial sequential analysis on all‐cause mortality in 18 lidocaine vs placebo or no intervention trials</b> </p> <p>Trial sequential analysis of lidocaine vs placebo or no intervention on all‐cause mortality in participants with or without proven myocardial infarction based on the diversity‐adjusted required information size (DARIS) of 25,777 participants. This DARIS was calculated on the basis of a proportion of participants with suspected myocardial infarction of 3.40% in the control group; RRR of 20% in the experimental intervention group; alpha (α) of 5%; beta (β) of 20%; and diversity of 22%. </p> <p>The cumulative Z‐curve (blue line) did not cross the conventional alpha 5% boundaries (green lines) at any time. After the 14th trial, the cumulative Z‐curve crosses the trial sequential monitoring boundary for futility. Accordingly, although only 45.5% (11,727/25,777) of the DARIS has been obtained, we can reject an intervention effect of 20% or larger. This implies that no additional trials may be needed to disprove an intervention effect of 20% relative risk reduction if bias can be ignored. Smaller risk reductions may require additional trials with larger sample sizes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Funnel plot on all‐cause mortality in participants with proven acute myocardial infarction in 16 lidocaine vs placebo or no intervention trials Funnel plot of data from the meta‐analysis of effects of lidocaine compared with placebo for preventing all‐cause mortality in individuals with proven acute myocardial infarction (16 trials). This figure shows low risk of publication bias. The circles show point estimates of the included randomised controlled trials. The pattern of distribution simulates an inverted funnel. Each half of the funnel plot includes eight trials. Larger trials are closer and upper to the pooled estimate. Effect sizes of the smaller trials are lower and are more or less symmetrically distributed around the pooled estimate. The right half of the funnel plot (near the bottom corner) shows two smaller trials with higher standard error and far of the point estimate." data-id="CD008553-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-06.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p><b>Funnel plot on all‐cause mortality in participants with proven acute myocardial infarction in 16 lidocaine vs placebo or no intervention trials</b> </p> <p>Funnel plot of data from the meta‐analysis of effects of lidocaine compared with placebo for preventing all‐cause mortality in individuals with proven acute myocardial infarction (16 trials). This figure shows low risk of publication bias. The circles show point estimates of the included randomised controlled trials. The pattern of distribution simulates an inverted funnel. Each half of the funnel plot includes eight trials. Larger trials are closer and upper to the pooled estimate. Effect sizes of the smaller trials are lower and are more or less symmetrically distributed around the pooled estimate. The right half of the funnel plot (near the bottom corner) shows two smaller trials with higher standard error and far of the point estimate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis on all‐cause mortality among participants with myocardial infarction in 16 lidocaine vs placebo or no intervention trials Trial sequential analysis of lidocaine vs placebo or no intervention on all‐cause mortality in participants with myocardial infarction based on the diversity‐adjusted required information size (DARIS) of 9854 participants. This DARIS was calculated on the basis of a proportion of participants with mortality by myocardial infarction of 5.38% in the control group; post hoc selected RRR of 25% in the experimental intervention group; alpha (α) of 5%; beta (β) of 20%; and diversity of 14%. The cumulative Z‐curve (blue line) did not cross the conventional alpha 5% boundaries (green lines). After the 12th trial, the cumulative Z‐curve crossed the trial sequential monitoring boundary for futility. Accordingly, although only 53.30% (5253/9854) of the DARIS has been obtained, we can reject an intervention effect of 25% or larger. Had we calculated the DARIS on the basis of a more realistic RRR like 20% (as we had planned) or less, the obtained information would represent a smaller part of the DARIS. Accordingly, the boundaries for futility would not have been crossed in such scenarios. Therefore, risk reduction of 20% or less may require additional trials with larger sample sizes." data-id="CD008553-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-07.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p><b>Trial sequential analysis on all‐cause mortality among participants with myocardial infarction in 16 lidocaine vs placebo or no intervention trials</b> </p> <p>Trial sequential analysis of lidocaine vs placebo or no intervention on all‐cause mortality in participants with myocardial infarction based on the diversity‐adjusted required information size (DARIS) of 9854 participants. This DARIS was calculated on the basis of a proportion of participants with mortality by myocardial infarction of 5.38% in the control group; post hoc selected RRR of 25% in the experimental intervention group; alpha (α) of 5%; beta (β) of 20%; and diversity of 14%. The cumulative Z‐curve (blue line) did not cross the conventional alpha 5% boundaries (green lines). After the 12th trial, the cumulative Z‐curve crossed the trial sequential monitoring boundary for futility. Accordingly, although only 53.30% (5253/9854) of the DARIS has been obtained, we can reject an intervention effect of 25% or larger. Had we calculated the DARIS on the basis of a more realistic RRR like 20% (as we had planned) or less, the obtained information would represent a smaller part of the DARIS. Accordingly, the boundaries for futility would not have been crossed in such scenarios. Therefore, risk reduction of 20% or less may require additional trials with larger sample sizes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis on cardiac mortality in 12 lidocaine vs placebo or no intervention trials Trial sequential analysis of lidocaine vs placebo or no intervention on cardiac mortality in participants with or without proven myocardial infarction based on the diversity‐adjusted required information size (DARIS) of 22,745 participants. This DARIS was calculated on the basis of a proportion of participants with cardiac mortality among those with suspected myocardial infarction of 1.51% in the control group; post hoc selected RRR of 30% in the experimental intervention group; alpha (α) of 5%; beta (β) of 20%; and diversity of 14%. The cumulative Z‐curve (blue line) crossed the conventional alpha of 5% (green line) after 3 trials suggested harm. After 10 trials, however, the cumulative Z‐curve (blue line) crossed the trial sequential monitoring boundary for futility. Accordingly, after only 36.4% (8277/22,745) of the DARIS had been obtained, we were able to reject an intervention effect of 30% or larger. Had we calculated the DARIS on the basis of a more realistic RRR like 20% (as originally planned) or less, the obtained evidence would represent a smaller part of the DARIS. Accordingly, boundaries for futility would not have been crossed in such scenarios. Therefore, risk reductions of 20% or less may require additional trials with larger sample sizes." data-id="CD008553-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-08.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p><b>Trial sequential analysis on cardiac mortality in 12 lidocaine vs placebo or no intervention trials</b> </p> <p>Trial sequential analysis of lidocaine vs placebo or no intervention on cardiac mortality in participants with or without proven myocardial infarction based on the diversity‐adjusted required information size (DARIS) of 22,745 participants. This DARIS was calculated on the basis of a proportion of participants with cardiac mortality among those with suspected myocardial infarction of 1.51% in the control group; post hoc selected RRR of 30% in the experimental intervention group; alpha (α) of 5%; beta (β) of 20%; and diversity of 14%. The cumulative Z‐curve (blue line) crossed the conventional alpha of 5% (green line) after 3 trials suggested harm. After 10 trials, however, the cumulative Z‐curve (blue line) crossed the trial sequential monitoring boundary for futility. Accordingly, after only 36.4% (8277/22,745) of the DARIS had been obtained, we were able to reject an intervention effect of 30% or larger. Had we calculated the DARIS on the basis of a more realistic RRR like 20% (as originally planned) or less, the obtained evidence would represent a smaller part of the DARIS. Accordingly, boundaries for futility would not have been crossed in such scenarios. Therefore, risk reductions of 20% or less may require additional trials with larger sample sizes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of data from the meta‐analysis of effects of lidocaine compared with placebo for preventing ventricular fibrillation in individuals with proven or non‐proven acute myocardial infarction (15 trials). This figure shows low risk of publication bias. Circles show point estimates of the included randomised controlled trials. The pattern of distribution simulates an inverted funnel. Trials are symmetrically distributed in each of the halves. Larger trials are closer and upper to the pooled estimate. Effect sizes of the smaller trials are lower and are more or less symmetrically distributed around the pooled estimate." data-id="CD008553-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-09.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Funnel plot of data from the meta‐analysis of effects of lidocaine compared with placebo for preventing ventricular fibrillation in individuals with proven or non‐proven acute myocardial infarction (15 trials). This figure shows low risk of publication bias. Circles show point estimates of the included randomised controlled trials. The pattern of distribution simulates an inverted funnel. Trials are symmetrically distributed in each of the halves. Larger trials are closer and upper to the pooled estimate. Effect sizes of the smaller trials are lower and are more or less symmetrically distributed around the pooled estimate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis on prevention of ventricular fibrillation in 15 lidocaine vs placebo or no intervention trials Trial sequential analysis of lidocaine vs placebo or no intervention on prevention of ventricular fibrillation in participants with or without proven myocardial infarction based on the diversity‐adjusted required information size (DARIS) of 19,271 individuals. This DARIS was calculated on the basis of a proportion of participants with ventricular fibrillation of 2.01% in the control group; post hoc selected RRR of 30% in the experimental intervention group; alpha (α) of 5%; beta (β) of 20%; and diversity of 24%. The cumulative Z‐curve (blue line) did not cross conventional alpha 5% boundaries (green lines). After the 10th trial, the cumulative Z‐curve crosses the trial sequential monitoring boundary for futility. Accordingly, after only 52.2% (10,066/19,271) of the DARIS had been obtained, we were able to reject an intervention effect of 30% or larger. Had we calculated the DARIS on the basis of a more realistic RRR like 20% (as originally planned) or less, the obtained evidence would represent a smaller portion of the DARIS. Accordingly, the boundaries for futility would not have been crossed in such scenarios. Therefore, risk reductions of 20% or less may require additional trials with larger sample sizes." data-id="CD008553-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-10.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p><b>Trial sequential analysis on prevention of ventricular fibrillation in 15 lidocaine vs placebo or no intervention trials</b> </p> <p>Trial sequential analysis of lidocaine vs placebo or no intervention on prevention of ventricular fibrillation in participants with or without proven myocardial infarction based on the diversity‐adjusted required information size (DARIS) of 19,271 individuals. This DARIS was calculated on the basis of a proportion of participants with ventricular fibrillation of 2.01% in the control group; post hoc selected RRR of 30% in the experimental intervention group; alpha (α) of 5%; beta (β) of 20%; and diversity of 24%. The cumulative Z‐curve (blue line) did not cross conventional alpha 5% boundaries (green lines). After the 10th trial, the cumulative Z‐curve crosses the trial sequential monitoring boundary for futility. Accordingly, after only 52.2% (10,066/19,271) of the DARIS had been obtained, we were able to reject an intervention effect of 30% or larger. Had we calculated the DARIS on the basis of a more realistic RRR like 20% (as originally planned) or less, the obtained evidence would represent a smaller portion of the DARIS. Accordingly, the boundaries for futility would not have been crossed in such scenarios. Therefore, risk reductions of 20% or less may require additional trials with larger sample sizes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-FIG-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lidocaine vs placebo or no intervention, Outcome 1: All‐cause mortality (participants with proven or non‐proven acute myocardial infarction)" data-id="CD008553-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Lidocaine vs placebo or no intervention, Outcome 1: All‐cause mortality (participants with proven or non‐proven acute myocardial infarction) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lidocaine vs placebo or no intervention, Outcome 2: All‐cause mortality (subgroup analysis by acute myocardial infarction‐only participants)" data-id="CD008553-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Lidocaine vs placebo or no intervention, Outcome 2: All‐cause mortality (subgroup analysis by acute myocardial infarction‐only participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lidocaine vs placebo or no intervention, Outcome 3: All‐cause mortality in acute myocardial infarction‐only participants (subgroup analysis by administration route for lidocaine)" data-id="CD008553-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Lidocaine vs placebo or no intervention, Outcome 3: All‐cause mortality in acute myocardial infarction‐only participants (subgroup analysis by administration route for lidocaine) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lidocaine vs placebo or no intervention, Outcome 4: All‐cause mortality (subgroup analysis according to intravenous administration)" data-id="CD008553-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Lidocaine vs placebo or no intervention, Outcome 4: All‐cause mortality (subgroup analysis according to intravenous administration) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lidocaine vs placebo or no intervention, Outcome 5: All‐cause mortality (subgroup analysis according to bolus‐lidocaine dose)" data-id="CD008553-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Lidocaine vs placebo or no intervention, Outcome 5: All‐cause mortality (subgroup analysis according to bolus‐lidocaine dose) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lidocaine vs placebo or no intervention, Outcome 6: All‐cause mortality (subgroup analysis according to number of lidocaine boluses)" data-id="CD008553-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Lidocaine vs placebo or no intervention, Outcome 6: All‐cause mortality (subgroup analysis according to number of lidocaine boluses) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lidocaine vs placebo or no intervention, Outcome 7: All‐cause mortality (subgroup analysis according to intravenous infusion dose)" data-id="CD008553-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Lidocaine vs placebo or no intervention, Outcome 7: All‐cause mortality (subgroup analysis according to intravenous infusion dose) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lidocaine vs placebo or no intervention, Outcome 8: All‐cause mortality (subgroup analysis by clinical setting)" data-id="CD008553-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Lidocaine vs placebo or no intervention, Outcome 8: All‐cause mortality (subgroup analysis by clinical setting) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lidocaine vs placebo or no intervention, Outcome 9: All‐cause mortality (subgroup analysis according to non‐suspected trials with industry bias compared with suspected trials with industry bias)" data-id="CD008553-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Lidocaine vs placebo or no intervention, Outcome 9: All‐cause mortality (subgroup analysis according to non‐suspected trials with industry bias compared with suspected trials with industry bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lidocaine vs placebo or no intervention, Outcome 10: All‐cause mortality (sensitivity analysis by attrition bias)" data-id="CD008553-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Lidocaine vs placebo or no intervention, Outcome 10: All‐cause mortality (sensitivity analysis by attrition bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lidocaine vs placebo or no intervention, Outcome 11: Cardiac mortality" data-id="CD008553-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Lidocaine vs placebo or no intervention, Outcome 11: Cardiac mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lidocaine vs placebo or no intervention, Outcome 12: Cardiac mortality (sensitivity analysis according to non‐suspected trials of industry bias versus suspected trials of industry bias)" data-id="CD008553-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Lidocaine vs placebo or no intervention, Outcome 12: Cardiac mortality (sensitivity analysis according to non‐suspected trials of industry bias versus suspected trials of industry bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lidocaine vs placebo or no intervention, Outcome 13: Ventricular fibrillation" data-id="CD008553-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Lidocaine vs placebo or no intervention, Outcome 13: Ventricular fibrillation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lidocaine vs placebo or no intervention, Outcome 14: Cardiovascular adverse events" data-id="CD008553-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Lidocaine vs placebo or no intervention, Outcome 14: Cardiovascular adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Lidocaine vs placebo or no intervention, Outcome 15: Neurological adverse events" data-id="CD008553-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Lidocaine vs placebo or no intervention, Outcome 15: Neurological adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lidocaine vs disopyramide, Outcome 1: All‐cause mortality" data-id="CD008553-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Lidocaine vs disopyramide, Outcome 1: All‐cause mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lidocaine vs disopyramide, Outcome 2: All‐cause mortality (sensitivity analysis by risk of attrition bias)" data-id="CD008553-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Lidocaine vs disopyramide, Outcome 2: All‐cause mortality (sensitivity analysis by risk of attrition bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lidocaine vs disopyramide, Outcome 3: Cardiac mortality" data-id="CD008553-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Lidocaine vs disopyramide, Outcome 3: Cardiac mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lidocaine vs disopyramide, Outcome 4: Ventricular fibrillation" data-id="CD008553-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Lidocaine vs disopyramide, Outcome 4: Ventricular fibrillation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lidocaine vs disopyramide, Outcome 5: Cardiovascular adverse events" data-id="CD008553-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Lidocaine vs disopyramide, Outcome 5: Cardiovascular adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lidocaine vs disopyramide, Outcome 6: Neurological adverse events" data-id="CD008553-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Lidocaine vs disopyramide, Outcome 6: Neurological adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Lidocaine vs tocainide, Outcome 1: All‐cause mortality" data-id="CD008553-fig-0032" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Lidocaine vs tocainide, Outcome 1: All‐cause mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Lidocaine vs tocainide, Outcome 2: All‐cause mortality (sensitivity analysis by risk of attrition bias)" data-id="CD008553-fig-0033" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Lidocaine vs tocainide, Outcome 2: All‐cause mortality (sensitivity analysis by risk of attrition bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Lidocaine vs tocainide, Outcome 3: Cardiac mortality" data-id="CD008553-fig-0034" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Lidocaine vs tocainide, Outcome 3: Cardiac mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Lidocaine vs tocainide, Outcome 4: Adverse events" data-id="CD008553-fig-0035" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Lidocaine vs tocainide, Outcome 4: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Lidocaine vs mexiletine, Outcome 1: All‐cause mortality" data-id="CD008553-fig-0036" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Lidocaine vs mexiletine, Outcome 1: All‐cause mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Lidocaine vs mexiletine, Outcome 2: Cardiac mortality" data-id="CD008553-fig-0037" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Lidocaine vs mexiletine, Outcome 2: Cardiac mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Lidocaine vs mexiletine, Outcome 3: Ventricular fibrillation" data-id="CD008553-fig-0038" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Lidocaine vs mexiletine, Outcome 3: Ventricular fibrillation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Lidocaine vs mexiletine, Outcome 4: Adverse events" data-id="CD008553-fig-0039" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Lidocaine vs mexiletine, Outcome 4: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Lidocaine vs propafenone, Outcome 1: Ventricular fibrillation" data-id="CD008553-fig-0040" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Lidocaine vs propafenone, Outcome 1: Ventricular fibrillation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Lidocaine vs propafenone, Outcome 2: Adverse events" data-id="CD008553-fig-0041" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Lidocaine vs propafenone, Outcome 2: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Lidocaine vs amiodarone, Outcome 1: Ventricular fibrillation" data-id="CD008553-fig-0042" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Lidocaine vs amiodarone, Outcome 1: Ventricular fibrillation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Lidocaine vs amiodarone, Outcome 2: Adverse events" data-id="CD008553-fig-0043" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Lidocaine vs amiodarone, Outcome 2: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Lidocaine vs dimethylammonium, Outcome 1: Adverse events" data-id="CD008553-fig-0044" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Lidocaine vs dimethylammonium, Outcome 1: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Lidocaine vs aprindine, Outcome 1: Adverse events" data-id="CD008553-fig-0045" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Lidocaine vs aprindine, Outcome 1: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008553-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/urn:x-wiley:14651858:media:CD008553:CD008553-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Lidocaine vs pirmenol, Outcome 1: Adverse event" data-id="CD008553-fig-0046" src="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_t/tCD008553-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Lidocaine vs pirmenol, Outcome 1: Adverse event</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/media/CDSR/CD008553/image_n/nCD008553-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008553-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Lidocaine compared with placebo or no intervention for acute myocardial infarction</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lidocaine compared with placebo or no intervention for acute myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with acute myocardial infarction<br/><b>Settings:</b> pre‐hospital and in‐hospital<br/><b>Intervention:</b> lidocaine<br/><b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo or no intervention</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lidocaine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: ranging between unknown and 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>35 per 1000</b><br/>(29 to 42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> <br/>(0.85 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11727<br/>(18 studies<sup>a</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac mortality</b> </p> <p>Follow‐up: ranging between unknown and 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b><br/>(11 to 23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b> <br/>(0.70 to 1.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8277<br/>(12 studies<sup>a</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall survival at 30 days after myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No trial assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventricular fibrillation</b><br/>Electrocardiogram </p> <p>Follow‐up: ranging between unknown and 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b><br/>(11 to 23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> <br/>(0.55 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10115<br/>(16 studies<sup>a</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events (AEs; adverse drug reaction): asystole</b> </p> <p>Follow‐up: ranging between unknown and 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> <p>(5 to 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.32</b><br/>(1.26 to 4.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6826</p> <p>(4 studies<sup>a</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>b,f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events (AEs; adverse drug reaction): sinus bradycardia</b> </p> <p>Follow‐up: ranging between unknown and 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> <br/>(27 to 73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.09</b><br/>(0.66 to 1.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2549</p> <p>(8 studies<sup>a</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>b,h,i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (AEs; adverse drug reaction): drowsiness/dizziness</b> </p> <p>Follow‐up: ranging between unknown and 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> <p>(29 to 81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.85</b><br/>(2.29 to 6.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2533<br/>(6 studies<sup>a</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>j.k.l</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Trials include participants with proven or unproven acute myocardial infarction.<br/><sup>b</sup>Downgraded two levels because of limitations in trial design or execution (high attrition bias).<br/><sup>c</sup>Assumed risk was gotten from control group risk (3.4%).<br/><sup>d</sup>Assumed risk was gotten from control group risk (1.5%).<br/><sup>e</sup>Assumed risk was gotten from control group risk (2.1%).<br/><sup>f</sup>Assumed risk was gotten from control group risk (0.41%).<br/><sup>g</sup>Downgraded one level because of imprecision (low number of events with an impact on the precision of effect estimates).<br/><sup>h</sup>Assumed risk was gotten from control group risk (4.1%).<br/><sup>i</sup>Downgraded one level because of imprecision (low number of events with an impact on the precision of effect estimates).<br/><sup>j</sup>Downgraded one level because of limitations in trial design or execution (high attrition bias).<br/><sup>k</sup>Downgraded one level because of imprecision (low number of events with an impact on the precision of effect estimates).<br/><sup>l</sup>Assumed risk was gotten from control group risk (1.3%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Lidocaine compared with placebo or no intervention for acute myocardial infarction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008553-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Lidocaine compared with disopyramide for myocardial infarction</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lidocaine compared with disopyramide for myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with myocardial infarction<br/><b>Settings:</b> in‐hospital<br/><b>Intervention:</b> lidocaine<br/><b>Comparison:</b> disopyramide </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Disopyramide</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lidocaine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: ranging between 12 hours and 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>98 per 1000</b><br/>(33 to 291) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.39</b> <br/>(0.47 to 4.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac mortality</b><br/>Follow‐up: ranging between 12 hours and 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b><br/>(9 to 200) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> <br/>(0.21 to 4.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a,b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall survival at 30 days after myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No trial assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventricular fibrillation</b> </p> <p>Follow‐up: 12 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>79 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> </p> <p>(3 to 242)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.32</b><br/>(0.04 to 2.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>e,f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events (AEs; adverse drug reaction): asystole</b> </p> <p>Follow‐up: 12 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> <p>(0 to 209)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b><br/>(0.01 to 7.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>e,f,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (AEs; adverse drug reaction):</b> <br/><b>sinoatrial block</b> </p> <p>Follow‐up: 24 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b><br/>2 to 438 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> </p> <p>(0.06 to 14.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>i,j,k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (AEs; adverse drug reaction):</b> <br/><b>cardiac blocks (high‐degree atrioventricular block and bundle)</b> </p> <p>Follow‐up: 24 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>152 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>86 per 1000</b><br/>(23 to 330) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.57</b><br/>(0.15 to 2.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>j,k,l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of limitations in trial design or execution (high attrition bias).<br/><sup>b</sup>Downgraded two levels because of imprecision (small sample and very low number of events with an impact on the precision of effect estimates).<br/><sup>c</sup>Assumed risk was gotten from control group risk (7%).<br/><sup>d</sup>Assumed risk was gotten from control group risk (4.1%).<br/><sup>e</sup>Downgraded one level because of limitations in trial design.<br/><sup>f</sup>Downgraded two levels because of imprecision (small sample and very low number of events with an impact on the precision of effect estimates).<br/><sup>g</sup>Assumed risk was gotten from control group risk (7.9%).<br/><sup>h</sup>Assumed risk was gotten from control group risk (2.6%).<br/><sup>i</sup>Downgraded one level because of limitations in trial design or execution (high attrition bias).<br/><sup>j</sup>Downgraded two levels because of imprecision (small sample and very low number of events with an impact on the precision of effect estimates).<br/><sup>k</sup>Assumed risk was gotten from control group risk (3%).<br/><sup>l</sup>Assumed risk was gotten from control group risk (15.2%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Lidocaine compared with disopyramide for myocardial infarction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008553-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Lidocaine compared with tocainide for myocardial infarction</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lidocaine compared with tocainide for myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with myocardial infarction<br/><b>Settings:</b> in‐hospital<br/><b>Intervention:</b> lidocaine<br/><b>Comparison:</b> tocainide </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Tocainide</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lidocaine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: 48 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b><br/>(5 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b> <br/>(0.08 to 17.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac mortality</b><br/>Follow‐up: 48 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b><br/>(5 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b> <br/>(0.08 to 17.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival at 30 days after myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither <a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a> nor <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a> assessed this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventricular fibrillation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0013" title="KeefeDL , WilliamsS , TorresV , FlowersD , SombergJC . Prophylactic tocainide or lidocaine in acute myocardial infarction. American Journal of Cardiology1986;57:527-31. [PMID: 3082175 ]">Keefe 1986</a> reported no participants with VF. <a href="./references#CD008553-bbs2-0025" title="RehnqvistN , ErhardtL , EricssonCG , OlssonG , SvenssonG , SjögrenA . Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction. Acta Medica Scandinavica1983;214:21-7. [PMID: 6414252]">Rehnqvist 1983</a> did not mention this outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (AEs; adverse drug reaction): any adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>444 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>751 per 1000</b> </p> <p>(476 to 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.69</b><br/>(1.07 to 2.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As the result of severe inconsistencies regarding reporting data on adverse events, we preferred to show the evidence using this approach </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of limitations in trial design and execution of trials.<br/><sup>b</sup>Downgraded two levels because of imprecision (small sample and very low number of events with an impact on the precision of effect estimates).<br/><sup>c</sup>Assumed risk was gotten from control group risk (6.3%).<br/><sup>d</sup>Assumed risk was gotten from control group risk (44.4%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Lidocaine compared with tocainide for myocardial infarction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008553-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Lidocaine compared with mexiletine for myocardial infarction</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lidocaine compared with mexiletine for myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with myocardial infarction<br/><b>Settings:</b> in‐hospital<br/><b>Intervention:</b> lidocaine<br/><b>Comparison:</b> mexiletine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Mexiletine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lidocaine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 48 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b><br/>(1 to 621) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> <br/>(0.01 to 7.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac mortality</b> </p> <p>Follow‐up: 48 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b><br/>(1 to 621) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> <br/>(0.01 to 7.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival at 30 days after myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neither <a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a> nor <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a> assessed this outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventricular fibrillation</b> </p> <p>Follow‐up: 48 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.00</b> <br/>(0.13 to 67.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events in the control group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (AEs; adverse drug reaction): atrioventricular block</b><br/>Follow‐up: 48 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b><br/>(1 to 621) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.33</b> <br/>(0.01 to 7.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events (AEs; adverse drug reaction): composite neurological adverse event (confusion, vertigo, nystagmus, vomiting and diplopia)</b><br/>Follow‐up: between 3 hours and 48 hours<sup>d</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>459 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>289 per 1000</b> </p> <p>(74 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.63</b><br/>(0.16 to 2.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of limitations in the trial design.<br/><sup>b</sup>Downgraded two levels because of imprecision (small sample and very low number of events with an impact on the precision of effect estimates).<br/><sup>c</sup>Assumed risk was gotten from control group risk (8.3%).<br/><sup>d</sup><a href="./references#CD008553-bbs2-0012" title="GobleAJ , HorowitzJD , MorrisP . A comparative trial of mexiletine and lignocaine in the treatment of ventricular tachyarrhythmias after acute myocardial infarction. Australian &amp; New Zealand Journal of Medicine1980;10(3):392-3. HorowitzJD , AnavekarSN , MorrisPM , GobleAJ , DoyleAE , LouisWJ . Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. Journal of Cardiovascular Pharmacology1981;3(3):409-19. [PMID: 6168823]">Horowitz 1981</a> and <a href="./references#CD008553-bbs2-0027" title="RolliA , BonattiV , FinardiA , FavaroL , BottiG . Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias [Studio comparativo tra l'efficacia antiaritmica della mexiletina e della lidocaina nelle aritmie ipercinetiche ventricolari]. Giornale Italiano di Cardiologia1981;11(4):468-76. [PMID: 6169578]">Rolli 1981</a> used 'composite neurological adverse' terms for reporting this adverse event.<br/><sup>e</sup>Assumed risk was gotten from control group risk (45.9%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Lidocaine compared with mexiletine for myocardial infarction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008553-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Lidocaine compared with propafenone for myocardial infarction</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lidocaine compared with propafenone for myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with myocardial infarction<br/><b>Settings:</b> in‐hospital<br/><b>Intervention:</b> lidocaine<br/><b>Comparison:</b> propafenone </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Propafenone</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lidocaine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival at 30 days after myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventricular fibrillation</b> </p> <p>Follow‐up: 24 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.00</b> <br/>(0.14 to 65.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control group had no event</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (AEs; adverse drug reaction): heart failure</b><br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 6.38</b> <br/>(0.32 to 127.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control group had no event</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (AEs; adverse drug reaction): bilateral bundle branch block</b><br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b><br/>(1 to 279) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.43</b> <br/>(0.02 to 10.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (AEs; adverse drug reaction): neuropsychiatric disturbances</b><br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 6.95</b><br/>(0.86 to 55.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control group had no event</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of limitations in trial design and execution of the trial.<br/><sup>b</sup>Downgraded two levels because of imprecision (small sample and very low number of events with an impact on the precision of effect estimates).<br/><sup>c</sup>Assumed risk was gotten from control group risk (2.8%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Lidocaine compared with propafenone for myocardial infarction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008553-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Lidocaine compared with amiodarone for myocardial infarction</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lidocaine compared with amiodarone for myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with myocardial infarction<br/><b>Settings:</b> in‐hospital<br/><b>Intervention:</b> lidocaine<br/><b>Comparison:</b> amiodarone </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Amiodarone</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lidocaine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: not stated</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiac mortality</b><br/>Follow‐up: not stated </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall survival at 30 days after myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0005" title="CapucciA , MelandriG , MantovaniB , MarestaA , MagnaniB . Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction. Giornale Italiano de Cardiologia1985;15:285-9. [PMID: 4018467]">Capucci 1985</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ventricular fibrillation</b> </p> <p>Follow‐up: not stated</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.44</b> <br/>(0.18 to 46.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No ventricular fibrillation in control group</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bradycardia</b><br/>Follow‐up: not stated </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b><br/>(1 to 512) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.23</b> <br/>(0.01 to 5.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypotension</b><br/>Follow‐up: not stated </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b><br/>(2 to 520) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.14</b> <br/>(0.01 to 2.60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diplopia plus sleepiness</b><br/>Follow‐up: not stated </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.06</b> <br/>(0.09 to 46.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No diplopia in control group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of limitations in trial design.<br/><sup>b</sup>Downgraded two levels because of imprecision (small sample and very low number of events with an impact on the precision of effect estimates).<br/><sup>c</sup>Assumed risk was gotten from control group risk (10%).<br/><sup>d</sup>Assumed risk was gotten from control group risk (20%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Lidocaine compared with amiodarone for myocardial infarction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008553-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Lidocaine compared with dimethylammonium for myocardial infarction</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lidocaine compared with dimethylammonium for myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with myocardial infarction<br/><b>Settings:</b> in‐hospital<br/><b>Intervention:</b> lidocaine<br/><b>Comparison:</b> dimethylammonium </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Dimethylammonium</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lidocaine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: unclear </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac mortality</b><br/>Follow‐up: unclear </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival at 30 days after myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventricular fibrillation</b><br/>Follow‐up: unclear </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0004" title="BergdahlB , KarlssonE , MagnussonJO , SonnhagC . Lidocaine and the quaternary ammonium compound QX-572 in acute myocardial infarction. A comparative study. Acta Medica Scandinavica1978;204(4):311-4. [PMID: 358766]">Bergdahl 1978</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypotension</b><br/>Follow‐up: unclear </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>312 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>266 per 1000</b><br/>(88 to 809) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b> <br/>(0.28 to 2.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tachycardia</b><br/>Follow‐up: unclear </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b><br/>(0 to 500) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.06</b> <br/>(0.00 to 1.0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bradycardia</b><br/>Follow‐up: unclear </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b><br/>(1 to 505) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.35</b> <br/>(0.02 to 8.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of limitations in trial design or execution (high attrition bias).<br/><sup>b</sup>Downgraded two levels because of imprecision (small sample and very low number of events with an impact on the precision of effect estimates).<br/><sup>c</sup>Assumed risk was gotten from control group risk (31.3%).<br/><sup>d</sup>Assumed risk was gotten from control group risk (50%).<br/><sup>e</sup>Assumed risk was gotten from control group risk (6.3%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Lidocaine compared with dimethylammonium for myocardial infarction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008553-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Lidocaine compared with aprindine for myocardial infarction</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lidocaine compared with aprindine for myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with myocardial infarction<br/><b>Settings:</b> in‐hospital<br/><b>Intervention:</b> lidocaine<br/><b>Comparison:</b> aprindine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Aprindine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lidocaine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 3 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac mortality</b><br/>Follow‐up: 3 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival at 30 days after myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventricular fibrillation</b> <br/>Follow‐up: 3 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0009" title="DepaepeA , BohynP , De MaertelaereM , DernierJ , CloetensW , De MeyD . Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct [Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde]. Acta Cardiologica2974;Suppl 18:423-32. [PMID: 4138738 ]">Depaepe 1974</a> did not mention this outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Coma</b><br/>Follow‐up: 3 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.00</b> <br/>(0.13 to 67.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No coma in control group</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b><br/>Follow‐up: 3 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.00</b> <br/>(0.27 to 94.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No seizures in control group</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Agitation</b><br/>Follow‐up: 3 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/>(2 to 628) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.20</b> <br/>(0.01 to 3.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of limitations in trial design.<br/><sup>b</sup>Downgraded two levels because of imprecision (small sample and very low number of events with an impact on the precision of effect estimates).<br/><sup>c</sup>Assumed risk was gotten from control group risk (16.7%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Lidocaine compared with aprindine for myocardial infarction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008553-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Lidocaine compared with pirmenol for myocardial infarction</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lidocaine compared with pirmenol for myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with myocardial infarction<br/><b>Settings:</b> in‐hospital<br/><b>Intervention:</b> lidocaine<br/><b>Comparison:</b> pirmenol </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo or no intervention</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lidocaine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 24 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac mortality</b><br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall survival at 30 days after myocardial infarction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventricular fibrillation</b> <br/>Follow‐up: 24 hours. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008553-bbs2-0007" title="CuendetBP . Pirmenol versus lidocaine in the treatment of ventricular arrhythmias at the acute phase of myocardial infarction. Double blind randomized study. Therapie1988;43(2):158. ">Cuendet 1988</a> did not assess this outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Safety (AEs; adverse drug reaction): any adverse event</b> </p> <p>Follow‐up: 24 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>555 per 1000</b> </p> <p>(235 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.11</b><br/>(0.47 to 2.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> <p>(1 study<sup>a</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>b,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Trial includes participants with proven or unproven acute myocardial infarction.<br/><sup>b</sup>Downgraded one level because of limitations in the trial design.<br/><sup>c</sup>Downgraded two levels because of imprecision (very small sample size and very low number of events with an impact on the precision of effect estimates).<br/><sup>d</sup>Assumed risk was gotten from control group risk (50%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Lidocaine compared with pirmenol for myocardial infarction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/full#CD008553-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008553-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Lidocaine vs placebo or no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality (participants with proven or non‐proven acute myocardial infarction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11727</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.82, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 All‐cause mortality (subgroup analysis by acute myocardial infarction‐only participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.79, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 All‐cause mortality in acute myocardial infarction‐only participants (subgroup analysis by administration route for lidocaine) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.79, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Intravenous route</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2042</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.82, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Intramuscular route</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.50, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Both routes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>407</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.56, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 All‐cause mortality (subgroup analysis according to intravenous administration) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Trials with infusion only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.33, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Trials with bolus followed by infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.92, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 All‐cause mortality (subgroup analysis according to bolus‐lidocaine dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Up to 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.61, 6.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 60 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.73, 3.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 75 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.70, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.4 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.32, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.5 1 mg/kg‐p</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.12, 5.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 All‐cause mortality (subgroup analysis according to number of lidocaine boluses) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 One bolus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.90, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Two bolus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>608</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.72, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 All‐cause mortality (subgroup analysis according to intravenous infusion dose) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 1 mg/min to 1.5 mg/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.71, 2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 2 mg/min to 3 mg/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.72, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 All‐cause mortality (subgroup analysis by clinical setting) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.79, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Pre‐hospital setting lidocaine use</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.46, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Hospital setting lidocaine use</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.69, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 Lidocaine use in both pre‐hospital and hospital settings</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.77, 3.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 All‐cause mortality (subgroup analysis according to non‐suspected trials with industry bias compared with suspected trials with industry bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.79, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Trials non‐sponsored by industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.82, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Trials sponsored by industry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.44, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 All‐cause mortality (sensitivity analysis by attrition bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Best‐worst case scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.30, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Worst‐best case scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [1.02, 4.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Cardiac mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.70, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Cardiac mortality (sensitivity analysis according to non‐suspected trials of industry bias versus suspected trials of industry bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.70, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Trials non‐sponsored by drug company</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.52, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Trials sponsored by drug company</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.77, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Ventricular fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.55, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Cardiovascular adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Asystole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6826</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.32 [1.26, 4.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 Sinus bradycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.66, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.3 Bundle branch block</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.80, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.4 Non‐complete atrioventricular block</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.75, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.5 Complete atrioventricular block</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.66, 4.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.6 Unknown grade atrioventricular block</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1727</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.75, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.7 Pulmonary oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.80, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.8 Cardiogenic shock</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.77, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.9 Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.81, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.10 Cardiac arrest</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.77, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.11 Heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.63, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Neurological adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.58 [0.59, 21.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 Drowsiness/Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.85 [2.29, 6.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.3 Nausea/Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.45, 5.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.4 Speech disturbances</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>869</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.34 [1.00, 18.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.5 Confusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6809</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.44 [0.76, 7.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.6 Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.26, 7.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.7 Global adverse events in central nervous system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [0.44, 11.31]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Lidocaine vs placebo or no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008553-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Lidocaine vs disopyramide</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.47, 4.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 All‐cause mortality (sensitivity analysis by risk of attrition bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Best‐worst case scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.08, 3.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Worst‐best case scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.75 [1.05, 7.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Cardiac mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.21, 4.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Ventricular fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 3.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Cardiovascular adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Pulmonary oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.12, 3.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Cardiogenic shock</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.19, 21.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.3 Asystole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.4 Sinoatrial block</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.06, 14.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.5 Cardiac blocks (high‐degree atrioventricular block and bundle branch block)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.15, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Neurological adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.61 [0.35, 123.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Lidocaine vs disopyramide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008553-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Lidocaine vs tocainide</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.08, 17.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 All‐cause mortality (sensitivity analysis by risk of attrition bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Best‐worst case scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.06, 6.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Worst‐best case scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.46 [0.25, 24.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Cardiac mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.08, 17.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Any adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.07, 2.68]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Lidocaine vs tocainide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008553-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Lidocaine vs mexiletine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Cardiac mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Ventricular fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 67.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Cardiogenic shock</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Atrioventricular block</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.3 Pulmonary oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.30, 7.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.4 Composite neurological adverse event (confusion, vertigo, nystagmus and diplopia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.16, 2.47]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Lidocaine vs mexiletine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008553-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Lidocaine vs propafenone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Ventricular fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.14, 65.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.38 [0.32, 127.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 Bilateral bundle branch block</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.02, 10.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.3 Neuropsychiatric disturbances</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.95 [0.86, 55.94]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Lidocaine vs propafenone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008553-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Lidocaine vs amiodarone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Ventricular fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.44 [0.18, 64.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Bradycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.01, 5.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.3 Diplopia plus sleepiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [0.09, 46.11]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Lidocaine vs amiodarone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008553-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Lidocaine vs dimethylammonium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.28, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 Rise in blood pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.01, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.3 Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.00, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.4 Bradycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.02, 8.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.5 Nausea/Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.02, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.6 Paraesthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.00, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.7 Vertigo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.19 [0.14, 72.69]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Lidocaine vs dimethylammonium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008553-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Lidocaine vs aprindine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 Coma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 67.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 Seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.27, 94.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.3 Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 3.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.4 Disturbance of speech</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.27, 94.34]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Lidocaine vs aprindine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008553-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Lidocaine vs pirmenol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.47, 2.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Lidocaine vs pirmenol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008553.pub2/references#CD008553-tbl-0018">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008553.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008553-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008553-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008553-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008553-note-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD008553-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008553-note-0010">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008553-note-0011">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008553\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008553\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008553\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008553\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008553\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008553\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008553\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008553\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008553\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008553\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008553\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008553\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008553\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008553\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008553\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008553\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008553\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008553\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008553.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008553.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008553.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008553.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008553.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724889828"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008553.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724889832"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008553.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e6dd38d51f4ca',t:'MTc0MDcyNDg5MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 